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ABSTRACT
DEVELOPMENT AND CHARACTERIZATION OF CASPASE ACTIVATABLE
GFP AND A FAMILY OF FLUORESCENT REPORTERS
FEBRUARY 2013
SAMANTHA B. NICHOLLS, B.S., UNIVERSITY OF VERMONT

Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Jeanne A. Hardy

The cellular process of programmed cell death, or apoptosis, is critical in homeostasis
and development. In addition it’s misfunction is implicated in an array of disease states
from cancer to neurodegeration, making it an attractive pathway for drug targeting. A
family of proteases, known as caspases, plays a central role in the apoptotic cascade
resulting in the ultimate destruction of the cell. We report a genetically encoded dark-tobright reporter of caspase activity used in E.coli, mammalian cells, and whole organisms
which can be used to monitor apoptosis. This reporter, caspase activatable green
fluorescent protein (CA-GFP) consists of GFP fused through a flexible linker containing
the caspase-3 and -7 recognition sequence, DEVD, to a hydrophobic peptide derived
from the influenza A viral M2 protein. This fusion reporter shows a significant
fluorescent response in the presence of active caspase. CA-GFP is unique in its ability to
hold GFP in a dark state prior to cleavage by active protease. We investigate the
mechanism of quenching, examining the structural characteristics which lead to the
inability of the GFP chromophore to mature in the presence of the peptide. In better
understanding the mechanism of quenching we can engineer CA-GFP to ultimately be
used in transgenic animal models. This requires the development of a palette of protease-
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activatable fluorescent proteins (PrA-FP) which would enable the monitoring of multiple
proteolytic events within a cell or organism in real time. Our development of this palette
of reporters, varying in their fluorescence and proteolytic response shows that CA-GFP
has the potential to be a powerful tool for the study of the role of apoptosis during
development in whole organism models and could be an important tool in understanding
the role of individual proteases within the complex biochemical environment in the cell.
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CHAPTER 1
INTRODUCTION: PROTEASE REPORTING AND MOLECULAR IMAGING
THROUGH FLUORESCENCE
1.1. Caspases and the apoptotic pathway
Apoptosis, or programmed cell death, is an essential pathway in eukaryotes. It is
critical for proper development and homeostasis. It is also one of the most widely
targeted pathways for drug design in the search for treatments for a diverse array of
diseases affected by its
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Mitochondrial Stress
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Apoptotic proteins are
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in the search for

Active Caspase-8
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groups work to find
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Figure 1.1. Apoptosis can be initiated through either the
unwarranted cell death
caspase-8 dependent extrinsic pathway or the caspase-9
dependent intrinsic pathway. Both the extrinsic and intrinsic
apoptotic pathways converge on the executioner caspases-3, -6, in diseases such as
and -7 ultimately leading to cell death. (Thanks to KP for
Alzheimer’s or to
figure)
minimize cellular destruction after a heart attack or stroke. One of the most popular and
plausible classes of proteins within the apoptotic pathway for successful drug targeting is
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the family of proteases known as caspases. Caspases are expressed in an inactive or
zymogen form in all cells and are held at bay until cell death is triggered. Apoptosis can
proceed through one of two pathways, an intrinsic pathway and an extrinsic pathway (Fig.
1.1). The intrinsic pathway is initiated through the release of pro-apoptotic factors, such
as cytochrome c, from the mitochondria. Cytochrome c then goes on to form a
heptameric complex with Apoptotic Protease Activating Factor-1 (Apaf-1), dATP, and
procaspase-9. The formation of this complex activates caspase-9 to cleave target enzymes,
which include caspases-3, -6, and -7, known collectively as the executioner caspases. In
the extrinsic pathway pro-apoptotic cytokines are bound. These receptors can then
associate with Fas associated protein with death domain (FADD) and caspase-8 or -10
and form the Death-Inducing Signaling Complex (DISC) activating caspase-8, which can
also activate the executioner caspases. Once the executioner caspases have been activated
they go on to cleave specific targets in the cell leading to apoptosis. In healthy cells,
however, executioner caspases (-3, -6, and -7) are antagonized by Inhibitor of Apoptosis
Proteins or IAP’s. In cancer cells IAP’s are over-expressed, leading to the repression of
apoptosis. The importance of caspases in apoptosis is central. They catalyze irreversible
protein cleaving reactions leading to apoptosis, which can be inhibited or activated by
small molecules and cellular factors. Understanding the molecular details of the
intricacies of the caspase mechanism of cleavage is critical for the rational design of
drugs for this class of proteins. It is also important to fully understand their collective and
unique roles in developmental processes as well as any non-apoptotic roles they may
have within normal cellular processes.
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Caspases are a class of cysteine

A

aspartate proteases and share a common
active-site diad (cysteine-histidine) (1).
They also share similar specificity for
substrate proteins, cutting after aspartate

B

Pro!

Large!

residues by cleaving the amide bonds in a

Small!

nucleophilic attack by the cysteine thiolate
at the amide carbonyl in specific aspartatecontaining motifs (2) (Fig. 1.2A). All
caspases are expressed as inactive
zymogens known as ‘procaspases’ that
immediately dimerize post-translationally.
The executioner caspases are constitutive
dimers that are activated through cleavage
Figure 1.2. Caspases share a common
active-site cysteine-histidine diad in
by an initiator caspase at two sites releasing
cleaving their substrates (A). Active
caspases are a heterotetramer of two large
the pro-domain and generating a large and
and two small subuints after cleavage of
the pro-domain and intersubunit linker (B)
small subunit (Fig. 1.2B). The active form
(Figure generated by SN in Pymol).
is a heterotetramer made of two large and two small subunits. Each active heterotetramer
contains two active sites containing what is referred to in protease terminology as a
subsite (S) pocket for substrate to bind. The specific binding site for each of the
recognized residues N-terminal to the cleavage site is referred to as the S1-SX site with
S1 being the residue after which the protease cleaves. The binding pocket which
accommodates the residue immediately prior to which the protease cleaves is referred to
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as the S1’ site. The substrate or peptide (P) is named similarly, with the residue after
which the protease cleaves being the P1 residue and the site prior to which the protease
cleaves the P1’ residue (Fig. 1.3).
One of the preferred substrate cleavage sequences for the executioner caspases -3
and -7 is the amino acid sequence DEVD (P4-P1) (3). Synthetic substrates with this
sequence are recognized by the executioner caspases. Since the study of caspases is so
important to understanding both

!"#$%"&'!(&)*+),-.,"&

P4-P3-P2-P1-P1’-P2’-P3’-P4’
S4-S3
3’-S4’
-S2-S
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disease and development, the ability to
monitor caspase activity both in vivo
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and in vitro is likewise critically

Figure 1.3. The substrate (S) binding pocket
of the protease accommodates the peptide
substrate (P) which is cleaved between the P1
and P1’ residues. (Figure generated by SN)

important. For the investigation of
caspase activity in vitro the most

common reporters are fluorogenic peptide substrates. These reporters are peptides
containing a sequence that can be recognized by a particular caspase and a covalently
attached fluorophore (3). The fluorophore is quenched while covalently coupled but gains
fluorescence upon cleavage.

1.2. Existing caspase reporter technologies
Apoptosis is a critical cellular process in the regulation of homeostasis and is an
important target in drug design. This significance has driven researchers to develop
several reporters of apoptotic and caspase activity, with the most common technologies
using small synthetic fluorogenic peptides that act as caspase substrates. While these
substrates have an exceptional signal-to-noise ratio (50,000) they are primarily useful in
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in vitro or cell-based applications but cannot be used in living organisms without
sacrificing the animal. One of the most useful of these reagents is the tetrapeptideaminoluciferin reagent Caspase-glo from Promega. In the presence of active caspase-3 or
-7 the aminoluciferin, which is a substrate for luciferase, is cleaved from the peptide.
When luciferase is added it produces a luminescent signal proportional to the caspase
activity which can be used in high-throughput screening of in vitro caspase activity or
whole cell caspase and apoptosis screens. This reagent is widely used and amenable to
several systems (4). However recent studies from our own lab have also shown that there
is a significant difference in the kinetics of cleavage of peptide substrates vs. protein
substrates (5) indicating that these short peptide substrates may not accurately reflect the
in vivo cleavage by all proteases. Therefore, there is a great need for a genetically
encoded caspase reporter that is more similar to a protein substrate and thus more
accurately reflects the activity of caspases against native substrates.
Several existing technologies use green fluorescent protein (GFP) and its variants
to report caspase activity in live cells. Park et al. have developed a GST-DEVD-EGFP
reporter, which is presented as a cost effective alternative for the expensive fluorescent
substrates currently used. They use the GST tag as a mechanism for anchoring the
reporter on GST-beads or by immobilization on a chip. After the addition of caspase and
a washing step, they can see cleavage has occurred both through immunoblotting as well
as by the loss of fluorescence which can be quantified (6). The obvious drawback is that
this is an on-to-off reporter, so small changes in caspase activity cannot be discerned and
this technology is not compatible with in vivo applications.
Many of these technologies use GFP or it’s derivative proteins, which fluoresce at
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a variety of wavelengths in a fluorescence resonance energy transfer (FRET) pair, or in
some combination with another fluorescent protein. FRET is a commonly used technique
in which fluorophores of two distinct excitation and emission wavelengths are used to
indicate proximity to one another. When the donor of the FRET pair is in close proximity
to the acceptor the emission of the donor excites the acceptor and the fluorescence at the
acceptor emission wavelength can be detected. When the pair of fluorophores is far apart
the signal from the acceptor drops off and only the donor wavelength can be detected.
Many of these FRET systems are based on reporters containing cyan and yellow
fluorescent protein variants fused through the DEVD caspase cleavage site. One of these
Cyan/Yellow reporters, SCAT3, which uses ECFP and Venus fluorescent proteins, has
been successfully used to perform live imaging of caspase activation in both Drosophila
and mice (7-9). Another FRET based caspase reporter is a real-time monitoring reporter
using double FRET CFP (cyan fluorescent protein)/YFP (yellow fluorescent protein)
/dsRFP (red fluorescent protein) reporting (10) . This system was used to correlate an
apoptotic timeline for multiple caspases in live cells under the induction of apoptosis.
Though the system could report apoptosis, it also displayed a very high background from
the multiple fluorescent proteins present in the cells at once, which is a limitation of all
the FRET based reporters. More recent developments of these FRET reporters have
developed FRET pairs which utilize green/red fluorescent proteins which decreases the
background. One example is CaspeR3, which fuses TagRFP and TagGFP through a 13
amino acid linker containing the DEVD cleavage site in the linker (11). While this
improves the signal over the Yellow/Cyan pair reporters, a dark-to-bright transition still
has an advantage in terms of its low background signal.
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One of the most notable of the existing caspase activity monitors is a reporter
molecule named ‘Apoliner’. Apoliner is a reporter fusion of a membrane signaling
sequence (mCD8), mRFP (monomeric red fluorescent protein), a caspase cleavage
recognition site, and EGFP. Before apoptotic cleavage the EGFP and mRFP can be
visualized in the membrane via confocal microscopy. When apoptosis is induced and
Apoliner is cleaved the EGFP is trafficked to the nucleus, physically separating the EGFP
and mRFP signals (12). However, Apoliner, like many of the technologies discussed
above, can only be utilized via microscopy.
Another reporter utilizes a GFP with diminished fluorescence in a fusion
construct that relies on N-rule cleavage, but this reporter in particular only reports a fivefold increase in the fluorescence after cleavage (13). Another reporter named the
multimodality reporter takes advantage of the plethora of imaging technologies by
making a reporter of a fluorescent protein, mRFP, a bioluminescence reporter, Firefly
Luciferase, and a positron emission topography reporter, thymidine kinase (14). While
this reporter was successful in tracking cleavage in vivo there was a very high
background and the increase in signal of any of the three reporters was only 2–fold,
which leads to a problematic signal to noise ratio.

1.3. Design of a genetically encoded dark-to-bright reporter
After assessment of the current technologies available for monitoring caspase
activity in a variety of systems, we determined the criteria we deemed most important in
the design of a novel reporter of apoptosis. First, it should be genetically encoded for
non-invasive monitoring. Genetically encoded reporters have an advantage in that they
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can be expressed in
individual cells eliminating
the need for cellular
delivery, reducing
potentially damaging effects
on the cell. This also
enables the reporter to be
expressed and purified
Figure 1.4. The CA-GFP is constructed of Green
Fluorescent Protein fused through a linker containing the
caspase-7 cleavage recognition sequence DEVD to the
M2 transmembrane domain, which quenches GFP
fluorescence. After cleavage by active caspase the GFP
fluoresces yielding a useful reporter of caspase activity.
(Figure generated using manual modeling of linker and
peptide fusion to GFP by SBN using Pymol)

which is cost effective in
comparison to many
expensive fluorogenic
peptide substrates.
Secondly, the response

should be a dark-to-bright fluorescence signal as fluorescence is by far one of them most
widely used methods of monitoring signal. By having a dark-to-bright response the
signal to noise ratio is maximized, allowing for unambiguous monitoring of activity. It
should also respond independently of any cellular co-factors for ease in detection. As the
system we wish to study is directly responsible for the degradation of protein substrates
within the cell, the response should be independent of any cellular pathways which will
ultimately be disrupted. Lastly, our ideal reporter should
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Table 1.1. Comparison of Existing Technologies to CA-GFP.
Temporal
Resolution

S/N
Ratio

Ac-DEVD-AFC
No
No
In Vitro
No
FRET
Yes
Yes
In Vivo/In Vitro
Yes
BRET
Yes
Yes
In Vivo/In Vitro
Yes
NES-DEVDYes
Yes
In Vivo/In Vitro
No
EYFP-NLS
Mem-mRFPYes
Yes
In Vivo
No
DEVD-NLS-EGFP
Ubiquitin-LETDYes
No
In Vivo
No
EGFP
PepA-NlucYes
Yes
In Vivo/In Vitro
No
DEVD-Cluc-PepB
CA-GFP
Yes
Yes
In Vivo/In Vitro
Yes
be amenable for in vitro, E.coli, FACS, mammalian cell and whole organism

High
Low
Low

Reporter

Genetically
Encodable

Multicolor

Organism

Low
Low
Low
High
High

applications. Each of these systems has distinct advantages in the study of apoptosis and
in the development of effectors of caspase activity.
In this work, Green Fluorescent Protein (GFP S65T), a mutant of GFP wherein
the chromophore is mutated to achieve an increase in fluorescence (15), was fused
through a linker to the transmembrane region of the influenza A protein M2 (Fig. 1.4).
The resulting fusion protein lacked the intrinsic fluorescence of GFP while still being
stably expressed in E. coli. To take advantage of this dark state the cleavage recognition
sequence for effector proteases caspase-3 and -7 (DEVD) was inserted into the linker
region of the construct. In the presence of active caspase the M2 peptide is cleaved and
the protein is able to fluoresce. Because of the low fluorescent background of the dark
state of caspase-activatable green fluorescent protein (CA-GFP) there is a clear signal of
caspase activity after the peptide has been cleaved. CA-GFP fulfills our criteria for an
ideal reporter and offers several advantages in its properties over existing technologies
(Table 1.1). We have sought to take advantage of this novel reporter of apoptotic activity
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as well as understand the mechanism through which the M2 peptide is able to quench the
GFP fluorescence. Here, we put forward a versatile and tunable platform for proteolytic
activity reporting and give mechanistic insight to help in the development and expansion
of this family of protease-activatable fluorescent proteins (PrA-FP’s).

1.4. The Fluorescent Protein Family
The importance of GFP and its many derivatives has been highlighted by the 2008
Nobel Prize in Chemistry being awarded to three of the most prominent researchers
responsible for the discovery of GFP and the development of numerous techniques
utilizing GFP. GFP was identified in the early 1960’s by Osamu Shimomura when the
protein was isolated from the jellyfish Aequorea victoria (16). Though Douglas Prasher
was the individual responsible for first cloning the GFP gene (17), it was further
investigated and expanded upon by the groups of Martin Chalfie and Roger Tsein with
whom Shimomura shares the Nobel Prize. Structural characterization by crystallography
was central to understanding how GFP functions (18). The fluorescent capabilities of the
protein are the result of a post-translational modification of three residues, Ser65-Thr66Gly67, in the center of the β-barrel structure of the protein, which form the chromophore.
When GFP is properly folded, the conformation of the helix in the center of the β-barrel
induces formation of the chromophore.
The research community did not just stop with a green fluorescent protein but
have expanded the color palette through extensive engineering to include other green,
yellow and cyan proteins. This was accomplished by rational design as well as through
directed evolution, performing point mutations on and around the chromophore region of
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GFP (19). The discovery of a homologous protein dsRed in a coral species by Sergey
Lukyanov (20) led to the development of a family of red fluorescent proteins extending
the range of the color palette into the near IR region and increasing the utility even
further of the fluorescent family of proteins. The Tsein lab has gone on to engineer a
protein, not related to the GFP or dsRed proteins, but with a very different structure
which emits light in the infrared range (21), further extending the capabilities of this large
class of molecular tools. Fluorescent probes with a further red-shifted emission
wavelength have a greater tissue depth penetrance and are therefore more useful in whole
organism imaging (22,23). The near IR and IR shifted variants are increasingly in
demand as imaging technology targeting cancer and other cell types of interest with
fluorescent labels improves.
Wild-type GFP is rarely used today; enhanced GFP (EGFP) is a commonly used
version that contains two fluorescence enhancing mutations, S65T and F64L. The
combination of these two mutations enhances the fluorescence intensity at the 488 nm
peak, normally the minor excitation wavelength, to 35 times that of wild type (15). This
allows for the use of FITC (Fluorescein IsoThioCyanate) filters, common in many
fluorescence instruments, to be used in exciting GFP. Also used commonly are the GFP
cycle 3 mutant (24) and a superfolder GFP (25). These mutants were engineered to have
a faster folding and chromophore maturation and to reduce aggregation.
Several groups have independently developed versions of GFP for protein
complementation assays. The general design of these reporters is that a portion of GFP
sequence is expressed independently from the rest, with one or both of the pieces fused to
a protein of interest. The two sections can range from being approximately equal in size
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as the versions developed by the Regan (26) and Kerppola (27) groups to the ‘split-GFP’
developed by the Waldo group which only removes the final strand of the β- barrel (28).
When the two independently expressed portions of GFP are drawn within close proximity
to each other by the interactions of their fusion partners they are able to assemble into the
β-barrel geometry, allowing for chromophore maturation. These split or bi-furcated
constructs are useful in determining if and where specific proteins of interest interact in a
cell.
Besides developing a variety of different colored fluorescent proteins, researchers
have also gone on to develop various reporter or ‘optical highlighter’ proteins. These
include proteins such as a photo-activatable GFP(29), Eos(30), Kaede(31), Dronpa(32),
and Kindling(33) proteins that have the ability to switch from either fluorescently ‘off’ to
‘on’ or green to red fluorescence when activated with UV light (for review see (34)) .
Kindling and Dronpa have the added benefit of being reversible in their transitions.
Kindling Fluorescent protein-1 (KFP1) can convert to red fluorescence upon irradiation
with green light. This state can relax back to non-fluorescence in the dark or can be
quenched back to the non-fluorescent state by irradiation of blue light (31,34). Dropna,
named after the Japanese word for the disappearance of a ninja, initially has green
fluorescence. This green fluorescence can be quenched by blue light to a non-fluorescent
state. It can then be activated to fluorescence by 400 nm irradiation in a reversible
process that can be repeated several times (32,34) .These photoactivatable fluorescent
proteins are an excellent tool for precise labeling and tracking of a variety of targets in
living systems as well as a great tool in kinetic microscopy, a field previously dominated
by fluorescence recovery after photobleaching (FRAP) techniques. However,
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photactivatable GFP variants have limited applicability outside of confocal microscopy
because these proteins only respond to exogenous visible or UV illumination but can not
directly respond to cellular or enzymatic cues.
1.5. GFP Structure and Chromophore Formation
GFP is formed by a stable β-barrel through the assembly of eleven β strands (Fig.
1.5) with a kinked helix formed on the interior of the barrel containing the three
sequential residues which make up the fluorescent chromophore (Fig. 1.6A). The three

Figure 1.5. GFP is formed by the assembly of 11 strands, shown as arrows, to form a βbarrel with a helix, shown as a cylinder at the center of the barrel, which contains the
three residues that undergo posttranslational modification to form the fluorescent
chromophore. (Figure generated by SBN)
amino-acid chromophore of wild-type GFP is formed by a cyclization reaction in which
the amide nitrogen of Gly67 initiates a nucleophilic attack on the carbonyl carbon of
Ser65, forming an imidazolone ring. The ring is then oxidized to a cyclic imine and the
carbonyl oxygen of Ser65 is dehydrated, fully conjugating the system and forming the
benzylidenedimethylimidazolinone chromophore (Fig. 1.6B). The chromophore is
protected from solvent within the stable β-barrel of GFP, allowing it to fluoresce. This
barrel is a very stable fold which is resistant to proteolysis (35) and has denaturation
temperatures nearing 80°C (36,37). The fold and ability of the chromophore to mature is
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also retained in several circularly permuted versions of the protein (38).

Figure 1.6. The three-dimensional structure of the GFP β-barrel (PDBID: 2YOG) with
the chromophore shown in sticks in the center of the barrel (A). The chromophore
undergoes an oxidation and dehydration to form the mature fluorescent form of the
protein (B). (Figure generated by SN using Pymol and Chemdraw)
Chromophore maturation is essentially irreversible, however, fluorescence can be
quenched through denaturation (39), exposing the chromophore to solvent, as well as
changes in pH (39,40) and physical compression (41). In each case quenching is
reversible by restoring the GFP to initial conditions, reestablishing the protection of the
chromophore and fluorescence is nearly immediately restored. As the fluorescence of
GFP is closely tied to the fully folded form of the protein it is often used as a model for
protein folding. It has been seen that the fluorescence is recovered much more quickly in
the case of fully-mature protein which has been denatured in vitro vs. that of protein
which has never attained the correct fold and therefore never matured (42). The in vivo
folding kinetics have been shown to be much longer than refolding kinetics (42). It is
hypothesized that the oxidation step is the slow step in the in vivo chromophore
maturation kinetics (43,44).
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1.6. The M2 Transmembrane Domain
The second protein in the fusion described in this document is the transmembrane
domain of the M2 protein, from influenza A virus. The selection of the M2
transmembrane domain was serendipitous when we discovered that fusing of the peptide
to the C-terminus of GFP resulted in a ‘dark’ fusion protein. The function of this protein
is to selectively channel protons. Mechanisms for transporting and channeling protons
through native membranes exist in nature. Several of these proteins are large integral
membrane proteins that contain several domains. M2 is a four helix bundle, the
transmembrane domain of which has been shown to
be responsible for proton transport (45). M2 also has
a very high selectivity for protons over other ions and
water (46). In order to fully understand the role that
the M2 peptide is playing in the quenching
mechanism of CA-GFP, it is important to recognize
Figure 1.7. M2 facilitates
dissociation of the coat proteins
and release of viral DNA
(Figure generated by SN)

what is known about the structure and properties of
this transmembrane domain.

This region has been extensively studied by several groups in order to determine
M2’s structure and mechanism. (47-49). M2 is a proton channel that has been shown to
be essential for the infection of the influenza virus. It has two main functions in the viral
life cycle. After the virus has been internalized by the host cell, it is delivered to the
secondary endosome. The mildly acidic pH of the endosomal compartment activates the
M2 channel, which permits protons to flow into the virion interior, decreasing the pH
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within the virion. This allows dissociation of the coat proteins, which can then release the
viral DNA for entry in the nucleus (Fig. 1.7). The second function of M2 is at a later
stage of the virus life cycle, when it is used to reduce the pH of the Trans-Golgi Network
(TGN). This function is necessary to increase the pH in vesicular compartments in order
to protect acid sensitive proteins prior to virus assembly (50,51) . The transmembrane
region of this channel has been widely investigated as a possible drug target for the flu
since inhibition of the channel should prevent viral replication (52,53).
The full-length M2 protein is 97 amino acids long with a 25-amino acid
transmembrane region located between a shorter N-terminal extracellular sequence, and a
larger intracellular C-terminal sequence. The transmembrane region forms a four-helix
bundle in which the α-helices pack with a 30-37° crossing angle (49,54) (Fig.1.8). This
transmembrane domain is studied independently of the full-length protein in most studies
and synthetic versions of the peptide have been seen to tetramerize and function as a
proton channel in this truncated form. There are currently several structures of the M2
transmembrane domain both with and without inhibitors amantidine and rimantadine
(Fig. 1.8). Two residues, His37
and Trp41, located at the Cterminus of the peptide are
responsible for the ‘gating’ of
the proton channel’s function. It
Figure 1.8. Structure of the M2 transmembrane channel at is widely accepted that when
pH 7.5-8 (PDBID: 2RLF) left, at pH 6.5 (PDBID: 3LBW)
the four His37’s in the bundle
center, and at pH 5 with inhibitor rimantadine bound
(PDBID :3BKD) right. The gating tryptophan residues are
shown as spheres. (Figure generated by SN using Pymol) are protonated they cause a
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conformational change in the nearby Trp41’s at the base of the channel (50,55). This
conformational change causes the channel to go from a ‘closed’ to an ‘open’
conformation which allows protons to flow through the channel (Fig. 1.8) (55-57).
Another proposed mechanism is that the helices themselves shift to allow protons to pass
in the open confirmation (47). Still another is that the channel itself is large enough to
hold water molecules and that the conformational change in the tryptophans allow only
the protons to be passed via a water bridge, but not entire water molecules (47). A recent
analysis of crystal structures of the pore at increasing pH values suggests that the
mechanism is based on both a conformational rearrangement of the helices as well as
proton movement through the pore (58). Kinetic data on the M2 current can fit either
Grotthus (proton hopping) or proton shuttling mechanisms, adding to the debate (59,60).
The extensive characterization of both the M2 transmembrane domain as well as
GFP in terms of their structure have been pivotal in understanding the underlying
mechanism of the dark state of CA-GFP. Throughout this thesis we show the variety of
potential applications of this unique dark-to-bright reporter (chapter I), our model for the
quenching mechanism of the dark state (chapter II), and our efforts to expand upon and
understand the limits of this reporter for broader applications (chapters IV and V). Our
goal is that through a detailed understanding of the mechanistic details of CA-GFP we are
able to better engineer a reporter which can be used not only for deconvolution of
individual caspase roles in the apoptotic pathway, but be useful in monitoring the activity
of any enzymatic process, such as phosphorylation and ubiquitination, in the cell.
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CHAPTER 2
CA-GFP: A GENETICALLY ENCODED DARK-TO-BRIGHT REPORTER FOR
CASPASE ACTIVITY

This chapter was published in part as: Nicholls, S.B., Chu, J., Abbruzzese, G., Trembley,
K.D., and Hardy, J.A., 2011. “Mechanism of a Genetically Encoded Dark-To-Bright
Reporter for Caspase Activity.” The Journal of Biological Chemistry, Vol. 286, No. 28,
24977-24986. SBN performed all purifications and biochemical assays as well as
experiments in bacterial cells and lysate. JC performed experiments and fluorescent
microscopy in mammalian cells. GA performed FACS experiments and analysis.

Abstract
Fluorescent proteins have revolutionized modern biology with their ability to
report the presence of tagged proteins in living systems. Although several fluorescent
proteins have been described in which the excitation and emission properties can be
modulated by external triggers, no fluorescent proteins have been described that can be
activated from a silent dark state to a bright fluorescent state directly by the activity of an
enzyme. We have developed a version of GFP in which fluorescence is completely
quenched by the appendage of a hydrophobic quenching peptide. The fluorescence can
be fully restored by catalytic removal of the quenching peptide, making it a robust
reporter of proteolysis. We have demonstrated the utility of this uniquely dark state of
GFP as a genetically encoded apoptosis reporter that monitors the function of caspases,
which catalyze the fate-determining step in programmed cell death. Caspase ActivatableGFP (CA-GFP) can be activated both in vitro and in vivo, resulting in up to a 45-fold
increase in fluorescent signal in bacteria and a 3-fold increase in mammalian cells. We
used CA-GFP successfully to monitor real-time apoptosis in mammalian cells.
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2.1 Introduction
The ever-growing palette of fluorescent proteins has arguably become the most
widely used set of tools in cell and developmental biology. These fluorescent proteins act
as markers for visualization of cellular processes, localization, gene expression patterns,
and protein function. A spectrum of fluorescent proteins are now available, further
expanding the multi-factorial imaging possibilities [for review see Ref. (1)]. The
variously colored, split and photo-activatable fluorescent proteins [for review see Ref.
(2)] are excellent tools for precise labeling and tracking of a variety of targets in living
systems, but there is still a need for tools that can report on the functional state of the
protein they interrogate. Many proteins are only activated by a post-translational event, so
genetically encoded fluorophores that undergo a change in fluorescent properties in direct
response to enzymatic action would meet this need. A dark-to- bright fluorescent reporter
would be especially useful for reporting enzymatic activity, as the low intrinsic
background would allow robust detection of even relatively rare events. Such a reporter
could enable the same level of real-time, noninvasive, longitudinal studies of enzymatic
activity as parent fluorescent proteins have enabled on expression and localization.
In an effort to develop and characterize a dark-to-bright activatable GFP, we
sought to apply our reporter to a complex biological pathway that would allow thorough
characterization of the quenching mechanism and kinetics of activation both in vitro and
in vivo. We ultimately selected apoptosis, the process of programmed cell death.
Apoptosis is essential for embryonic patterning and vertebrate development at all stages
and is causally involved in up to half of human diseases lacking suitable treatment (3).
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Thus, methods for monitoring apoptosis longitudinally would provide a full temporal
understanding of the contributions of apoptosis to tissue formation, remodeling, response
to drug treatment, and disease progression.
Apoptosis can be activated through an intrinsic caspase-9/apoptosome-dependent
pathway or through an extrinsic, caspase-8/DISC complex-dependent pathway. Caspase8 and -9 are apical initiators in the proteolytic cascade cleaving and thereby activating the
downstream executioners, caspase-3 and -7. Cleavage of caspase-3 or -7 removes a
prodomain and cuts an intersubunit linker, generating a small and a large subunit from
each half of the dimer. Activated executioner caspases then cleave a select group of
substrates (4), sentencing the cell to death. Caspase activation is the fate-determining step
in the irreversible onset of apoptotic cell death, so they offer the most accurate and
sensitive enzymatic indicator of apoptosis. Caspases show exquisite specificity for
cleaving after aspartic acid residues in well-defined recognition sequences. The
recognition specificities of the executioner caspases have been extensively mapped in
vitro (5-9) and in vivo (10,11). The canonical and widely used recognition sequence
comprising the amino acids DEVD remains an appropriate and selective sensor of
executioner caspase activity (12).
Executioner caspase activity can be quantified using fluorogenic peptide
substrates containing a caspase-recognition sequence linked to a synthetic fluorophore,
whose fluorescence is completely quenched prior to cleavage (13). The synthetic nature
of these peptide reporters clearly precludes their expression in living systems. A great
deal of effort to date has focused on developing genetically encoded fluorescent apoptosis
reporters based on cleavage by caspases. Because of the pervasive need for monitoring
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apoptotic cell death, several clever genetically encoded apoptosis reporters have been
developed.
The largest class of genetically encoded apoptosis reporters uses fluorescence
resonance energy transfer (FRET) pairs separated by caspase cleavage sites. These
reporters monitor a change in the FRET intensity upon caspase cleavage (14-16). The
multimodality reporter uses copies of the caspase-recognition sequence to link a
fluorescent protein, a bioluminescent protein, and a positron emission tomography
reporter, which can each be more readily detected after caspase cleavage (17). The
Apoliner and ApoAlert™ reporters use nuclear localization sequences to target a
fluorescent protein to the nucleus following caspase cleavage (18). Apoptosis in these
cells can be visualized based on changes in fluorescent protein localization. Another
reporter relies on destruction of green fluorescent protein (GFP) using a tag for ubiquitindependent degradation, which can be proteolytically removed by active caspase (19). The
continued development of apoptosis reporters suggests that none to date have fully
optimized brightness, sensitivity, and reporting mechanism.
An ideal apoptosis reporter would be genetically encodable, yet function in vitro,
have very low background and high signal, consist of a single activatable fluorophore
requiring no cofactors or additional biological processes, and be amenable to use in
whole organisms, cells, microscopy, and flow cytometry. The caspase activatable- green
fluorescent protein we have developed meets all of these criteria. The dark-to-bright
transition in direct response to enzymatic activation constitutes a new class of fluorescent
reporter.
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2.2 Results
2.2.1 Design of CA-GFP
Within the goal of developing a new dark-to-bright version of GFP, we sought an
application area that would provide stringent activity requirements and a useful and
interesting framework for characterization of the quenching and dark-to-bright transition
both in vitro and intracellularly. We selected the proteolytically controlled pathway of
apoptotic cell death as a first application for the dark-to-bright version of GFP.
Fusion of a variety of proteins has been observed to silence GFP fluorescence
(20) which led us to design a
fluorescent reporter based on this
quenching principle (Fig. 2.1). We
discovered that fluorescence of GFP
(S65T) is quenched completely
(0.9–1.5% of GFP fluorescence
Figure 2.1. CA-GFP consists of Green fluorescent
protein (green) fused through a flexible linker
containing the caspase-3 and -7 recognition sequence
DEVD (blue) to a 27-amino acid quenching peptide
on the C-terminus (gray). After cleavage of the
peptide by active caspase GFP fluorescence is
recovered, shown in the manually rendered models
(bottom)

remained) when our first candidate,
a 27-amino acid peptide derived
from the tetrameric proton channel
domain of influenza M2 protein,
was fused to the GFP carboxy

terminus (Fig. 2.1). This full quenching proved to be an important component in
maximizing sensitivity. To make a caspase-activatable GFP (CA-GFP) the caspase
recognition sequence (DEVD) was inserted between GFP and the quenching peptide.
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2.2.2. CA-GFP Can Be Activated and Observed in Cells
To assess the response of CA-GFP to active caspase, CA-GFP was expressed in
bacterial cells in the presence or absence of full-length active caspase-7 or the
catalytically inactive C186A mutant. Only co-expression with active caspase-7 resulted
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similar kinetics (21), further

Figure 2.2. CA-GFP becomes fluorescent only upon
cleavage by active caspase. Cleavage and
fluorescence of bacterially co-expressed CA-GFP
with active (WT) or inactive (C186A) caspase-7.
Full-length caspase-7 undergoes auto-zymogen
processing to generate the active, two-chain form of
caspase-7. Mutation of the catalytic cysteine in the
C186A mutant yields the inactive single chain
procaspase-7 zymogen. Fluorescence of CA-GFP in
lysates is shown on top; there is a 45-fold increase in
fluorescence in the presence of active caspase-7.
Immunoblot probed with anti-caspase-7 large
subunit antibody is shown at center with an
immunoblot probed with anti-GFP antibody shown
at the bottom. CA-GFP is only fluorescent after
cleavage in the presence of active caspase.
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supporting the conclusion that the
increase in fluorescence is due to
caspase proteolytic activity. The
gain of GFP fluorescence in the
presence of wild-type caspase-7
(Fig. 2.2 top) correlated with
cleavage of CA-GFP by caspase
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microscopy (Fig. 2.3A
and B). Cells expressing
Figure 2.3. CA-GFP fluorescence is robust enough for
fluorescence microscopy and flow cytometry. BL21 (DE3) E. CA-GFP alone or with
coli cells expressing (A) CA-GFP alone or (B) CA-GFP with
inactive caspase-7 C186A or (C) CA-GFP with active wildinactive caspase-7
type caspase-7. Differential interference contrast (DIC) images
(left). Fluorescent microscopic images (center) of live cells.
showed no green
Intact cell flow cytometric analysis of GFP fluorescence (right)
listing the fraction of cells with GFP fluorescence. Scale bars
fluorescence, whereas
represent 10 µM.
CA-GFP expressed with wild-type caspase-7 yielded cells that were visibly green (Fig.
2.3C). These populations are also distinguishable by flow cytometry. 90% of cells
expressing CA-GFP with active caspase-7 are fluorescent, whereas fewer than 1% are
green in the absence of caspase activity.

2.2.3. CA-GFP is an apoptosis reporter in mammalian cells
While CA-GFP responds robustly to the activity of human caspase expressed
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heterologously in bacteria, perhaps the most significant application for CA-GFP is as a
reporter of apoptosis in mammalian cells, where caspase activity governs apoptotic cell
death. Treatment of CA-GFP-transfected NIH 3T3 cells with staurosporine (STS), a
documented apoptosis inducer (22-24), resulted in a time-dependent change in cell
morphology, which is consistently observed during apoptosis (Fig. 2.4A). !!A
concomitant increase in cellular CA-GFP fluorescence was also observed as expected
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Figure 2.4. CA-GFP is fluorescently activated in mammalian cells
undergoing apoptosis. A, fluorescent response of CA-GFP-transfected
NIH 3T3 cells at indicated times after induction of apoptosis with
staurosporine (STS). Scale bar represents 50 µm. Br; Brightfield
microscopy. G, GFP fluorescence. B, CA-GFP cleavage after induction of
apoptosis is observed as a function of time by immunoblotting with an
anti-GFP antibody. C, appearance of cleaved caspase-3 was observed
after induction of apoptosis by immunoblotting with an anti-caspase-3
antibody. Tubulin was probed as a loading control. D, fraction of
transfected cells that are fluorescent (white bars) and fraction of cleaved
CA-GFP (black bars) in cells induced to undergo apoptosis. *,
significance level; p_0.05 relative to zero time point.
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(Fig. 2.4A, lower panels). Cleavage of CA-GFP was monitored by Western blot for GFP
at various times after induction of apoptosis. A smaller fragment of cleaved CA-GFP
appeared as a function of time after treatment with staurosporine (Fig. 2.4B). Cleavage of
CA-GFP was consistent with the appearance of cleaved (active) caspase-3 (Fig. 2.4C).
The observation that both GFP fluorescence and CA-GFP cleavage increase during
apoptosis (Fig. 2.4D) indicates that CA-GFP functions as a mammalian apoptosis
reporter on a population level. In control cells, increases in fluorescence, CA-GFP
cleavage and the appearance of active (cleaved) caspase-3 were all correlated suggesting
that CA-GFP is sensitive enough to report on even low levels of active caspases.
To uncover the details of CA-GFP expression and activation in mammalian cells,
we performed time-lapse imaging of single cells expressing CA-GFP. To afford an
internal, optically distinct fluorescent control, we generated the expression construct CAGFP-IRES-mLumin that constitutively expresses both CA-GFP and the red fluorescent
protein mLumin, which is a brighter, more photostable derivative of mKate (25). After
addition of staurosporine to induce apoptosis, GFP fluorescence increased markedly (Fig.
2.5A). CA-GFP begins to be activated immediately and appears to remain localized in the
cytoplasm for 3 h until the nuclear membrane is permeablized. This is consistent with
previously reported executioner caspase activity, which is cytoplasmic in the early stages
of apoptosis (26), however, this is the first observation of the direct relationship of
caspase activity to the loss of the nuclear membrane integrity. Notably, the red
fluorescence of mLumin is present throughout the cell, including inside the nucleus prior
to apoptosis. In untreated control cells, green and red fluorescence increased minimally
and to approximately the same degree over the time course of the observation (Fig. 2.5B).
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Red fluorescence also increases during apoptosis, due to shrinking of the volume of the
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Figure 2.5. The response of CA-GFP can be measured in single cells
undergoing apoptosis. A, time-lapse confocal images of NIH 3T3 cells coexpressing CA-GFP and mLumin were recorded at the indicated times
following treatment with STS (A) to induce apoptosis or without STS
treatment as a control (B). DIC; differential interference contrast images
showing changes in cell morphology. G, green channel monitoring CA-GFP
fluorescence. R, red channel, monitoring mLumin (control) fluorescence.
Scale bar represents 25 µm. B and C, ratio of green (GFP)/red (mLumin)
fluorescence for (C) untreated control or (D) staurosporine-treated cells.
Ratios for six (C) or four (D) independent cells were measured. The G/R ratio
of cells 1 and 2 shown in panel (A) are indicated as 1 or 2 in plot (D).!
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cell, which is a hallmark of apoptosis (27). Quantification of the green and red signals
showed that only CA-GFP responds to apoptotic stimuli.
The ratios of green/red fluorescence for the untreated control cells (Fig. 2.5B) and
for the staurosporine-treated cells induced to undergo apoptosis (Fig. 2.5A) were
quantified. The appearance of GFP fluorescence in apoptotic cells appeared with related
kinetics in all cells, however, cell-to-cell variations were observed. The variation in the
kinetics of GFP fluorescence occurred in a manner that is consistent with cell-to-cell
differences in morphological changes and cell death kinetics. One of the apoptotic cells
observed had very low fluorescence, which may be due to lower efficiency of
transfection in that cell (the lowest green/red ratio Fig. 2.5C and 2.5D). The ratio of
green/red fluorescence in the apoptotic cells was 3-fold higher than in control untreated
cells, indicating that CA-GFP responds to apoptotic signals with a 3-fold increase in
signal over background.

2.2.4. CA-GFP in whole animal models
As mentioned previously our ideally designed reporter would be a useful tool not
only in vitro, in bacterial systems, in mammalian systems, and in FACS sorting, but also
in whole animal models. One animal model which has been well studied in terms of
developmental apoptosis and is growing in popularity in drug screening applications is
the zebrafish model. Zebrafish are a useful model because of their transparency, allowing
for effective microscopy throughout the development of the embryo, as well as their rapid
development. Zebrafish are also a very well characterized model system, having a fully
sequenced genome as well as extensive mapping of the early stages of development. We
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first began by injecting DNA constructs of
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GFP (S65T) and CA-GFP into zebrafish
embryos. After extensive trials of STS
C

D
!

treatment of wild-type (uninjected) and
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concentrations and the developmental
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stage of treatment, it was determined that
STS treatment was too harsh for the
H
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injected embryos. As the developmental
apoptosis map is well mapped in zebrafish
(28) it was determined that areas known to

Figure 2.6. DNA injection of GFP and CAGFP in zebrafish. The transmitted light
(left) and fluorescence (right) images
embryos injected with Tol2-CMV-GFP (AD) or Tol2-CMV-CA-GFP (E-H). The
embryos shown in (C/D) and (G/H) are
treated with apoptosis inducer hydroxyurea.

undergo apoptosis at specific life cycle
stages would be observed for fluorescence
in GFP, CA-GFP, and buffer injected
control embryos. While there was some
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observable difference in CA-GFP vs. the
two controls the expected punctate pattern
of apoptosis was not observed.
To address the issue of mosaicity in
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expression our collaborators, the lab of

Figure 2.7. Quantification of fluorescence
Gerald Downes at UMass Amherst in the
of the area of the imaged embryo shows a
10-fold increase in fluorescence signal in the
Biology department, generated a new
treated CA-GFP injected embryos over
those not treated with apoptosis inducer
hydroxyurea. The GFP injected controls did construct for DNA injection, a Tol2-CMVnot show a significant difference in treated
and untreated embryos.
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CA-GFP and Tol2-CMV-GFP, as well as constructs for each CA-GFP and GFP for
generating capped and poly-A-tailed mRNA for injection. They also determined that
treatment of the zebrafish with 30 mM hydroxyurea (HU) triggered effective widespread
apoptosis within the embryos. After injection of embryos with the Tol2-CMV constructs,
fluorescence images of treated and untreated organisms did not appear to show a
difference in the treated or untreated embryos as the fluorescence signal was weak (Fig.
2.6). Fluorescence was quantified over the area of the embryo to show a 10-fold increase
in fluorescence in treated embryos over the untreated control (Fig. 2.7). Though these
results are encouraging as to the success of CA-GFP in zebrafish it appears as though
CA-GFP is not effective in transient expression assays. To be effectively used for single
cell studies the signal-to-noise ratio needs to be improved. Efforts to generate a
transgenic line of zebrafish stably expressing CA-GFP are ongoing.
!
2.3 Discussion
CA-GFP is directly activated by caspase activity and no other cellular
components are essential. On the other hand, one possible reason for the more effective
fluorescent conversion of CA-GFP in bacterial cells over other systems may be the
presence of additional cellular factors, such as bacterial chaperone proteins. In
mammalian cells CA-GFP conversion to the bright state can be seen in 20–40 min, which
is consistent with the timing of caspase activation and the irreversible initiation of
apoptosis (29), suggesting that some cellular factors (potentially macromolecules or
metabolites) accelerate the maturation process over in vitro conditions where maturation
of purified protein is slower (60 min). Therefore, although some maturation time is
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required, CA-GFP still is able to accurately report caspase activity during apoptosis.
Similarly in split GFP, association of the two halves of the protein is not the rate-limiting
step but rather subsequent maturation of the chromophore dictates the kinetics of the
appearance of fluorescence (30). The maturation of CA-GFP in vitro is similar to that of
split GFP (30), which has also proven to be an incredibly useful technology.
CA-GFP is unique among fluorescent protease reporters in its transition from a
quenched dark state to a bright state upon cleavage. This type of reporter was inspired by
small molecule fluorogenic substrates that transition from dark to bright fluorescence
upon protease activity. The utility of a dark-to-bright transition stems from its low
fluorescent background and use of a single fluorophore. The caspase-mediated increase in
CA-GFP fluorescence is 45-fold in bacteria compared with the next most sensitive
reporter, CyPet-YPet, in which a 3.3-fold increase in FRET fluorescence is observed (30).
This gain in fluorescence makes CA-GFP readily applicable to protease profiling in
bacteria and for engineering protease specificity by directed evolution methods using
sorting by flow cytometry. In mammalian cells, the increase in CA-GFP fluorescence is
also higher than other apoptosis reporters. CA-GFP fluorescence increases 3-fold upon
induction of apoptosis and activation of caspases, whereas the next two strongest
reporters give 0.6-fold (19) and 2-fold (17) increases in fluorescence upon caspase
cleavage.
The response of CA-GFP to caspases is not reliant on any other biological
processes, and is therefore suitable for monitoring caspase activity under any cellular
conditions. Other classes of caspase reporters rely on nuclear localization of fluorescent
proteins (18,19) or on proteosome-based degradation and thus are dependent on processes
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such as nuclear translocation, the integrity of the nuclear pores and membrane or proper
functioning of the proteosome to observe apoptosis. During apoptotic cell death all
biological processes ultimately shut down, potentially impacting the utility of reporters
that rely on other biological pathways. The fact that localization of CA-GFP is not
essential for monitoring caspase activity also allows CA-GFP to report on the integrity of
the organellar membranes, as we observed for the first time using our geneticallyencoded reporter and time-lapse imaging. In mammalian cells CA-GFP has proven to be
an effective tool for time-resolved observation of subcellular events in apoptosis. The fact
that CA-GFP shows no fluorescence in the nucleus in early apoptosis suggests that it is
working accurately. The executioner caspases have been shown to localize in the
cytoplasm in the early stages of apoptosis, only entering the nucleus in later stages after
the nuclear membrane has been compromised (26). Caspases have been shown to target
two of the twenty nuclear pore components, Nup93 and Nup96 (31). Once the nuclear
pore is compromised, larger proteins such as caspases and CA-GFP tetramers are able to
pass into the nucleus. CA-GFP requires neither translocation nor additional cofactors and
thus is useful for a wider array of applications than other reporters. These include
monitoring apoptosis in intact living organisms without the need for sectioning or highresolution microscopy and flow-cytometric sorting of apoptosing cells from healthy cells.
The fact that several caspase-reporting technologies have been developed prior to
CA-GFP reflects the importance of apoptosis in modern biomedical research and the
demand for new, better apoptosis reporting methods. CA-GFP combines dark-to-bright
fluorescence, the most positive property of the synthetic peptide-based fluorophores, with
the important advantage of being genetically encoded, to produce a new class of
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apoptosis reporter. We recognize that the CA-GFP platform is also amenable to
substitution of both the protease recognition site and the fluorescent protein leading to
reporters for many proteases in a range of colors (See Chapter IV). A panel of CA-GFP
derivatives of various colors and with various protease sensitivities would enable
simultaneous imaging of a number of proteolytic cascades. It is also possible to envision
engineering reporters based on the silenced state of GFP that respond to the action of
other enzyme families. As we move forward with zebrafish and ultimately mouse models
incorporating CA-GFP we hope to create an important contribution to the study of not
only developmental apoptosis in organisms, but a tool for in vivo drug screening and
toxicity assessment.

2.4. Materials and Methods
2.4.1. Molecular cloning
The gene for dark GFP (S65T) (referred to as GFP from this point forward) was created
by PCR, amplifying the GFP gene using a reverse primer that also encoded the 27 amino
acid quenching peptide derived from the transmembrane region of influenza M2. This
PCR product was ligated into the XhoI and NdeI sites of pET21b (Novagen). A sequence
encoding the linker (LEVLFQGP) was then inserted between the GFP and M2 genes
using a site-directed mutagenesis using overlapping inverted primers and amplification of
the entire plasmid similar to the QuikChange® (Agilent) approach. The newly inserted
linker sequence was then mutated to encode the caspase-7 cleavage recognition site
(DEVDFQGP). The final sequence of CA-GFP protein is GFP with the fusion of
DEVDFQGPCNDSSDPLVVAASIIGILHLILWILDRL at the C-terminus. This construct
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was used for expression and purification of CA-GFP. The CA-GFP gene was then
amplified by PCR and ligated into NdeI and XhoI of the pBB75 vector (a gift from
Adrien Batchelor), which has a p15 origin of replication, different than the pET family of
vectors which have ColE1 origins of replication. This plasmid was used for co-expression
of CA-GFP with caspase-7. The mammalian expression vectors pCA-GFP and
pGFPSTOP were constructed by insertion of the CA-GFP or GFP, obtained by PCR into
the NheI and EcoRI sites of pmKate2-C (Clontech, Palo Alto, CA, USA). CA-GFP from
pCA-GFP was isolated and ligated into the NheI and EcoRI sites of pT-CD8- IRES
SCN2B (a kind gift from Dr. Alfred George, Vanderbilt University) to produce pT-CAGFP-IRES-SCN2B. The resulting plasmid was cut with SalI and NotI and the coding
sequence for mLumin (25) (mKate2-S158A) was inserted, generating pTCA- GFP-IRESmLumin. All constructs were confirmed by sequencing.

2.4.2. Lysate-based GFP fluorescence assay
CA-GFP was cotransformed with either wild-type caspase-7 or the C186A caspase-7
mutant into the BL21(DE3) strain of Escherichia coli. 50-mL cultures were inoculated
from a 5 mL dense overnight culture, allowed to grow to an OD600 of 0.6 at 37 °C and
induced with 1 mM IPTG for 18 h at 25 °C. One mL of the culture was centrifuged using
a tabletop centrifuge, the media was decanted and the pellet resuspended in 400 µL of a
lysis buffer (0.5 mg/mL lysozyme, 2 units DNAase). The suspension was lysed by freezethaw and the lysate was then centrifuged using a tabletop centrifuge. 100 µL of the
supernatant was analyzed on a Molecular Devices Spectramax M5 spectrophotometer,
measuring fluorescence (Ex. 475 nm/Em. 512 nm) in a costar 96-well flat bottom black
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plate.

2.4.3. Immunoblotting of bacterial cultures
Aliquots of the cultured and lysed CA-GFP/capase-7 expressing E. coli samples
described above were reserved for immunoblotting analysis. SDS-loading buffer was
added to lysate samples and the samples were boiled for 10 min. Three identical SDSPAGE minigels were run. One gel was stained with Coomassie dye and imaged with a
Gel Doc work station (Syngene). A second gel was transferred to a nitrocellulose
membrane and immunoblotted using rat monoclonal anti-mouse caspase-7 antibody
(Sigma) that is specific for the caspase-7 large subunit. The third gel was also transferred
to a nitrocellulose membrane and immunoblotted using a mouse IgG monoclonal antiGFP primary antibody (Abgent). Gels immunoblotted with either anti-caspase-7 or antiGFP primary antibodies were treated with anti-mouse IgG alkaline phosphatase produced
in goat (Sigma) and visualized using 1-StepTM NBT/BCIP (Thermo Scientific).

2.4.4. Fluorescence microscopy
To prepare samples of E. coli for imaging, 50 mL LB cultures of CA-GFP, CA-GFP cotransformed with inactive caspase-7, and CA-GFP co-transformed with wild-type
caspase-7 were inoculated from dense 5 ml overnight cultures and grown to an OD600 of
0.6. They were induced with 1 mM IPTG and grown 16–18 h at 25 °C. From these
cultures 1-mL aliquots were spun down for 1 min at 13,000 rpm in an Eppendorf tabletop
centrifuge. The media was decanted and the pellet was resuspended in PBS. Slides were
prepared from these samples for DIC and fluorescence images taken using a Nikon
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Spot/E600 fluorescent microscope. All fluorescence images used the same exposure time
of 150 ms.

2.4.5. Flow cytometry
Flow cytometric analysis was performed on a Becton Dickinson (BD) LSR II configured
with a 488 nm blue laser and a 530/30 nm bandpass filter. Samples were prepared by
harvesting 300 µL of cultures expressing CA-GFP with or without wild-type or C186A
caspase-7, induced overnight as described above. Cells were washed twice with PBS and
resuspended at a final concentration of 5x107 cells/mL. With BD FACS Diva Software,
measurements were recorded for 10,000 cells analyzed at a rate of 200 events s -1. A gate
was set to define a target population of fluorescent cells by including only events with a
higher GFP intensity than cells expressing CA-GFP alone (uncleaved CA-GFP).

2.4.6. Cell culture and transfection
NIH 3T3 cells were obtained from ATCC and cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 100 units/ml penicillin, 100g/ml streptomycin,
2mM glutaMAX and 10% fetal bovine serum (Atlanta Biologicals). Cultures were
maintained in a humidified atmosphere of 5% CO2 in air at 37 °C. For transfection, cells
were plated in 12-well plates or 35-mm dishes (70– 80% confluence), cultured for 12 h
and transfected with 1.5 g of plasmid DNA per 35mm well using 6l Fugene HD (Roche)
according to the manufacturer’s instructions. For induction of apoptosis, cells were
incubated with 1 M staurosporine (STS, Ascent Scientific NJ) for a period of time as
indicated in “Results.” Controls were treated with vehicle alone (0.05% DMSO).
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2.4.7. Immunoblotting of mammalian cultures
NIH 3T3 cells were transiently transfected with the indicated expression vectors and
treated with 1 M staurosporine (STS) or left untreated. Cells were harvested at the
indicated time points and solubilized in loading buffer (62.5 mMTris-HCl pH6.8, 2%
SDS, 41.7 mM dithiothreitol (DTT), 10% glycerol, 0.01% bromphenol blue). After being
boiled for 5 min, proteins were resolved on a 5–20% gradient gel or 12% homogenous
SDS-PAGE gel and electrotransferred to PVDF membranes for immunoblotting using
enhanced chemiluminescence detection. Primary antibodies against GFP (1:5000),
caspase-3 (1:1000), and -tubulin (1:5000) were applied. Mouse monoclonal anti-GFP
(Clone 3F8.2) and anti-tubulin (Clone AA2) antibodies were purchased from Millipore,
rabbit polyclonal anti-caspase-3 antibody from Cell Signaling (San Diego, CA) and HRPconjugated goat anti-mouse IgG and goat anti-rabbit IgG from Jackson ImmunoResearch
Labs (West Grove, PA).

2.4.8. Live cell imaging
Epifluorescence was performed on an inverted wide-field fluorescence microscope
(TE2000; Nikon, Japan) equipped with a cooled CCD camera (Qimaging, Canada) and a
Plan Fluor 10/0.30 objective using Elements imaging software (Nikon). GFP
fluorescence was captured using a 515/30 filter. Time-lapse, confocal imaging was
carried out on a Zeiss LSM 510 Meta Confocal Microscope (Zeiss, Germany) over a 6-h
period. GFP and mLumin (20) were excited at 488 nm and 543 nm, respectively, and
fluorescence detected at 520/30 nm (for GFP) and 585LP nm (for mLumin) using a 40
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(1.3 N.A.) oil immersion objective lens. The live cells were maintained in 12.5 mM
Hepes buffered DMEM and kept at 37 °C with a 5% CO2 atmosphere using heaters and a
CO2 regulator. Images from the confocal microscope were manually focused and
captured every 20 min using LSM510 software (version 4.2; Zeiss). All fluorescence
images were corrected by subtracting the background and analyzed using ImageJ and
Adobe Photoshop 9.0. The ratio of green fluorescence intensity at each time point (IGt)
was compared with the red fluorescence intensity (IRt) corrected for the initial intensity
green:red ratio, IGt/IRt:IG0/IR0. The ratio was calculated based on the average pixel
value for the whole cell, wherein IGt and IRt are the fluorescence intensities of GFP and
mLumin at the indicated time point. As cells changed their morphology during imaging,
the whole cell region was determined separately in each image.

2.4.9. Statistical analysis for live cell imaging
Manual cell counting was performed with ImageJ software using the Cell Counter
plugin. More than 1000 cells were counted for both treatment and control groups.
Statistics were calculated using Excel. Statistical significance was assessed by an
unpaired Student two-tailed t test. Values were considered statistically significant at
p 0.05.

2.4.10. Zebrafish injections of CA-GFP
To generate the DNA constructs for the initial DNA injections the genes for CA-GFP and
GFP were amplified using PCR and ligated into the ApaI and EcoRI restriction sites of
the pBluescript vector (Stratagene). The Tol2-CMV-GFP and Tol2-CMV-CA-GFP
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constructs as well as the constructs to generate the capped and poly-A-tailed mRNA were
generated in the Downes lab. Zebrafish were injected at the 1-4 cell stage and incubated
at 25°C overnight until embryos reached the 24-27 hours past fertilization (hpf) stage.
Embryos which were to be treated were then decorionated and treated with either STS (in
intial trials) or 30 mM hydroxyurea to induce apoptosis. Embryos treated with STS were
then moved to a neutral buffer for an additional incubation period and then observed.
Fluorescence was quantified over the area of the embryo using a confocal microscope.
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CHAPTER 3
MECHANISTIC INSIGHTS INTO THE CA-GFP DARK STATE
This chapter was published in part as: Nicholls, S.B., Chu, J., Abbruzzese, G., Trembley,
K.D., and Hardy, J.A., 2011. “Mechanism of a Genetically Encoded Dark-To-Bright
Reporter for Caspase Activity.” The Journal of Biological Chemistry, Vol. 286, No. 28,
24977-24986. This chapter was also submitted in part as: Nicholls, SB and Hardy, J.A.
2012. “Structural Basis of Fluorescence Quenching in Caspase Activatable GFP”.
Protein Science. SBN performed all experiments in this chapter.

Abstract
Apoptosis is a critical process involved not only homeostasis and development
but a wide variety of disease states as well. Caspases are the ultimate executors of the
programmed cell death pathway. As caspases play such a central role in this widely
studied process there is demand for technologies with which to study caspase activity.
Our reporter of caspase activity, caspase activatable-GFP (CA-GFP), is unique in its
advantageous ‘dark’ state, where chromophore maturation of the GFP is inhibited by the
presence of a C-terminal hydrophobic quenching peptide. Here we show not only that
the lack of fluorescence is due to an immature chromophore, but also that CA-GFP does
not fold into the robust β-barrel of GFP until the peptide has been cleaved by active
caspase. Both CA-GFP and GFP1-10, a truncated version of the wild-type protein lacking
the final strand of the barrel, appear to have similar secondary structure, which differs
from that of the mature GFP. A similar susceptibility to proteolytic digestion indicates
that this shared structure is not the robust, fully formed GFP β-barrel. We have
developed a model that as CA-GFP is translated in vivo it follows the same folding path
as wild-type GFP, however the presence of the peptide does not allow for CA-GFP to
form the barrel of the fully matured GFP. CA-GFP is therefore held in a ‘pro-folding’
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intermediate state until the peptide is released, allowing it to continue folding into the
mature barrel geometry. The understanding of the structural basis of the dark state of the
reporter will enable manipulation of this mechanism in the development of reporter
systems for any number of cellular processes.

3.1 Introduction
In the previous chapter (chapter II) our reporter of caspase activity, CA-GFP, was
introduced. This reporter is composed of the green fluorescent protein (GFP), the caspase
recognition sequence, DEVD, and a quenching peptide derived from the tetramerization
domain of influenza M2 protein (Fig. 3.1). When CA-GFP is expressed under conditions
where active caspases are present, CA-GFP is cleaved and the quenching peptide is
released and fluorescence is gained. Due to its response to caspases and the dark state
prior to cleavage, CA-GFP has been a robust reporter of caspase activity. In bacteria
heterologously
expressing caspases, we
Figure 3.1. CA-GFP is constructed from the Green Fluorescent observe a 50-fold
Protein (S65T) GFP fused to a linker containing the caspase-3
increase in fluorescence
and -7 recognition sequence DEVD to the 27 amino acid
quenching peptide (QP) derived from the transmembrane
after caspase
domain of influenza M2.
cleavage(1). In mammalian systems, where low levels of active caspases are present
constitutively, the fluorescent background is higher, and we observe a 3-fold increase in
fluorescence upon induction of apoptosis. Although this increase in fluorescence is lower
than in bacterial systems, it is still superior to any other genetically-encoded caspase
reporter systems.

"#!

Caspases are cysteine proteases that control a variety of biological cascades
including apoptosis, inflammation and neurodegeneration. Development of the caspase
reporter was motivated by the fact that caspases play central roles in many processes in
development and human disease. Monitoring caspases contributes to our ability to
observe and understand apoptosis in the context of organismal development and
predicting drug toxicity mediated by apoptosis. Although a number of caspase reporters
had been developed previously, the genetically encoded characteristic of CA-GFP makes
it amenable to a number of applications that cannot be fulfilled by existing reporters. The
most striking characteristic of CA-GFP is its profoundly dark state prior to caspase
cleavage. As a consequence the signal-to-noise for CA-GFP is strikingly improved
compared to other previously reported caspase reporters.
The goal of this chapter is to understand the underlying structural implications of
the peptide fusion which leads to the dark state of CA-GFP. Understanding the dark state
of CA-GFP would enable us to improve the response time of CA-GFP, optimize the
florescent increase upon cleavage of CA-GFP, and finally enable us to design reporters
for other enzymatic processes.

3.2 Results
The most broadly applicable attribute of CA-GFP is the fully quenched nature of
the uncleaved state. To fully harness the potential of CA-GFP for other uses, it is
essential to understand the structural basis of the dark state at a mechanistic level. The
goal of this work is to assess the overall folded state of CA-GFP to determine what
structural factors prevent fluorescence of GFP prior to removal of the peptide.

!

"#!

3.2.1. CA-GFP requires no cofactors and can be activated in vitro
To better understand the mechanism by which CA-GFP is activated, and to
determine whether activation of CA-GFP was dependent on some intracellular
components, cleavage of CA-GFP in vitro was tested. Purified active caspase-7 and
purified CA-GFP were incubated together in a minimal buffer and cleavage of CA-GFP
by wild-type caspase-7 was observed as a function of time (Fig. 3.2A). During the
cleavage assay, a gain in fluorescence was
A!

also observed for CA-GFP (Fig. 3.2B).
This suggests that the transition from the
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Figure 3.2. CA-GFP can be activated in
vitro. A, cleavage of CA-GFP by wildtype
caspase-7 from 0 min to 18 h. (overnight). B,
gain of fluorescence during in vitro cleavage
of CA-GFP by caspase-7 (black line) with
error bars (gray). C, CA-GFP cleavage
precedes appearance of fluorescence.
Percentage of total fluorescence (white) and
cleaved CA-GFP (black) at each time point
(n _ 3(S.D.)).

CA-GFP seems to be slower than in
mammalian cells where CA-GFP
fluorescence appears within 20 min after
activation of caspases (chapter II). This lag
in acquisition of fluorescence for purified
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CA-GFP is similar to the in vitro chromophore maturation time for purified GFP S65T,
which occurs on the timescale of 27 to 122 min depending on the starting state of the
protein (2,3).

3.2.2. Chromophore maturation is prevented in dark CA-GFP
CA-GFP cleavage and fluorescence
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GFP the chromophore is formed by a cyclization
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H3C

reaction in which the amide nitrogen of Gly-67
initiates nucleophilic attack on the carbonyl
carbon of Thr-65, forming an imidazolone ring.
Next the ring is oxidized (loss of 2 Da) to a

Figure 3.3. CA-GFP silencing relies
on prevention of chromophore
maturation. A, absorbance spectra of
GFP and CA-GFP suggest that CAGFP chromophore is non-functional.
B, Chromophore maturation is a posttranslational reaction which occurs in
three sequential residues at the center
of the GFP barrel. C, mass spectra of
GFP and CA-GFP tryptic fragments
indicate that the CA-GFP
chromophore has not undergone the
maturation reaction.

cyclic imine and the carbonyl oxygen of Thr65
is dehydrated (loss of 18 Da), fully conjugating
the system (Fig. 3.3B) (2,4). Thus the
maturation state of the chromophore can be
observed as a change in the mass of the protein
(loss of 20 Da). We compared the mass spectra
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of tryptic peptides from dark CA-GFP and mature, green GFP (Fig. 3.3C). The mature
chromophore-containing fragment (2449.2 Da) was observed for GFP as expected. The
partially reacted intermediate in which only ring oxidation has occurred was also
observed (2467.2 Da). This direct observation of the oxidized intermediate is the first
observation for an S65T intermediate and supports other mechanistic studies on
maturation of other versions of GFP (5) in which the oxidation step occurs prior to
dehydration. In dark CA-GFP only the unreacted, immature peptide (2469.3 Da) was
observed, indicating that the CA-GFP quenching peptide prevents chromophore
maturation. The gain in the intensity
of circular dichroism signal is
consistent with an increase in the
multimeric state of the protein. The
oligomeric state of CA-GFP, GFP,
and cleaved CA-GFP were assessed
by size exclusion chromatography
Figure 3.4. Size exclusion chromatogram for
GFP, CA-GFP and cleaved CA-GFP. The
observed molecular weights demonstrate that
GFP and cleaved CA-GFP are monomers, while
uncleaved CA-GFP predominantly resembles a
tetramer. The molecular weights for the
standards are marked as diamonds. The expected
and observed molecular weights by size
exclusion chromatography for GFP, CA-GFP
and cleaved CA-GFP are shown below.

(Fig. 3.4). The majority of the GFP
and cleaved CA-GFP in solution is
monomeric (Fig. 3.4). Uncleaved CAGFP exists predominantly as a species
which resembles a soluble trimer or
tetramer, which is consistent with the

oligomeric state of the parent quenching peptide. The apparent tetramers may have
exposed hydrophobic patches, as some portion of the CA-GFP is also found in higher
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order oligomer, presumably clusters of this smaller order oligimer. Based on this
observation oligimerization even to small ordered oligomers such as trimer/tetramer of
CA-GFP appears to be sufficient for quenching GFP fluorescence.

3.2.3. CA-GFP has secondary structure similar to GFP1-10
Like native GFP, CA-GFP is soluble when over-expressed in bacterial cells (3),
suggesting that the GFP -barrel domain of CA-GFP is globally folded. To assess the fold
of CA-GFP in the dark state, purified CA-GFP and GFP were analyzed by circular
dichroism spectroscopy. While the spectra of non-fluorescent CA-GFP and fluorescent
wild-type GFP are not superimposable (Fig.
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3.5), the similarity in the spectral features were
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observed in all GFPs. The fact that GFP is
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known to be a stable and well-folded β–barrel
Figure 3.5. Circular dichroism spectra
of GFP and CA-GFP indicate that both
proteins are folded into a predominantly
β-sheet structure.

protein suggests that CA-GFP is likewise a
folded protein despite the fact that the CD
spectra are not superimposable, particularly at

wavelengths greater than 225 nm. Several other factors also suggest that CA-GFP is in a
folded state. CA-GFP is soluble in solution for an extended period of time and is not
prone to aggregation-induced insolubility. CA-GFP can also be cleaved rapidly by active
caspases, suggesting that it is not massively aggregated and therefore resistant to
proteolytic cleavage. On the other hand, the fact that CA-GFP does form some high-order
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oligomers suggests that the stability of the protein has been compromised by the
appendage of the quenching peptide. Thus, we sought to determine whether CA-GFP is
folded into the β-barrel observed in mature wild-type GFP or whether CA-GFP forms a
stable, partially-folded intermediate.
The folding pathway for
GFP has been studied
previously by a number
of groups (7-13). It is
now clear that folding of

Figure 3.6. A. The structure of the GFP β-barrel (PDB
ID:2YOG, green) with the chromophore residues shown as
sticks. The 11th strand of the barrel, removed in the GFP1-10
construct is highlighted in blue. B. The CD spectra of GFP,
CA-GFP and GFP1-10 are superimposed to allow assessment
of the overall shape of the three spectra. The maximum
intensities of the three spectra have been scaled for the
relative concentration of each protein. The non-scaled molar
intensities of these proteins can be seen in Figure 3.7.

GFP occurs cotranslationally and that
proper folding into the
GFP β-barrel only occurs
once the entire protein

(strands 1 through 11) has been translated (14,15). Despite the fact that all 11 strands
must be available for proper folding of GFP, it is possible to cut GFP following the 10th
strand to!make split GFP (16). In the split-GFP system, co-expression of GFP strands 110 (GFP1-10) with the 11th strand allows reassociation of the 11th strand with GFP1-10 and
folding of the GFP β –barrel (Fig. 3.6A). Once the full GFP β-barrel is formed the
chromophore is competent to mature, and split GFP becomes fluorescent. Chromophore
maturation in split GFP occurs with similar kinetics to CA-GFP (16,17). We
hypothesized that CA-GFP might adopt a stable, partially folded structure similar to that
of GFP1-10. Indeed, the overall shape of the GFP1-10 spectrum was also indicative of a
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predominantly β-strand structure (Fig. 3.6B). More importantly, the spectra for GFP1-10
and CA-GFP are nearly superimposable indicating a high degree of similarity between
the two that differs somewhat from mature GFP.

Figure 3.7. Circular Dichroism spectra. A. The CD spectra of GFP from 200-250 nm
collected at five degree increments from 20-90°C. The 20°C spectra is shown in the
darkest shading; the 90°C spectra in the lightest shading and intermediate temperatures
are shown in increasingly light color as a function of temperature. Spectra are plotted as
the mean residual ellipticity (MRE x 103: degree!cm2!dmol-1! number of residues-1) as a
function of wavelength B. The CD spectra of CA-GFP collected and shown as in A. C.
The CD spectra of GFP1-10 collected and shown as in A. D. The melting profile of GFP
as monitored by CD signal at 214 nm plotted as a function of temperature. E. Melting
profile of CA-GFP. F. Melting profile of GFP1-10.
In addition to the shape of the CD spectra, the thermal stability of CA-GFP also
provides insight into the structure relative to mature GFP and GFP1-10. To assess stability,
we collected spectra from 200-250 nm of each protein every five degrees as the
temperature was raised from 20-90°C (Fig. 3.7A-C). As was the case with the CD spectra,
the denaturation properties of CA-GFP are more similar to GFP1-10 than to GFP. As the
temperature was increased for mature GFP the molar ellipticity decreased. Previous work
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has suggested that an increase in CD signal is a sign of aggregation (18). Thus it appears
that as GFP becomes unfolded it is prone to aggregation. In the cases of both GFP1-10 and
CA-GFP the signal very gradually increases as a function of temperature up to 85°C.
After this temperature the signal precipitously drops, suggesting a significant aggregation
occurring at the highest temperatures. The melting profile can be illustrated by plotting
the molar ellipticity at a selected wavelength as a function of temperature. We observed
the greatest temperature-dependent change in CD signal at 214nm, so we have reported
those data, (Fig. 3.7D-E), but similar trends are seen at wavelengths > 210 nm. The
measured melting temperature (Tm) for GFP of 76°C, closely agrees with published value
of 78°C based on loss of fluorescence (17,19). The curves for both GFP1-10 and CA-GFP
cannot be fit to a two-state melting model but show similar stability profiles to one
another. These data suggest that CA-GFP adopts an ensemble of structures that have
more similar thermodynamic
properties to GFP1-10 than to
mature GFP.
CA-GFP adopts an
oligomeric state greater than
a monomer and consistent
Figure 3.8. The size exclusion chromatogram of GFP (MW
27.7 kDa), CA-GFP (32 kDa), cleaved CA-GFP (28.2
kDa), and GFP1-10 (20.5 kDa). GFP and cleaved CA-GFP
elute at a retention volume consistent with a monomeric
form of the protein. The dark CA-GFP elutes as two peaks
with retention volumes consistent with a population that is
50% lower order oligomer (putatively trimer or tetramer)
and 50% higher oligomer. GFP1-10 elutes in the void
volume indicating a largely aggregated population
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with a trimer or tetramer by
size exclusion
chromatography. We aimed
to compare the oligomeric
state of CA-GFP to mature

GFP and GFP1-10 as further insight into the organization of CA-GFP. As expected, GFP
elutes as a monomer. Approximately 50% of CA-GFP being in a low order oligomeric
state and 50% higher-order oligomer (Fig. 3.4). In contrast, GFP1-10 elutes in a single
peak at the void volume of the Superdex 200 column (Fig. 3.8), indicating a highly
aggregated state. The size exclusion chromatography analysis corroborates the
observations from CD, suggesting that GFP1-10 exists in a higher oligomeric state than
CA-GFP, which is more oligomeric than GFP. Thus, CA-GFP appears to have
oligomerization properties that are intermediate between mature GFP and GFP1-10.
We reasoned that structural studies of CA-GFP would be dramatically eased if we
attained oligomerically homogeneous preparations of CA-GFP. We also isolated the loworder oligomeric form of CA-GFP following size exclusion chromatography and allowed
it to re-equilibrate at room temperature for 1 or 18 hours. Following incubation CA-GFP
had re-equilibrated to a mixture that contained both low-order and high-order oligomers
in time-dependent manner. We tried extensively to identify detergent-containing
conditions that would shift CA-GFP entirely to a homogenous low oligomeric state, but
were unsuccessful in this pursuit. Despite this we performed extensive crystallization
trials, reasoning that perhaps crystallization solely of the low oligomeric state could occur.
These crystallization trials were also uniformly unsuccessful. Thus, we think it likely that
CA-GFP does not exist in a single homogenous conformation in solution but is indeed a
mixture of highly oligomeric species as observed by size exclusion chromatography.

3.2.4. β-Barrel of CA-GFP not fully formed
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To further investigate whether the solution structure of CA-GFP more closely
resembles the mature GFP or GFP1-10, we subjected all three proteins to limited
proteolysis by proteinase K (Fig. 3.9A). Proteinase K cleaves proteins relatively nonspecifically following aromatic and aliphatic amino acids and is thus a useful means of
achieving nearly full proteolysis. The propensity of GFP1-10 towards aggregation has been
suggested to indicate the presence of a less ordered folding intermediate of GFP. We
expect that such a folding intermediate should be relatively more susceptible to
proteolysis. In contrast, fully folded GFP is notoriously resistant to proteolytic cleavage
due to the stability of the β-barrel (20). As predicted, GFP was resistant to digestion up
to 10 minutes while both CA-GFP and GFP1-10 were nearly fully digested within one
minute (Fig. 3.9A). This strong susceptibility to digestion suggests that the β-barrel
structure, which renders GFP resistant to the proteinase K treatment, is not present in CAGFP.

Figure 3.9. Protease susceptibility of GFP, CA-GFP and GFP1-10. A. GFP, GFP1-10, and
CA-GFP were subjected to digestion by proteinase K. Samples were collected an
analyzed at 0, 1, 2, 5, and 10 minutes. GFP is highly resistant to digestion while GFP1-10
and CA-GFP are nearly completely degraded after 1 min. B. The GFP β-barrel is drawn
(green) with the predicted caspase-6 VELD cleavage sequence (blue) highlighted. The
sequence falls in the center of one of the first β-strand while caspases are predicted to
cleave in loop regions. C. GFP, GFP1-10, and CA-GFP were subjected to digestion by
caspase-6. Caspase-6 is capable of cleaving GFP at a single site near the N-terminus. GFP
is resistant to digestion while GFP1-10 and CA-GFP undergo partial cleavage after a twohour incubation.
""!

Whereas Proteinase K has broad specificity and cleaves most proteins at multiple
sites, caspase are very specific proteases, recognizing particular aspartate-terminated tetra
peptide motifs. Caspase-6 has a preference for cleaving protein substrates within loop
regions at the recognition sequence VEXD (21). Thus, caspase-6 cleavage serves as a
useful indicator of the ordered structure of a particular region of a protein containing a
recognition motif. A caspase-6 compatible sequence, VELD (residues 16-19), is present
natively in the N-terminal region of GFP, CA-GFP and GFP1-10. This VELD sequence is
present in a fully folded GFP in the center of the first β-strand (Fig. 3.9B). We
hypothesized that if this region of CA-GFP and GFP1-10 is organized into a protected βstrand conformation like that in mature GFP, caspase-6 would be unable to access the site
and cleave the protein. As anticipated, GFP is resistant to cleavage by caspase-6 after
incubation for 2 hours at room temperature (Fig. 3.9C). In contrast, caspase-6 is able to
partially cleave both CA-GFP and GFP1-10 within 5 minutes. This suggests the first
strand region of CA-GFP and GFP1-10 (Fig. 3.9B) is not likely in a β-strand and likely
exists in a
disordered or loop
conformation.
Together,
limited proteolysis
by proteinase K

Figure 3.10. TROSY NMR HSQC spectra. A. Spectra of GFP
collected at 37°C. B. Spectra of CA-GFP also at 37°C. The spectra
of GFP is indicative of a well-folded protein while the spectra of CAGFP resembles that of an unfolded protein.
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and caspase-6
indicate that GFP1-

10

and CA-GFP lack the stable β barrel structure present in mature GFP. If prevention of

chromophore maturation is caused by the presence of a less folded stable folding
intermediate or by small perturbations in a mostly formed β-barrel geometry then
TROSY-HSQC NMR spectroscopy with 15N labeled GFP and CA-GFP would indicate a
spectral shift for specific residues. A CA-GFP spectrum with chemical shifts similar to
those of GFP could indicate which residues were being perturbed if the differences were
subtle. The spectrum of GFP (Fig. 3.10A) showed several well-defined and well
distributed peaks, consistent with a well folded protein (22). The spectra of CA-GFP (Fig.
3.10B) looked much different than the control spectra and the signal resembled that of an
unfolded protein with little chemical shift dispersion (23). In sum, these experiments
suggest that CA-GFP does not fold into a stable β-barrel conformation and is more
similar to GFP1-10 than to the mature GFP.

3.2.5. CA-GFP exists in ‘pro-folding’ conformation.
The similarity of CA-GFP to the GFP1-10 conformation as assessed by CD and
proteolysis suggests a number of potential models for how the quenching peptide
prevents chromophore maturation. Due to the sequential proximity of the quenching
peptide to the C-terminal 11th strand of GFP, we favor the model that fusing the
quenching peptide to the GFP C-terminus may prevent proper folding of the final 11th
strand in CA-GFP. With the 11th strand unable to complete the GFP barrel, the
environment for chromophore maturation is never attained so CA-GFP remains in the
dark state with an immature chromophore until the quenching peptide is cleaved and
released. Dissociation of the quenching peptide allows the GFP barrel to properly fold,
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with the quenching peptide on the GFP
N-terminus (nCA-GFP) (Fig. 3.11A).

Figure 3.11. A. Constructs of CA-GFP and Nterminally tagged nCA-GFP with their relative
fluorescence when co-expressed in E.coli with
active caspase-7 or an inactive version caspase7 C186A. CA-GFP shows a 40-fold increase in
fluorescence in the presence of active caspase
vs. nCA-GFP which shows less than 4-fold. B.
Western blots of the CA-GFP and nCA-GFP cotransformations with active and inactive
caspase. The top blot was probed with an antiGFP primary antibody shows that CA-GFP is
fully cleaved in the presence of active caspase
while nCA-GFP is only partially cleaved. The
bottom blot was probed with a primary antibody
specific for the large sub-unit of caspase-7
shows that caspase-7 is cleaved and active in the
case of the wild-type (WT) and in the fulllength, unprocessed inactive form in the case of
the C186A mutant.
!

To compare the effectiveness of nCAGFP with that of CA-GFP, we cotransformed E. coli with nCA-GFP and
either active caspase-7 or an inactive
variant where the active site cysteine
has been mutated to an alanine (C186A).
In the absence of active caspase, nCAGFP was equally ‘dark’ as the Cterminal fusion, CA-GFP, suggesting
that the quenching peptide was equally

effective at disrupting assembly of the GFP barrel thereby preventing chromophore
maturation. However, when nCA-GFP was co-expressed with active caspase-7, it showed
less than a 3.8-fold increase in fluorescence in E. coli lysates (Fig. 3.11B). ! This is in
contrast to the C-terminal construct, CA-GFP, which shows a greater than 40-fold
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increase in fluorescence when cleaved by active caspase. Western blot analysis using an
anti-GFP antibody shows that nCA-GFP is only partially processed in comparison to CAGFP (Fig. 3.11C), indicating the linker region is less accessible to proteolytic cleavage
than in the C-terminal fusion. Partial digestion of nCA-GFP when co-expressed with
active caspase indicates that the linker region may be less accessible to the protease. The
low fluorescence recovery is then due to a smaller fraction of nCA-GFP being cleaved
and a smaller portion of the cleaved protein attaining the mature barrel geometry to allow
for chromophore maturation. Thus, it is clear that the conformational state attained by
CA-GFP is better poised to allow cleavage, refolding, chromophore maturation and
regaining fluorescence. Given the greater propensity for the C-terminal fusions of the
quenching peptide to be cleaved and recover fluorescence, we can conclude that the dark
state can be attained by a variety of unfolded and partially folded states. Nevertheless, the
partially folded, partially aggregated state that CA-GFP obtains has more optimal
properties for cleavage and refolding than that induced by adding the quenching peptide
to other parts of GFP, such as the N-terminus.
The notion that folding of GFP is integral to the quenching mechanism is further
supported by our observation that the quenching peptide is not capable of preventing
fluorescence when appended to superfolder GFP (sfGFP). Superfolder GFP was
developed by Waldo and coworkers to fold with faster kinetics and therefore is less prone
to aggregation (24). When the quenching peptide is fused to the C-terminus the
fluorescence of GFP is not quenched (data not shown). We predicted that a shorter linker
would be a more stringent test of the quenching ability of the peptide. A CA-superfolder
GFP (CA-sfGFP) construct was made with a shorter linker (DELD) rather than the longer
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CA-GFP
nCA-GFP
CA-sfGFP
!

THGMDELYKDEVDFQGPCNDSSDP
LILWILDRLDEVDFQGPMVSKGEE
THG------DELD-------SSDP!
GFP

Linker

Peptide !

Figure 3.12. Sequence alignment of linker
regions of CA-GFP, nCA-GFP and CAsfGFP. The GFP portion of the protein is
shown in green, the linker in blue, and the
peptide in black. CA-sfGFP has a much
shorter linker region than CA-GFP and
nCA-GFP.

linker in CA-GFP (DEVDFQGP, Fig. 3.12)
but the resulting CA-sfGFP was still
brightly fluorescent suggesting that the
kinetics of folding is involved in the
quenching mechanism that is at work in
CA-GFP. Thus, we venture to state that
CA-GFP exists in a relatively optimal

folding competent or ‘pro-folding’ state. Although we cannot firmly conclude that CAGFP is quenched by prevention of the 11th strand from inserting into the partially formed
barrel, this model is compatible with our observations.

3.3. Discussion
A number of studies have reported other versions of GFP in which maturation of
the chromophore is prevented (16,25,26). GFP is a β -barrel protein in which all the 11 βstrands must be properly assembled to attain the fluorescent state. In each of these
darkened states the GFP chromophore is not mature and maturation of the chromophore
only occurs when the full GFP barrel assembles. Only when the chromophore is in
precisely the correct structural environment can the reaction to form the chromophore
occur. For all of the split GFP variants a substantial number of amino acids (10-50% of
the protein) are missing, so it is not surprising that these proteins do not attain the
properly folded state. In contrast, CA-GFP is composed of all the amino acids necessary
for GFP to fold. We hypothesize that some aspect of CA-GFP folding may be suboptimal as chromophore maturation does not occur. Thus we expect that structural
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changes within the GFP portion of CA-GFP must be present, preventing the chromophore
from maturing. These structural perturbations could range from very minor, similar to the
R96A or R96M mutants (27), to more catastrophic as is the case with the split versions of
GFP. While CA- GFP is robust at reporting global apoptosis events a dark reporter that
housed a more rapidly maturing chromophore would enable us to capture more rapid
kinetic details of the apoptotic cascade.
One of the key features of CA-GFP is the mechanism by which the quenching
peptide silences fluorescence. The M2 protein, from which the CA-GFP quenching
peptide is derived, forms active tetramers. The dark state of CA-GFP appears to be folded
by circular dichroism and is soluble, forming low order oligomers under identical
conditions in which GFP is fully fluorescent. The oligomerization of CA-GFP prevents
formation of the mature chromophore and thus fluorescence. Cleavage of CA-GFP
releases GFP, which can then undergo the necessary conformational rearrangements
enabling chromophore maturation. Thus, it initially appeared that even low order
oligomerization was sufficient to induce a slightly strained, but folded conformation of
GFP that disallowed chromophore formation. It is not unprecedented that subtle changes
to GFP, similar to oligomerization, prevent chromophore maturation. Although GFP is a
stable and independently folding protein, subtle changes in the environment around the
chromophore can dramatically affect fluorescence and the rate of chromophore
maturation. For example, maturation of the chromophore in the S65T version of GFP,
which adds but a single methyl group to the chromophore cavity is 4.4-fold faster than
wild-type GFP. In the R96M variant, the lack of a positive charge drastically changes
maturation from hours to months (27). When GFP is compressed with an atomic force
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microscope tip, the hydrogen-bond network inside the GFP barrel is broken, resulting in a
non-fluorescent chromophore(28). Even a subtle change in pH (to pH 6.5) is sufficient to
quench fluorescence (29,30). When GFP is split to remove the last of the 11 β-strands in
the GFP barrel, fluorescence is silenced. Association of GFP1–10 (amino acids 1–214)
with GFP11 containing only the 11th strand (amino acids 215– 230) results in recovered
fluorescence (38).
Based on these early observations our initial model of the structure of CA-GFP in
the dark state was that of a well-formed β-barrel conformation similar to that of mature
GFP, with the presence of the quenching peptide inducing subtle perturbations,
potentially a result of oligomerization, inhibiting chromophore maturation. The fully
formed β-barrel of GFP has been shown to be impressively robust. Once the barrel has
folded and the chromophore is mature it requires fairly extreme conditions to disrupt the
fluorescence and unfold the protein. Melnik et al. showed that even after partial
digestion the fluorescence of the cycle-3 mutant remained nearly unchanged. They
hypothesized that the proteases may cleave in loops but that the barrel remained formed
and ‘sticks’ to the chromophore to retain fluorescence. They also observed that GFP
fluorescence was unaffected in concentrations of urea up to 4M (31). For example, when
a trypsin site was engineered into a loop to remove the 11th strand, the protein still had to
be denatured and refolded to remove the cleaved strand from the barrel (32). As we
observed throughout this study, CA-GFP lacks the remarkable stability of the mature fold,
leading us to speculate that it does not exist in the fully formed β-barrel conformation but
potentially as a stable intermediate along the native folding pathway.
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Several recent protein-folding studies have pointed out that the canonical models
of protein folding fail to take into account the kinetics and sterics of co-translational
folding (15,33-35). One recent study has shown that a stable folding intermediate
consisting of the first 10 strands of GFP forms prior to the 11th strand’s release from the
ribosome tunnel (15). It follows that if CA-GFP is folding co-translationally, as GFP
does, it will sample the same folding intermediates as the WT protein prior to release of
the 11th strand. As the peptide is the last portion to be translated and released it is possible
that the quenching peptide interferes with the folding of the final stave of the barrel.
Since CA-GFP is in a ‘pro-folding’ state, after the peptide is released a majority of the
individual CA-GFP molecules can proceed to the native GFP fold.
This is slightly different from the case of nCA-GFP where the very hydrophobic
peptide is being translated and released from the ribosome first, leading to a very
different sampling of folding states as it is being translated. The grouping of long
stretches of hydrophobic residues has been shown to lead to an increase in aggregation
(36), which could lead to very different folding intermediates being sampled than the
native GFP. This type of behavior has been harnessed to use GFP as a folding reporter.
When peptides or proteins have been fused to the N-terminus of GFP, fluorescence is an
indication of the stably folded state of the fused peptide or protein, whereas unstably
folded protein or peptide fusions prevent GFP fluorescence (37,38). Our results suggest
that the quenching peptide is not well folded and therefore leading to a less stably folded
intermediate of the GFP barrel in nCA-GFP.
The differences in the oligomeric states of CA-GFP and GFP1-10 suggest that CAGFP is in a more advanced folding intermediate conformation than GFP1-10. CA-GFP has
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a SEC profile consistent with 50% of the protein being a trimer/tetramer. The
heterogeneous mixture suggest that there may be several intermediate folding states
present as these conformations tend towards self-aggregation (33) with the majority being
in a similar stable state that forms a low order oligomer. This is in contrast to the largely
aggregated GFP1-10. It is not surprising that GFP1-10 is in an aggregated state; even the
robust mature GFP can be coaxed to aggregate upon the addition of 2,2,2-trifluoroethanol
(TFE), a chemical commonly used to induce aggregation in proteins (39). The
observation that CA-GFP is not as aggregated then supports the hypothesis that it is more
ordered than GFP1-10.
If the dark state of CA-GFP is dictated by the co-translational folding of the GFP
barrel then faster folding variants of GFP should change the fold in the presence of the
quenching peptide. The fact that superfolder GFP remains fluorescent in the presence of
the quenching peptide indicates that folding kinetics control the dark or bright properties
of this class of reporters. The improved folding kinetics of sfGFP prevent populating
kinetic traps required for the quenching peptide to function. Thus, in order to develop the
next generation CA-GFPs with faster response times, it will also be important to develop
quenching peptides that can interact with GFP folding intermediates on a more rapid time
scale.
In consideration of the structural insights we report above we propose a working
model of the dark state of CA-GFP. We envision that as CA-GFP is being translated the
N-terminus begins sampling the native GFP folding states. The presence of the
quenching peptide on the C-terminus prevents it from attaining the fully mature β barrel
conformation and it is trapped in a stable, ‘pro-folding’ intermediate. After the
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quenching peptide is cleaved and released the GFP barrel is then allowed to fold into the
robust fold and the chromophore matures, yielding fluorescence. Controlling the folding
path of CA-GFP to attain a rapidly maturing chromophore yet maintaining the dark state
will be critical in further development of the next generation of CA-GFP reporters. Once
a more detailed understanding of the ‘pro-folding’ state is attained the ability to engineer
further fluorescent protease reporters as well as expand the utility of the platform to
respond to other enzymatic processes will be greatly eased.

3.4. Materials and methods
3.4.1. Molecular cloning
CA-GFP was generated by amplification of GFP (S65T) by PCR using a reverse
primer encoding the 27 amino acid transmembrane domain of the M2 protein of the
influenza A virus. After amplification of the new gene it was ligated into the XhoI and
NdeI sites of pET21b. A linker sequence containing the caspase-3 and -7 cleavage
recognition site DEVD was then inserted between GFP and the peptide by site-directed
mutagenesis using overlapping inverted primers and amplification of the entire plasmid
similar to the QuikChange® (Agilent) approach for a final fusion sequence of
DEVDFQGPCNDSSDPLVVAASIIGILHLILWILDRL at the C-terminus of GFP. The
expression construct for GFP (S65T) GFP1-10 was generated by inserting a stop codon
(UAA) after residue K214 using the same site-directed mutagenesis approach using GFP
(S65T) in pET21b as the template. CAsf-GFP was generated in a similar approach by
amplification of the sfGFP (a kind gift from the Waldo group) gene by PCR using a
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reverse primer encoding the linker region as well as the 27 amino acid transmembrane
domain of M2. This gene was then ligated into the XhoI and NdeI sites of pET21b vector.
The N-terminal peptide version of CA-GFP (nCA-GFP) was generated by
separately amplifying the peptide (M2) region from the GFP region of the gene using two
primers to amplify the M2 and two primers to amplify GFP. The first primer (P1)
annealed to the N-terminal region of GFP with the linker sequence included N-terminally
to the GFP. The second primer (P2) annealed to the C-terminal of GFP and included a
stop codon (UAA) and the restriction site for XhoI. The third primer (P3) Included an
NdeI restriction enzyme site as well as a 6His sequence and annealed to the N-terminal
region of the M2 portion of the CA-GFP gene. The last primer (P4) annealed to the Cterminus of M2 and included the same sequence for the linker as P1, giving primers P1
and P4 a 24 bp overlapping region. The GFP fragment was then amplified using primers
P1 and P2 while the M2 portion was amplified using primers P3 and P4. After gel
purification of the amplified fragments they were combined and allowed to anneal
through the overlapping region for five PCR cycles before the addition of primers P2 and
P3 which then amplified the full length gene. The gene was then ligated into pET21b
into NdeI and XhoI sites. The final sequence of the N-terminal peptide and linker is
MHHHHHHMCNDSSDPLVVAASIIGILHLILWILDRLDEVDFQGP.

3.4.2. Protein expression and purification
CA-GFP, CA-sfGFP, nCA-GFP, GFP1-10, and GFP were transformed into E. coli
strain BL21(DE3) for expression. One liter cultures of 2xYT media were inoculated with
1 mL of dense overnight culture and grown at 37°C to an OD600 of 0.6. The cultures
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were then induced with 1mM isopropyl.β-D-1- thiogalactopyranoside (IPTG) at 25°C for
three hours. Cells were then harvested by centrifugation and disrupted by
microfluidization. After centrifugation at 15,000 x g for 45 min. the proteins were
purified from supernatant using Co2+ affinity chromatography (HiTrap Chelating HP,
GE). The column was washed with a buffer of 50 mM imidazole, 300 mM NaCl, 50 mM
NaH2PO4 pH 8.0 and eluted in a buffer of 300 mM imidazole, 300 mM NaCl, 50 mM
NaH2PO4 pH 8.0. Protein purity was assessed by gel electrophoresis; proteins were
estimated to be at lease 95% pure.
Cleaved CA-GFP was obtained by co-expression of CA-GFP and wild type fulllength caspase-7 lacking the His6 tag. Flasks containing 1 liter of 2xYT media were
inoculated with 1 mL of dense culture and grown at 37 °C to an OD600 of 0.6. The
cultures were then induced using 1 mM isopropyl -D-1- thiogalactopyranoside (IPTG)
and the temperature reduced to 25 °C for three hours of expression. Cells were harvested
by centrifugation and disrupted by microfluidization. Clarified lysates were prepared by
centrifugation at 15,000 x g for 45 min.
Wild-type caspase-7 was expressed from a plasmid comprising pET23b with fulllength caspase-7 gene (40) (gift of Guy Salvesen). This plasmid was mutagenized by
QuikChange (Stratagene) to introduce the C186A mutation. Wild-type or C186A
caspase-7 were expressed in E. coli strain BL21(DE3). Protein expression was induced
with 1mM IPTG and allowed to proceed for 12–18 h at 14 °C. Wild-type caspase-7 was
purified by affinity chromatography on a Ni-NTA superflow column (Qiagen) developed
with a step gradient of 250 mM imidazole. Eluted caspases were further purified using
ion exchange chromatography on a 5 mL High-Q column (Bio-Rad) with a linear
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gradient from 50mM to 750mM NaCl. The purity of all mutants was assessed by SDSPAGE gel stained with Coomassie Blue (Bio-Rad) and found to be 95% pure.
The caspase-6 E. coli codon-optimized sequence gene construct in pET11a was
transformed into the BL21(DE3) T7 express strain of E. coli (NEB). The cultures were
grown in 2xYT media with Amp (100 mg/L, Sigma-Aldrich) at 37 °C until they reached
OD600=0.6. The temperature was reduced to 20 °C and cells were induced with 1 mM
IPTG (Anatrace) to express soluble His-tagged protein. Cells were harvested after 18 h to
ensure complete processing. Cell pellets stored at -20 °C were freeze-thawed and lysed
in a microfluidizer (Microfluidics, Inc.) in 300 mM NaCl, 2 mM imidazole, and 50 mM
Tris (pH 8.5). Lysed cells were centrifuged at 18,000 g to remove cellular debris. The
filtered supernatant was loaded onto a 5-mL HiTrap Ni-affinity column (GE Healthcare).
The column was washed with 300 mM NaCl, 50 mM imidazole, and 50 mM Tris (pH
8.5), and the protein was eluted with 300 mM NaCl, 250 mM imidazole, and 50 mM Tris
(pH 8.5). The eluted fraction was diluted by five-fold into 2 mM DTT and 20 mM Tris
(pH 8.5) buffer to reduce the salt concentration. This protein sample was loaded onto a 5mL Macro-Prep High Q column (Bio-Rad Laboratories, Inc.). The column was developed
with a linear NaCl gradient and eluted in 120 mM NaCl, 2 mM DTT, and 20 mM Tris
(pH 8.5) buffer. The eluted protein was stored at -80 °C in the above buffer conditions.
The identity and purity of the purified caspase-6 was analyzed by SDS-PAGE.

3.4.3. in vitro CA-GFP cleavage and fluorescence assay
Samples containing 10 µM CA-GFP with or without 9 µM wild-type caspase-7
were prepared at time zero to assess the ability of caspase-7 to digest CA-GFP directly.
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At initiation of the reaction 100 µL aliquots of the digest and controls were added to a
costar 96-well black plate, and the fluorescence was measured every 5 min (Ex. 475
nm/Em. 512 nm) for 15 h at 27 °C. The remainder of the sample was incubated at 27 °C
in 15 µL aliquots to which SDS loading buffer was added at time points of 0, 5, 10, 15,
20, 30, 60, 90, 120 min, and at 15 h. These samples were then run on an SDS-PAGE gel
to determine the ratio of cleaved to uncleaved CA-GFP. The percent of cleaved product
was determined by quantification using GeneTools software (product version 4.00) on
gels imaged with a Gel Doc work station (Syngene).

3.4.4. Absorbance of GFP chromophore
To measure the absorbance spectra of the GFP chromophore, 100 µL of purified
CA-GFP and GFP were buffer exchanged into a buffer containing 10 mM NaH2PO4, pH
7 using Millipore Ultra-free 5K NMWL membrane concentrators and diluted to a
concentration of 10 µM. The absorbance spectra were collected on a Molecular Devices
Spectramax M5 spectrophotometer measuring absorbance from 350 –550 nm in a Costar
UV, flatbottom 96-well plate (product number 3635).

3.4.5. Mass spectrometry
Purified CA-GFP and GFP samples were run on a one-dimensional SDS-PAGE
gel and Coomassie stained. The bands of interest were excised and cut into 1x1mM
pieces and incubated in water for 1 h. The water was removed and 250 mM ammonium
bicarbonate was added. For reduction the gel slices were incubated with 45 mM DTT at
50 °C for 30 min. After cooling to room temperature the cysteines were then alkylated by
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incubation with 100 mM iodoacetamide for 30 min at room temperature. The gel slices
were washed twice with water, which was then removed and a 50:50 (50 mM ammonium
bicarbonate: acetonitrile) mixture was placed in each tube, and samples were incubated at
room temperature for 1 h. The solution was then removed and 200 µL of acetonitrile was
added to each tube at which point the gels slices turned opaque white. The acetonitrile
was removed, and gel slices were further dried in a SpeedVac. The gel slices were then
rehydrated in a 2 ng/L solution of trypsin (Sigma) in 0.01% ProteaseMAX Surfactant
(Promega): 50mM ammonium bicarbonate for 21 h at 37 °C. The supernatant of each
sample was then removed and placed in a separate 0.5 mL Eppendorf tube. Gel slices
were further dehydrated with 60 mL of 80:20 (acetonitrile: 1% formic acid). The extract
was combined with the previous supernatants of each sample and further purified using a
micro Zip Tip (Millipore). The tryptic fragments were analyzed using matrix-assistedlaser desorption/ionization Time-of-Flight (MALDI-TOF) and subsequent MS/MS using
a Shimadzu Biotech Axima TOF2 (Shimadzu Instruments) mass spectrometer to
determine the maturity of the chromophore. The observed mass loss in GFP is due to
oxidation of the Tyr-66 (loss of two daltons) and dehydration (loss of eighteen daltons)
during the chromophore maturation process.

3.4.6. Circular dichroism spectroscopy
Repeating structures such as helices and -sheets rotate circularly polarized light
differently such that the degree of protein secondary structure can be estimated from a
circular dichroism spectra. Purified CA-GFP and GFP were prepared at a 10 µM
concentration as described for absorbance measurements. CD spectra were measured on a
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J-715 circular dichroism spectrometer (Jasco) at 25 °C. For temperature-wavelength
scans purified proteins were buffer exchanged into a buffer containing 10 mM NaH2PO4,
pH 7 using Millipore Ultra-free 10K NMWL membrane concentrators and diluted to ~10
µM as determined by A280 nm using a Nanodrop 2000C Spectrophotometer. CD spectra
were measured on a J-715 circular dichroism spectrometer at intervals of every 5 degrees
from 20-90 °C at a rate of temperature increase of 1°C per minute in a quartz cuvette with
a 0.1 cm pathlength.

3.4.7. Size exclusion chromatography
The size of CA-GFP (1 mg/ mL), GFP (1 mg/mL) , GFP1-10 (1.5 mg/mL) and
cleaved CA-GFP (0.6 mg/ mL) was determined by SEC using a Superdex 200 10/300 GL
column (GE Healthcare). The molecular weight of each was determined by comparison
to molecular weight standards albumin (66 kDa), carbonic anhydrase (29 kDa),
ovalbumin (45 kDa), and ribonuclease A (14.7 kDa) with blue dextran 2000 used to
determine the void volume of the column (Sigma product No. MW-GF-1000). The
curves were normalized for the respective protein concentrations.

3.4.8. Proteolysis
Proteolysis of 20 µM CA-GFP, GFP 1-10, and GFP by the addition of 500 nM
Proteinase K (Sigma) was performed in a buffer of 50 mM Tris pH 7.5, 5 mM CaCl2.
Aliquots were taken from the reaction at 0, 1, 2, 5, and 10 minutes and added to protease
inhibitor phenylmethylsulfonyl fluoride (PMSF) to stop the reaction. SDS loading buffer
was then added to the samples, which were boiled for 10 minutes and analyzed by SDS-
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PAGE. The presence of the PMSF made the loading of samples onto the SDS-PAGE gel
challenging but was aided by an additional 10% glycerol added to the SDS-PAGE
running buffer, the addition of 1 µL of 10X SDS-PAGE running buffer to each reaction
prior to loading to ensure the appropriate pH, the chilling of the samples, gel and running
buffer prior to loading. It was also necessary to load the gel with a low voltage (50V)
current being applied so that the sample would be drawn into the gel quickly.

3.4.9. Cleavage by Caspase-6
Purified CA-GFP, GFP1-10, and GFP were incubated with purified active caspase6 at room temperature in a buffer of 100 mM HEPES pH 7.5, 10% sucrose, 0.1% CHAPS,
30 mM NaCl, and 5 mM DTT. Aliquots of each reaction were taken at 0, 5, 10, 30, 60,
and 120 minute time intervals and added to SDS loading buffer with DTT and
immediately boiled for 10 min to stop cleavage. The samples were then assessed using
SDS-PAGE to determine cleavage at each time point.

3.4.10. TROSY NMR
15

N labeled CA-GFP and GFP were obtained by growth in M9 minimal media

using 15N ammonium chloride as its sole nitrogen source (Cambridge isotopes) (41). A 20
mL LB culture was inoculated from a dense overnight culture. After reaching an OD600
of 0.5, the cells were spun down and washed once with PBS. The cells were resuspended
in 100 ml 15N labeled M9 media. The culture was incubated about 3.5 hours at 37°C
until reaching an OD600 of 0.5. The doubling time of the cells in the M9 media was
approximately 90 min in agreement with published values (42). The culture was then
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diluted into 200 mL of labeled M9. After incubation at 37°C until reaching an OD600 of
0.5 once more the culture was diluted to 1L of labeled M9 and then induced with 1mM
isopropyl β-D-1- Thiogalctopyranoside (IPTG) at 25°C for three hours. The 15N labeled
proteins were purified as described above. The proteins were buffer exchanged using
Millipore Ultra-free 10K NMWL membrane concentrators into a buffer of 10 mM NaCl,
2.7 mM KCl, and 6 mM NaH2PO4 pH 7.2 at a concentration of 60 µM.
15

1

H-

N Transverse relaxation optimized spectroscopy (TROSY) spectra in this study were

obtained at 37 °C on a 700-MHz Varian NMR system equipped with a cryogenically
cooled triple-resonance probe. Spectra were processed using NMRpipe (43) and analyzed
using Cara(44).

3.4.11. Lysate-based CA-GFP fluorescence assays
Expression constructs for CA-GFP with the peptide on either the C- or N-terminus,
CA-GFP and nCA-GFP respectively, in pET21b (Amp) was co-transformed in the
BL21(DE3) strain of E. coli with either a constitutive two chain version of caspase-7 (C7
CT) or full-length inactive caspase-7 where the active site cysteine has been mutate to an
alanine (C186A). Both versions of caspase-7 were contained in the vector pBB75 (Kan).
50 mL cultures were inoculated from dense overnight cultures and grown at 37°C to an
OD600 of 0.6. Cultures were then induced with 1mM IPTG at 25°C for 18 hours. Two
mL of each culture was centrifuged and resuspended in 800 µL a buffer of 0.5 mg/mL
lysozyme (Sigma) and 2 units DNAase (NEB). Cells were lysed using four cycles of
freeze-thaw and the supernatant (100 µL) was analyzed for fluorescence (Ex. 475 nm/Em.
512 nm) in a co-star 96-well black plate on a Molecular Devices Spectramax M5
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spectrophotometer. Fluorescence values were normalized based on the relative OD of
each culture.

3.4.12. Western blotting
Samples of supernatant prepared as described for the lysate fluorescence assays of
CA-GFP or nCA-GFP each co-transformed with either the active WT caspase-7 or the
inactive C186A caspase-7 (above) were taken. Three identical SDS-PAGE gels were run
of the four samples. One was stained with Coomassie, two gels were transferred onto
Hybond-ECL™ nitrocellulose membrane (GE Healthcare) and blocked overnight in a
solution of 0.03 mg/mL BSA in TBS. One was then blotted with an anti-GFP
(Millipore) monoclonal mouse primary antibody, and the other was blotted with a mouse
primary antibody recognizing the large subunit of caspase-7 (Sigma). The western blots
were then treated with anti-mouse IgG alkaline phosphatase produced in goat (Sigma)
and visualized using 1-Step™ NBT/BCIP (Thermo Scientific).
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CHAPTER 4
A VERSATILE PLATFORM FOR PROTEASE REPORTING

This chapter will be submitted in part as: Wu, P., Nicholls, S.B. and Hardy, J.A., 2012.
“A Versatile Platform for Protease Reporting.” Biophysical Journal. SBN performed
profiling of caspase activity against caspase-activatable reporters as well as development
and characterization of CA-CerFP, CA-CitFP, CA-mNeptune, DVPA-GFP, and HIVAGFP. PW developed and characterized C6A-GFP and HRA-GFP and their respective
derivatives including all constructs with a stop codon inserted in the linker region.

Abstract
Proteases are one of the most important and historical utilized classes of drug
targets. To effectively study this class of proteins, which encodes nearly 2% of the
human proteome, it is necessary to develop effective and cost-efficient methods to report
on their activity both in vitro and in vivo. One of the most important classes of proteases
both in terms of homeostatic regulation and drug design is the caspase family. Caspases
are responsible for carrying out the process of programmed cell death, a function
necessary for the regulation of cells. This important class of proteases is a relevant drug
target for a variety of diseases such as cancer and neurodegenerative diseases. We have
previously discussed our reporter of caspase activity, CA-GFP (chapters II and III). CAGFP is a genetically encoded dark-to-bright reporter of caspase activity in a variety of
systems. Here we show the utility of CA-GFP as a platform for the creation of a family
of protease reporters by engineering the linker region, which includes the protease
recognition site, as well as the fluorescent protein used.
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4.1. Introduction
The use of genetically encoded fluorescent reporters has become increasingly
important in the study of proteolytic activity both in vitro and in vivo [for review see (1)].
Proteases are at the center of the most critical cellular cycles and pathways and are one of
the most common drug targets for drug design [for review see (2)]. Several
metalloproteases have been successful drug targets for treatment of hypertension while
proteases involved in blood coagulation have been the target for treatment of blood
disorders for over half a century. Viral proteases are an important drug target as well in
wide spread viruses such as HIV, Dengue, and West Nile Virus which affect millions of
people worldwide. One important class of enzymes, the caspase family, is central to the
critical process of apoptosis, or programmed cell death, and therefore has become an
important drug target for treating a variety of diseases. Caspases are a family of
cysteine-aspartate proteases that cleave cellular substrates in response to cellular stress
and inflammation ultimately leading to cell death. Once the apoptotic cascade is
activated, initiator caspases (-8 and -9) are triggered to cleave the zymogen forms of the
executioner caspases (-3, -6, and -7) into the large and small subunits, which make up the
active form of the protease. Activation of the executioners is the last irreversible step in
the apoptotic cascade ultimately leading to cell death. The search for activators of
caspases could lead to new cancer therapies, initiating cell death in rapidly dividing
cancer cells, while inhibitors of caspases could provide treatments for neurodegenerative
diseases or control of tissue damage in instances such as post heart attack. To validate
any protease as an appropriate drug target, we first need the ability to easily and cost
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effectively assess the activity of the protease in it native biological setting as well as in
the presence and absence of drug candidates.
It is important to understand not only the in vitro activity of these drug targets but
also the biologically relevant in vivo function. Current technologies for studying protease
activity in a native cellular context include FRET, luciferase, and positron emission
(PET) reporters similar to those discussed specifically for caspases in Chapter I and II.
We have recently reported the development of a genetically encoded, dark-to-bright
reporter of caspase activity(3). This reporter is multi-functional in that it can be used
both in vitro and in vivo and in both bacterial and mammalian systems to indicate the
activity of executioner caspases (chapter II). Our caspase-activatable reporter was
designed by fusing GFP
(S65T) through a
Figure 4.1. Construct of CA-GFP showing the GFP (green)
fused through the flexible linker, containing the protease
recognition sequence, to the quenching peptide (gray).

flexible linker containing
the caspase-3, and -7
recognition sequence

DEVD to a hydrophobic 27-amino-acid peptide on the C-terminus (Fig. 4.1). The
presence of this peptide inhibits chromophore maturation in GFP until it is removed in
the presence of active caspase.
As our CA–GFP has been shown to be useful in the reporting of caspase-7
activity we sought to use this as a model for the further design of other proteolytic
reporters including other caspases as well as additional proteases. Caspase-6 has
recently been shown to play a unique role in both Alzheimer’s (4) and Huntington
diseases (5), cleaving APP and Huntingtin proteins respectively at sites unique from
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caspase-3 cleavage. It has therefore been deemed an important drug target in the
prevention and treatment of neurodegenerative diseases. In order to effectively target
caspase-6 with therapeutics it is also necessary to assess the effect that such an inhibitor
would have on homeostasis throughout the body. One example is a recent study
showing another role of caspase-6 in the maintenance on the prostate tissue(6) . In order
to assess the efficacy and off target effects of any caspase-6 specific therapeutics it is
necessary to specifically monitor caspase-6 activity in a biological context. A caspase-6
specific CA-GFP would enable longitudinal monitoring in cells and whole organism
models of caspase-6 activity both during homeostasis as well as in response to potential
drug candidates.
The recently revealed non-apoptotic role of caspase-6 in neurodegenerative
diseases and in prostate function implies the possibility that other caspases may have
roles independent of the apoptotic cascade as well. Though caspases have been profiled
to have differences in their substrate preferences, despite their similar active sites, by
profiling of peptide libraries (7) much is still unknown about the differences in their
cellular substrates. In order to effectively assess the unique roles of each caspase it is
essential to have the ability to simultaneously monitor the activity of multiple caspases.
To do so using CA-GFP requires the ability to change not only the protease recognition
sequence in the linker region but the fluorescence color as well in order to differentiate
the activities. While GFP is a ubiquitous tool in molecular biology an entire palette of
fluorescent proteins has been developed [for review see (8)]. By expanding the color
palette of our reporter it could become a useful tool in imaging multiple proteolytic
events within a cell. As the fluorescence from the red fluorescent protein family has been
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shown to have a greater tissue depth penetrance (9,10) a red-shifted version would
dramatically improve our ability to monitor proteolytic events, particularly in transgenic
animals. The first half of this chapter focuses on our engineering of the linker region to
respond to caspase-6 as well as other biomedically relevant proteases while the second
half describes the development of reporters which fluoresce at a variety of wavelengths to
enable robust simultaneous reporting of multiple proteases.

4.2. Results and discussion
We hypothesize that CA-GFP can act as a tunable platform for a variety of
applications and that by substitution of other protease recognition sites in the linker
region we can develop a family of Protease Activatable (PrA) reporters. To develop new
versions of CA-GFP that could respond to additional proteases, we found it was first
necessary to understand the essential characteristics and parameters of the linker region
that allow fluorescence recovery after proteolytic cleavage. In addition, the similarity in
structure of the various colors within the GFP family of fluorescent proteins leads us to
believe that the color of the reporter is also tunable.

4.2.1 Development of a caspase-6 activatable-GFP
Until very recently caspase-6 has been viewed as being very structurally and
functionally similar to the two other executioner caspases -3 and -7. More recent studies
have shown that caspase-6 not only has structurally unique states from the canonical
caspase structure (11-13) but that it also may have unique non-apoptotic roles namely in
neurodegenerative diseases (4,5). CA-GFP has been shown to be a robust in vivo reporter
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for executioner caspases both in E. coli. and in mammalian cells (3). In order to build a
Caspase-6 Activatable GFP reporter (C6A-GFP) that would allow us to distinguish the
activity of caspase-6 from that of caspases-3 and -7, we replaced the DEVD linker
sequence in CA-GFP with the caspase-6 recognition sequence VEID (C6A-GFP or
VEIDF-GFP) (Table 4.1).
Table 4.1. Constructs used throughout the studies with the linker sequence as well as
any additional mutations listed. ê indicates the site of cleavage by the intended protease; *
indicates a stop codon.!
Version of –
GFP reporter
CA-GFP
C6A-GFP or
VEIDF-GFP
VEIDF-GFPe
C6A-GFPe or
VEIDG-GFPe
VEIDE-GFPe
VEIDK-GFPe
C7A-GFPe or
DEVDF-GFPe
LEVLF-GFP or
LEVLF-GFP
HRA-∆YKGFP
HRA-GFP or
LEVLG-GFP
DEVLF-GFP
DEVLG -GFP
EEVLF-GFP
DEVEF-GFP
DEVEG-GFP
DEVCF-GFP
DEVSF-GFP
VEIDF-GFP
PEHDF-GFP
LEHDF-GFP
DEVD*
DEVDFQ*
LEVL*
LEVLFQ*
DEVL*
DEVLFQ*
EEVLFQ*
EEVEFQ*
VEID*
CA-CerFP
CA-CitFP
CA-mNeptune
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Linker Sequence

Additional Mutations

DEVD!FQGP
VEID!FQGP

Intended Protease
Caspase-7
Caspase-6

VEID!FQGP
VEID!GQGP

D27E
D27E

Caspase-6
Caspase-6

VEID!EQGP
VEID!KQGP
DEVD!FQGP

D27E
D27E
D27E

Caspase-6
Caspase-6
Caspase-7

LEVLFQ!GP
LEVLFQ!GP
LEVLGQ!GP
DEVLFQ!GP
DEVLGQ!GP
EEVLFQ!GP
DEVEFQ!GP
DEVEGQ!GP
DEVCFQ!GP
DEVSFQ!GP
VEIDFQ!GP
PEHDFQ!GP
LEHDFQ!GP
DEVD*
DEVDFQ*
LEVL*
LEVLFQ*
DEVL*
DEVLFQ*
EEVLFQ*
EEVEFQ*
VEID*
DEVD!FQGP
DEVD!FQGP
DEVD!FQGP

hR3C Protease
Deletion of Y273 and K274 of GFP

hR3C Protease
hR3C Protease
hR3C Protease
hR3C Protease
hR3C Protease
hR3C Protease
hR3C Protease
hR3C Protease
hR3C Protease
hR3C Protease
hR3C Protease
hR3C Protease

F64L, Y66W, S72A, Y145A, H148D
T65G, V68L, Q69M, S72A, T203Y
mNeptune Fluorescent protein; M2
peptide on N-terminal
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Caspase-7
Caspase-7
Caspase-7

The resulting construct

;
/&7
89,/$:

6422

was dark before

5222

cleavage by caspase-6 as
3422

expected, indicating that
2
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the quenching peptide

%&'($ %&'()$ %&'()$ %&'(*$ %&'(&$
,-./ *)0
*)01 *)01
*)01

%&'(+$
*)01

functioned analogously
as in CA-GFP. However,
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Figure 4.2. Whole cell fluorescence of caspase-6 activatable
reporter constructs. VEIDGe has the greatest fluorescence
response in the presence of active caspase-6 (gray bars) vs.
cotransformation with an empty pET vector (white bars).
Western blot analysis showed that the VEID version of the
reporter was being cleaved at an N-terminal site.

when co-transformed
with active caspase-6 in
E. coli there was no
observable fluorescence
(Fig. 4.2A), despite the

fact that there was observable cleavage by western blot analysis (Fig. 4.2B). After
comparison of the cleavage pattern observed with that of a construct in which a stop
codon was inserted after the VEID in the linker (Table 4.1), we recognized that the
cleaved fragments assessed by western blot using
!"#$

anti-GFP antibody were not at the expected
molecular weight. Closer analysis of the
sequence of GFP revealed a VELD sequence at

Figure 4.3. The three dimensional
structure of GFP (PDBID: 2YOG)
with the VELD (residues 24-27)
highlighted in the strand. (Figure
modeled in Pymol and Adobe
Illustrator courtesy of PW)

residues 24-27 near the N-terminus of the
fluorescent protein (Fig. 4.3). As GFP is very
sensitive to truncations at either termini (14), it
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was not surprising that no fluorescence was observed. We then mutated Asp27 into Glu
(D27E) to eliminate the internal VELDG sequence within GFP. The resulting VEIDFGFPe was also dark prior to cleavage but a small amount of fluorescence was observable
when co-transformed with active caspase-6 (Fig. 4.2A). Unfortunately, VEIDF-GFPe did
not show as strong a fluorescence increase as C7A-GFP. We had previously found that
CA-GFP and derivatives could be optimized best when expression constructs that express
the mature, cleaved form of the caspases were used. In our lab we call these the CT or
constitutively two-chain versions of the caspases. In these experiments we had used
caspase-6 CT (pC6 FL D179 CT), so we could expect that differences in recovery of
fluorescence were likely due to the intrinsic amount of cleavage not to differences in the
levels of active caspase-6.
Western blotting with an anti-GFP antibody showed that VEIDF-GFPe is not well
cleaved in the co-expression (Fig. 4.2B) although mature caspase-6 is expressed in
appropriate levels, as assessed by western blotting (data not shown). This is not due to a
shortage of caspase-6 activity, as in a control VEID-GFP construct that only has VEID
linker but not the D27E mutation, a majority of the expressed VEID-GFP reporter is
clearly cleaved. VEID is the reported caspase-6 preferred substrate sequence. From
literature, caspase-6, unlike caspase-7 and -3, does not have strong residue preference at
its P1’ subsite (15). However interestingly, in VEID-GFP co-expressed with caspase-6
the majority of the reporter is apparently cleaved at the N-terminal VELDG site, but not
at the linker site. While western blotting results suggest that there is also a fraction of
VEID-GFP reporter cleaved at both the N-terminal VELDG site and the VEID linker, we
did not observe any bands representing a single cleavage at the VEID linker only. This
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strongly suggests that caspase-6 cleaves the N-terminal VELDG site first and that
capsase-6 prefers a glycine at the P1’ subsite in our reporter construct. In light of this, we
further modified the VEIDFQ linker in VEIDF-GFPe into VEIDGQ. The resulting
VEIDG-GFPe reporter yields a strong fluorescent signal increase upon co-expression
with active caspase-6. As caspase-7 and -3 have P1’ preference of small residues
especially glycine, a low level increase on fluorescent signal upon caspase-7 coexpression is expected. Residues including Glu and Lys are frequently found in the P1’
subsite of substrates of caspase-6 but not in casp-3 and -7 substrates (7). However,
introducing Glu or Lys at the P1’ does not improve the signal strength of the reporter (Fig.
4.2A). Therefore, although P1’ Gly increases the basal fluorescent level in our C6A-GFPe
reporter co-expression with both empty pET vector and casp-7, VEIDG-GFPe is still
overall our best reporter considering the strong signal increase upon caspase-6 activity.

4.2.2. Profiling of caspase activity using C6A- and C7A-GFP
While all caspases have very similar catalytic diad geometries during substrate
cleavage, they have been shown to have differences in their cleavage site preferences due
to differences in the residues that comprise the peptide recognition sub-sites (S1-S4) (7).
To profile the activity of caspases-3, -6, -7, and -8 against our caspase-6 and -7 reporters
C7A-GFPe (DEVDF-GFPe) and C6A-GFPe (VEIDG-GFPe) co-transformations with both
the active and inactive forms each of the caspases was performed and the resulting
fluorescence in E. coli lysates was determined for each case (Fig. 4.4). In the case of
C6A-GFPe all of the caspases tested showed at least a 3-fold increase in activity in the
presence of the active caspase. Additional investigation is necessary in the case of C6A-
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GFPe co-transformed with the inactive

Relative Fluorescence

C6A-GFPe

7500

Inactive Caspase

Active Caspase

caspase-8 to ensure efficient
5000

expression, as it was not observed by
2500

western blot (Fig. 4.4 top), however
0

co-expression with the active caspaseCasp-3

Casp-6

Casp-7

Casp-8

8 demonstrated efficient cleavage. As

Relative Fluorescence

C7A-GFPe

15000

Inactive Caspase

Active Caspase

expected the strongest response was

10000

from caspase-6 ! (greater than 14-fold)

5000

(Fig. 4.4 top). Western blotting using

0

an anti-GFP antibody shows that in the
Casp-3

Casp-6

Casp-7

Casp-8

Figure 4.4. The relative fluorescence of C6AGFPe (top) and C7A-GFPe (bottom) in response to
co-transformation with inactive (white) or active
(gray) caspases -3, -6, -7, and -8. Below the
fluorescence an anti-GFP western blot shows the
cleavage or lack thereof in each case.
Fluorescence measurements of each case are as
follows: C6A-GFPe with inactive caspase-3
(n=1), active caspase-3 (n=4), inactive caspase-6
(n=2), active caspase-6 (n=2), inactive caspase-7
(n=4), active caspase-7 (n=4), inactive caspase-8
(n=2), and active caspase-8 (n=2). For C7A-GFPe
with inactive caspase-3 (n=1), active caspase-3
(n=4), inactive caspase-6 (n=2), active caspase-6
(n=2), inactive caspase-7 (n=2), active caspase-7
(n=2), inactive caspase-8 (n=4), and active
caspase-8 (n=4).

presence of caspase-7 C6A-GFPe is
only partial processed, indicating that
while it is able to cleave the caspase-6
cleavage sequence VEID, it does not
prefer this recognition sequence.
Thus, it appears that C6A-GFPe is a
reasonably good reporter for caspase6 activity, since caspase-6 triggers 3-4
fold greater response than other
related caspases.

In the case of the C7A-GFPe, caspase-7 clearly triggers the greatest response (Fig.
4.4 bottom). It was surprising to us that though caspases -3 and -8 were able to
efficiently cleave C7A-GFPe, they did not result in a similar level of fluorescence
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reporting as caspase-7. This observation remains an open question in the lab. Caspase-3
is generally considered a more robust protease than caspase-7. Caspase-3 has a catalytic
rate (kcat/KM =1.8 µM-1s-1) nearly one order of magnitude higher than caspase-7 (kcat/KM
=0.4 µM-1s-1)(16). Although caspase-3 and -7 share the same preferred recognition
sequence when assessed with peptide substrates (DEVD) it is possible that due to it’s
higher turnover number caspase-3 cleaves other E. coli proteins and therefore more
detrimental to the cell over the 18 hour induction period. It is also possible that it is
cleaving the reporter at additional sites, as was observed at the N-terminal VELDG site in
the original C6A-GFP. We do not observe any additional bands by western blot, however,
it is possible that if the additional sites cleave the reporter into sufficiently small
fragments the antibody would no longer be able to recognize them. It preliminarily
appears that the GFP portion of C7A-GFPe may house a second recognition site that
decreases activity. In cells co-expressing DEVD*, which expressed GFP with DEVD at
the C-terminus followed by a stop codon (*), with inactive caspase-3 (C163A) the
fluorescence is more than seven-fold of that with the active caspase-3. Though these
results are preliminary this suggests that active caspase-3 is cleaving GFP in a location
that leads to its decreased fluorescence. This site has not yet been identified but is the
subject of ongoing work in the lab. Although caspase-8 prefers the recognition sequence
LETD (7), is has previously been reported to cleave at the caspase-7 recognition
sequence DEVD(17). We also observe efficient cleavage of C7A-GFPe though the
fluorescence recovery is lower than one might expect for this level of cleavage. The
observation that multiple caspases have the ability to cleave the substrates typically
thought to be predominantly recognized by other caspases supports the idea that while
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caspases are reported to have very specific cleavage preferences they are able to
recognize the substrate of the other caspases in the absence of the intended caspase (18).
The efficient processing of the reporter with the notable lack of fluorescence as seen in
the cases of caspase-8 cleavage of both C6A-GFPe and C7A-GFPe and caspase-7
cleavage of C6A-GFPe is somewhat confounding. In the latter case there is only partial
processing observed, however, the fluorescence is approximately half that expected for
50% processing. Further investigation is necessary to ensure processing is occurring at
precisely the expected linker site and no other. Sequence analysis does not suggest any
compelling secondary cleavage sites, as was the case with caspase-6 cleavage of the first
C6A-GFP (VEIDF-GFP) construct. On the other hand, secondary cleavage sites that
decrease the response to other caspases could have some advantages. In particular we
have taken advantage of this characteristic when we have used CA-GFP variants for
directed evolution experiments.

4.2.3 Engineering new proteolytic recognition: human Rhinovirus 3C
By successfully engineering a caspase-6 reporter we gained some insight into how
the CA-GFP concept could be adapted to report on other biomedically important
proteases. In addition to building a relevant reporter, we also wanted to target a protease
with a similar recognition sequence to the one in CA-GFP but that would cleave in a
different position so that we could assess whether the length of the remaining C-terminal
tail after cleavage would impact fluorescent recovery.

We varied the linker sequence in

our new protease activatable (PrA-GFP) reporter to yield a specific reporter for human
rhinovirus 3C (hR3C) protease which also is commercially available as PreScission®
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Protease (GE Healthcare). hR3C has a preferred substrate sequence of LEVLFQGP (19).
Our initial design changed the DEVDFQGP sequence in CA-GFP to LEVLFQGP,
yielding a reporter with a moderate 5-8 fold increase in fluorescence upon hR3C protease
co-expression. Not only is the fluorescence increase much less than for CA-GFP coexpression with caspase-7, the relative fluorescence after cleavage is also very low in
comparison to CA-GFP or C6A-GFPe (Fig. 4.5A). This is not due to different expression
level of the reporter nor is it related to the completeness off the proteases digestion (data
not shown). Sequences of CA-GFP and LEVLFQ-GFP are identical other than the
substitution of two aspartates (D) for the two leucines (L) in the linker. Due to the
position of the cleavage site within the recognition sequence, caspase-7 generates a
DEVD C-terminus in CA-GFP while hR3C protease yields LEVLFQ at the C-terminus,
giving a C-terminal remnant two residues longer in length. In order to increase the
reporter detectability while keeping its specificity against hR3C protease, we made a
spectrum of variations by point mutations of several linker residues. We first investigated
the impact of length of C-terminal remnant. We removed Tyr and Lys residues just
preceding the LEVLFQ sequence (HRA-∆YKGFP, Table 1) to yield a C-terminus with
equal length to DEVD, and we did not observe significant improvement in signal. We
then focused on the LEVLFQ linker, especially the two leucines which represent the only
sequence difference between CA-GFP and LEVLFQ-GFP. We replaced the leucines in
LEVLFQ-GFP with negatively charged or hydrophilic residues. Replacing the two
leucines indeed leads to significant increase in fluorescent signal in all the new reporters
(Fig. 4.5A). Both DEVLFQ-GFP and EEVLFQ-GFP show a strong increase in
fluorescence upon co-expression of hR3C protease while still maintaining recognition for
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cleavage. Other linker variants either
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have lower signal strength or higher
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background in the dark state.
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LEHDFQ-GFP shows a similar signal
to noise ratio and even stronger signal
"

strength, however, LEHD is a
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caspase-9 recognized sequence and
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therefore it is not specific to hR3C
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protease.
Figure 4.5. A. Fluorescence response of PrAGFPs containing various linker sequences to
human Rhinovirus 3C (hR3C) (top), B.
Constructs with a stop codon (*) inserted at the
expected cleavage site were also tested to
determine the effect the C-terminal remnant had
on fluorescence recovery. The remnant LEVLFQ,
the reported hR3C cleavage recognition sequence,
yields the lowest fluorescence recovery indicating
that this remnant may have deleterious influence
on refolding of GFP and chromophore maturation.

In our efforts to investigate
why the LEVLFQ-GFP reporter has a
lower fluorescent signal, we
introduced stop codons either after
the glutamine in the linker to mimic
the C-terminus generated by hR3C
cleavage, or before the phenylalanine

to mimic the length of the remnant in CA-GFP cleavage by caspase-7. Our results clearly
show that the C-terminal LEVLFQ remnant strongly affects the fluorescent signal of GFP
(Fig. 4.5B), likely due to the clustering of four hydrophobic residues which may lead to
aggregation and prevent GFP chromophore maturation. As expected, when we replaced
the phenylalanine with glycine in the reporters, we also observed further fluorescent
increases, both before and after cleavage. In LEHDG-GFP the linker sequence may be
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too different from an optimized hR3C substrate and therefore is not well recognized (Fig.
4.5A).

4.2.4. Engineering viral protease recognition: Dengue virus protease and HIV
Protease
We sought to further expand our PrA-FP family by the inclusion of reporters for
two additional viral proteases of particular interest in drug design. The first is a reporter
for Dengue virus protease. Worldwide there are 2.5 billion people at risk of infection
with Dengue fever (20). Dengue is unique from other viruses, which are traditionally
combated by vaccination, in that effective vaccination requires a tetravalent vaccine
which has not been successfully developed (21). In an alternative to vaccination the viral
protease, Dengue Virus Protease (DVP), is one of the targets for drug design in the
development of new therapies for this global health problem. DVP2 is a serine protease
responsible for the processing of the viral polyprotein and recognizes the substrate
sequence GRR (22). Dengue virus has been shown to induce apoptosis in infected cells
(23), therefore having a Dengue virus protease reporter (DVPA-GFP) would allow realtime imaging of the activation of the viral proteases leading to the activation of the
apoptotic cascade. The first DVPA-GFP design simply replaced the first three residues
of the CA-GFP linker (DEV) with the DVP2 recognition sequence GRR, leaving the
remainder of the linker identical (Table 4.2).
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Table 4.2. Comparison of the linker sequence
of CA-GFP and the DVPA-GFP and HIVAGFP reporters (! indicates the site of
cleavage by the intended protease).
Version of GFP Reporter Linker Sequence
CA-GFP
DEVD!FQGP
DVPA-GFP
GRR!DFQGP
DVPA-GFP_v1
GRR!GFQGP
DVPA-GFP_v2
DEGRR!GGP
HIVA-GFP
VSFNF!PQITL

Expression of the DVPA-GFP in E. coli
showed that this alteration of the linker
sequence did not alter the presence of the
critical dark state of the reporter.
Incubation of
ep
DVP2
purified

DVPA-GFP with active DVP2 did not yield any
change in fluorescence even after 18-24 hr incubations.
SDS-PAGE analysis of the reaction did not indicate
any cleavage of the reporter,
er,DVPA-GFP_v1

DVPA-GFP_v1 + DVP2

although analysis was
complicated by the fact
that DVP2 has a
molecular weight of 30.5
kDa, very close to that

DVPA-GFP_v2

DVPA-GFP_v2 + DVP2

of DVPA-GFP so it was
difficult to accurately

assess cleavage.
Further
investigation of the
literature revealed that

Figure 4.6. Two-dimensional gel analysis of dengue virus
protease 2 (DVP2) (top) with two DVP2 activatable reporters
DVPA-GFP_v1 (middle) and DVPA-GFP_v2 (bottom).
Each reporter was run after a 24 hr incubation with the
protease (right) and independent from the protease (left).
Though the bands are broad and not conclusive it does not
appear as though there is any significant cleavage of the
reporter by the protease.
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DVP2 has a very low preference for charged residues in the P1’ substrate sub-site (22),
suggesting that the linker sequence may not be ideal for cleavage. Two further DVPAGFP constructs were cloned, changing the P1’ site to a more preferred residue, glycine
(DVPA-GFP_v1), and in one construct moving the recognition sequence further from the
C-terminus of GFP (DVPA-GFP_v2). Both of these additional constructs also exist in a
dark state when expressed, however, once again neither showed any increase in
fluorescence after a 24 hr incubation of purified reporter with active DVP2. Western blot
analysis of the cleavage was attempted however the DVP2 appears to cross-react with the
anti-GFP antibodies used further confounding this analysis. We undertook a two
dimensional gel analysis to facilitate separation of DVP from DVPA-GFP. Though the
results were not definitive due to the broad band of both proteins from the isoelectric
focusing, the results did not indicate any cleavage (Fig. 4.6). A GST-tagged version of
DVP2 was constructed in an effort to better separate the two proteins in SDS-PAGE
analysis however the GST fusion further diminished the already low catalytic activity (on
the order of minutes-1, data not published) of the DV protease, so this approach also
proved intractable and work on DVPA-GFPs has been suspended. Future development of
a DVPA-GFP may be more complicated than other proteases because of the low catalytic
activity of the existing protease construct. While caspases have evolved to cleave a
variety of substrates and prefer to cut in loop regions DVP2 has evolved for a much more
specific function in the viral life cycle. It is possible that there are exosites which help
DVP2 recognize its polyprotein substrate specifically rather than only the active site
geometry dictating cleavage. This is plausible given the fact that non-specific cleavage
could lead to premature cell death or the triggering of an immune response, which would
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be detrimental to the viral life cycle. A very slow protease may be sufficient for cleaving
the polyprotein, due to the proximity of the intramolecular cleavage reaction and this low
catalytic turnover may be beneficial in avoiding degradation of necessary host
components. Alternatively, DVP2 may simply be a very primitive protease due to its
origins.
Another important proteolytic drug target is HIV protease. There are currently
several FDA approved therapeutics that target HIV protease however the ability of the
virus to rapidly acquire resistance to these therapies has led to a continuing need for
candidate drugs. A cost effective and robust reporter such as CA-GFP would allow for
high throughput screens of activity in the presence of potential inhibitors as well as assist
in directed evolution approaches studying this rapid acquiring of resistance. The
substrate recognition sequence for HIV protease is significantly longer than that of the
previously discussed reporters. Though HIV protease recognizes several sequences we
chose the sequence of the transframe (TF) – protease (PR) domain cleavage site;
VSFNFPQITL (24) (Table 4.2). HIVA-GFP was also dark when expressed in E. coli.
Co-transformations with the protease did not yield any increase in fluorescence. This is
most likely due to the fact that HIV protease forms inclusion bodies when expressed in
bacteria and is therefore not available in the cytosol as was the case for the previously
tested proteases on other PrA-GFPs.
Due to the difficulties of expressing active proteases, so far we were unable to
verify the successful activation of or DVPA or HIVA-GFP reporters. However,
development of these reporters was nonetheless informative. It shows that we can alter
and even extend the linker region while maintaining the dark state of the reporter. This
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indicates that though the tail remnant after cleavage could affect fluorescence recovery,
the length or the sequence of the linker itself is not as essential as the quenching peptide
in maintaining the dark state of the PrA-GFPs. This further fortifies our hypothesis that
CA-GFP is a flexible platform that can be engineered to fit into the need of a broad
protease activity monitoring.

4.2.5. Engineering various colors of PrA-FPs for multi-protease reporting
As discussed above, caspase-6 has a unique role in neurodegeneration and is
therefore a target of drug development independent of the other executioners. With an
effective C6A-GFP we can monitor caspase-6 activity in neurons and other cell types to
determine specific activity levels in comparison to the activity levels of caspase -3 and -7.
We could also monitor the activity of executioner caspases simultaneously to ensure that
caspase-6 is self-activating in these situations and not being activated by any of the
initiator or even inflammatory caspases through an unknown mechanism. The ability to
simultaneously monitor multiple caspases at once depends firstly on the ability to have
multiple reporters with linker sequences correlating to the reporter preference of each
caspase and secondly these reporters need to have minimally overlapping spectral
properties. For example if C6A-CerFP, C7A-CitFP, and a C1A-mNeptune were all
monitored simultaneously in neuron cells we would be able to observe caspase-6
activation independently of -7 as well as monitor any conditions which lead to the
inflammatory caspases (caspase-1) contributing to caspase-6 activation (25). These
experiments are currently being done using antibody recognition of full-length and
cleaved caspases (26) however, this requires the expensive and time consuming process
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of developing antibodies for each form of each caspase. It also is assuming that the
activity of the caspase is strictly correlated with it’s form, which while true in vitro, may
not necessarily be the case in all in vivo scenarios. This method also requires fixing and
staining of samples for imaging. The CA-FP’s would allow for real-time imaging in
whole organisms, allowing for a much more in depth analysis of the molecular processes.
As several of the various color shifted version of GFP result from only a few
point mutations, we hypothesized that the color of the fluorescent protein in CA-GFP
could be shifted to cyan and yellow versions without disrupting the mechanism of the
dark state. We designed CA-Cerulean (27) (CA-CerFP) and a CA-Citrine (28) (CACitFP) versions of
our reporter which
both still contain the
caspase-7
recognition sequence
DEVD in the linker.
These fluorescent
proteins have
minimally

Figure 4.7. The constructs for CA-CerFP, CA-CitFP, and CAmNeptune. The constructs for CA-CerFP and CA-CitFP are
identical to CA-GFP with the exception of the color shifting point
mutations in the GFP portion of the reporter. CA-mNeptune has
the quenching peptide fused to the N-terminus of the mNeptune
fluorescent protein derived from Entacmaea. All three reporters
have a significant response to active caspase (colored bar) when
compared to the response inactive caspase (white bar).
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overlapping
excitation and
emission
wavelengths and
both have the highest

quantum yield for their color class (29) giving them the most potential for the best signal
to noise ratio possible. Both versions are in a dark state when co-expressed in E. coli
with the inactive caspase-7 C186A and have a significant increase in fluorescence when
co-expressed with active caspase-7 (Fig. 4.7). This demonstrates that the CA-GFP
platform is adaptable and can be modified to produce various colors of reporters. We also
were motivated to see if the dark state existed in a version using a red fluorescent protein.
Red-shifted fluorescent proteins are becoming more widely used as their emission
properties fall within the ‘critical window’ for whole organism imaging due to the deep
tissue penetrance for red wavelengths of light and the absence of background
autofluorescence in tissues in this spectral region. The red fluorescent proteins (RFPs)
are derived from Entacmaea quadricolor (30). While they have a different protein
sequence to GFPs from Aequora, the protein folding of the two families are strikingly
similar. We selected mNeptune (10) for its improved brightness and spectral properties in
the near IR region increasing its popularity for in vivo imaging. In our first design of CAmNeptune we fused the M2 peptide through an identical linker as CA-GFP to the Ctermius of mNepture, however, this protein showed a considerable level of fluorescence
prior to cleavage. As we had already observed that an N-terminal fusion of M2 to GFP
resulted in a dark state prior to cleavage (nCA-GFP, chapter III) we reasoned that we may
see a similar effect with mNeptune. The resulting N-terminal fusion, CA-mNeptune has
a very low fluorescent background and over a thirty-fold increase in signal when cleaved
by active caspase after cotransformation in E.coli.
Though all three reporters have a very clear activation and are an improvement
over the signal to noise of comparable reporters the CA-mNeptune, CA-CerFP and CA-
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CitFP reporters differ greatly in their overall fluorescence intensity as well as their foldincrease in fluorescence over the background from CA-GFP. We reasoned that this is
due not only to the difference in published quantum yields of the mNeptune (10),
Cerulean (27) and Citrine (28) variants but also due to the differences in folding kinetics
of the different fluorescent proteins (31,32) (see Chapter III) (Table 4.3).
Table 4.3. The values for the increase in fluorescence for each reporter as well as the
reported quantum yield for each fluorescent protein and the brightness of each reporter
after cleavage by active caspase-7 in E.coli lysates relative to CA-GFP.
Reporter
C7A-GFP
C7A-CerFP
C7A-CitFP
C7A-mNeptune

Fold-Increase
upon Cleavage
45±4
18±2
12±7
32±5

Relative
Brightness
1
0.06
12
0.002

Quantum Yield of
Fluorescent Protein*
0.66 (33)
0.62 (27)
0.76 (28)
0.20 (34)

Ex. λ
(nm)
475
433
513
530

Em. λ
(nm)
512
475
529
650

In designing the CA-mNeptune we began with a C-terminal fusion of the quenching
peptide similar to the CA-GFP constructs, however, we found that we see lower
fluorescence background before cleavage when the peptide is fused to the N-terminus.
We designed N-terminal constructs in the GFP reporters as well but observed much lower
fluorescence recovery (see Chapter III). We reason that this difference is due to the
differences in the folding intermediates of the two different proteins and their respective
abilities to fold into the conformation necessary for chromophore maturation after
cleavage of the peptide. The four fluorescent proteins described here; GFP, Cerulean,
Citrine, and mNeptune constitute a panel of spectrally distinct fluorescent proteins which
have individually been engineered for improved brightness in their respective families of
color (cyan, yellow and red). Each can be used individually to monitor specific
proteolytic events or together to watch several events using multi-channel imaging. The
CA-mNeptune in particular has potential for effective use in whole animal models as
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mNeptune’s fluorescence falls in the ‘near-infrared window’ which minimizes
background from water and hemoglobin in tissue.

4.3. Conclusion
CA-GFP has proven itself a useful and effective reporter of caspase activity and
apoptosis in a variety of systems (Chapter II). Throughout this chapter we have shown
that CA-GFP can be manipulated not only to change the protease specificity of the
reporter but the color of fluorescence as well. By expanding the color palette PrA-FPs
can be used in multiplex microscopy, FACS sorting, and directed evolution applications.
While there are challenges in engineering PrA-FP’s they are similar to the challenges that
exist in the development of any reporter. The reporter can only be as specific as the
protease it is monitoring. The character of the protease is the most important factor in the
design, all potential processing sites must be considered as well as the propensity of the
protease to cleave in specific secondary structure conformations, such as a loop. The
ability of multiple proteases to cleave a similar substrate is also a major limitation as in
the example of the LEHDF-GFP, which can be cleaved by hR3C protease but is also the
substrate for caspase-9. This overlapping specificity may be overcome by the use in
conjunction with small molecule inhibitors for one class of proteases while monitoring
the activity of the desired protein.
In order to be effective in isolating the activity of a specific caspase
independently of the others it is imperative that the reporter only responds in the presence
of the selected protease. Our profiling results indicate that while we see significantly
higher fluorescence in the case of the caspase the reporter was designed for, there is still
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signal from the other caspases as well and the level of selectivity is not ideal. The ability
of caspases to cleave secondary sites, as we found in caspase-6 may be used to our
advantage if we design a reporter which could be activated in the presence of the desired
caspase but inactivated by secondary cleavage if multiple caspases are active. This is
obviously not a useful reporter in the case of apoptosis where all caspases are activated,
but could be useful in verifying the unique non-apoptotic activities of caspases, such as
the activation of caspase-6 and only caspase-6 in neuronal cells; if caspases other then
caspase-6 are active the we will not see any fluorescence. This reporter would also
necessitate a multiple reporter system, similar to that used in mammalian cells in chapter
II, where a constitutively active fluorescent protein is co-expressed to ensure expression
of the reporter.
Our observation that caspases have not had the same affinity for their respective
PrA-FP’s as reported for peptide substrates correlates with the idea that the small peptide
substrates that have been widely used to characterize protease activity may not be
reflecting the entire selectivity properties of proteases and that when presented with a
protein substrate the sterics and kinetics are significantly different. The size and active
site conformations of some proteases may not allow for efficient processing of the linker
regardless of the sequence. A better understanding of the sterics and geometry of the
linker region are necessary to ensure that it is fully accessible. It has also recently been
recognized that small tetrapeptide substrates do not take into account any P1’ preferences
of the proteases. Recently it has been reported that though caspases-3 and -7 share the
same P1-P4 specificity that the P6, P5, P2’ and P3’ residues were able to contribute to
caspase-7 specificity in substrates (35). These extended recognition properties may not
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only suggest why we do not observe the same cleavage kinetics as with tetrapeptide
substrates but also gives us an advantage in designing specificity as more is understood
about the extended recognition preferences of caspases.
The study of proteases and their activity is an expansive and important genre of
research and we hope that our examples of the versatility of the CA-GFP reporter
platform encourage other researchers to utilize this technology in their respective fields.

4.4. Materials and methods
4.4.1. Molecular cloning
Caspase-6 and hR3C protease reporters: CA-GFP in pBB75 contains a DEVDFQ
linker as previously described (3). All caspase-6 and hR3C protease reporter variations,
unless specified, are based on this construct with the DEVDF sequence in CA-GFP
mutated to corresponding sequences by site-directed mutagenesis using overlapping
inverted primers and amplification of the entire plasmid similar to the QuikChange®
(Agilent) approach. In all constructs denoted GFPe (Table 4.1), an additional D27E
mutation has been introduced by site directed mutagenesis to eliminate the internal
caspase-6 recognition site (VELDG, residues 24-28) in GFP.
DVPA-GFP and HIVA-GFP were generated using site-directed mutagenesis
using overlapping inverted primers and amplification of the entire plasmid similar to the
QuikChange® (Agilent) approach on the linker region using CA-GFP as the parent
plasmid. DVPA-GFP_v1 and _v2 were also generated similarly by introducing mutation
in the linker region of DVPA-GFP.
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CA-CerFP and CA-CitFP: The CA-CerFP construct was developed by
replacement of the codons for the following residues in CA-GFP F64L, S72A, Y66W,
Y145A, and H148D. These substitutions were made through multiple rounds of single
point mutagenesis using a modified QuikChange® (Agilent) protocol with CA-GFP in
pET21b as the template plasmid. The CA-CitFP construct was developed also using CAGFP in pET21b as the template plasmid for replacing resides T65G, V68L, Q69M, S72A,
and T203Y through multiple rounds of modified Quikchange® mutagenesis.
The CA-mNeptune expression construct was generated by amplifying the peptide
(M2) region from the CA-GFP gene separately from the mNeptune gene using two
primers to amplify M2 and two primers to amplify mNeptune. The mNeptune parent was
generated by replacement of the codons for M41G, A45V, S61C, A158C, and Y197F in
the mKate2 gene in the pmKate2C vector (Evrogen). The first primer (P1) annealed to
the N-terminal region of the mNeptune gene with the linker sequence included N-terminal
to the mNeptune gene. The second primer (P2) annealed to the C-terminus of mNeptune
and included a stop codon (UAA) and the restriction site for XhoI. The third primer (P3)
included an NheI restriction enzyme site as well as a 6His sequence and annealed to the
N-terminal region of the M2 portion of the CA-GFP gene. The last primer (P4) annealed
to the C-terminus of M2 and included the same sequence for the linker as P1, giving
primers P1 and P4 a 24 bp overlapping region. The mNeptune fragment was then
amplified using primers P1 and P2 while the M2 portion was amplified using primers P3
and P4. After gel purification of the amplified fragments they were combined and
allowed to anneal through the overlapping region for five PCR cycles before the addition
of primers P2 and P3 which then amplified the full length gene. The gene was then
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ligated into pACYC pETDuet vector into NheI and XhoI sites. The final sequence of the
N-terminal peptide and linker is
MHHHHHHMCNDSSDPLVVAASIIGILHLILWILDRLDEVDFQGP which is
appended to the N-terminus of mNeptune. The full-length construct was then further
amplified using PCR and ligated into the EcoRI and NotI sites of pET21b. (We thank Jun
Chu for construction of the CA-mNeptune gene in the pACYC vector).

4.4.2. Fluorescence assays in cell lysates
Expression constructs for the fluorescent protein reporters CA-GFP, CA-CerFP,
CA-CitFP, and CA-mNeptune, each in the pET21b vector, which also contains an
Ampicillin (Amp) resistance gene, were co-transformed via electroporation in
BL21(DE3) strain E. coli with expression constructs for an active constitutively twochain version of caspase-7 or a full-length inactive version of caspase-7 in which the
active site cysteine has been mutated to alanine (C186A) in the vector pBB75, which also
contains a Kanamycin (Kan) resistance gene. 50 mL LB cultures supplemented with 100
µg/mL ampicillin and 40 µg/mL kanamycin were inoculated with 50 µL from a dense 5
mL overnight culture and incubated until reaching an OD600 of 0.6. The cultures were
then induced with 1 mM IPTG for 18hrs at 25°C. From each sample 800 µL aliquots
were taken in duplicate, pelleted by centrifugation and resuspended in a buffer of 0.5
mg/mL lysozyme and 2 units DNAase. After lysis with four cycles of freeze-thaw the
supernatant of each sample was measured for fluorescence. CA-GFP (Ex. 475/ Em. 512
nm), CA-CerFP (Ex. 433/Em. 475 nm) and CA-mNeptune (Ex. 530 / Em. 650 nm)
fluorescence measurements were taken in a co-star 96-well black plate on a Molecular
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Devices Spectramax M5 spectrophotometer. CA-CitFP (Ex. 515 / Em. 529 nm)
fluorescence was measured on a JASCO FP-6500 spectrofluorometer using a quartz cell.
Fluorescence values were normalized to the total number of cells in culture, which was
estimated from the relative OD600 of each culture.

4.4.3. Fluorescence assays in whole cells
Expression constructs for caspase-6 or hR3C protease reporters contained in the
pBB75 vector (Kan) were co-transformed into the BL21(DE3) strain of E .coli with either
an active constitutively two-chain version of caspase-6 (13) in pET11b (Amp), an hR3C
protease in GEX- vector (Amp), a gift from M. Romanowski , or with an empty pET21b
(Amp) vector as a control. 2 mL auto-induction media (AIM) cultures were inoculated
from a dense 100 µL overnight LB(Amp/Kan) culture with 100 µg/mL Amp and 40
µg/mL Kan and incubated until reaching an OD600 of 0.6-0.9. The cultures were then
incubated for 18hrs at 16°C. From each sample, the cells are rinsed with PBS,
resuspended and diluted in PBS to a final OD600 of 2.0. 200 µL of this diluted suspension
was measured for GFP fluorescence (Ex. 475/ Em. 512) in a co-star 96-well black plate
on a Molecular Devices Spectramax M5 spectrophotometer.

4.4.4. Protease profiling of C7A- and C6A- GFPe
Expression constructs for the reporters C7A-GFPe and C6A-GFPe in the vector
pBB75 with Kan resistance were co-transformed into the BL21(DE3) strain of E. coli
with expression constructs for either active or inactive variants of caspases -3, -6, -7, -8,
and -9 in pET vectors, which also contain an Amp resistance gene. In the case of
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caspase-3 expression construct, the active version was the wild-type human caspase-3
sequence in pET23b and the inactive version was the active site knock out C163A. For
caspases-6 (pET11a) and -7 (pET23b), the active versions are constitutively two-chain
constructs that express the large and small subunits separately and which require no
further processing for activation. The inactive version of caspase-6 is a full-length
uncleavable (FLUC) (pET11a) version in which all self-processing sites have been
mutated to alanine (D23A, D179A, D193A) to prevent cleavage into the large and small
subunits therefore yielding the protein inactive. The inactive version of caspase-7 is the
full-length human sequence with the active site cysteine mutated to alanine to prevent
activity. In the case of caspase-8 both the active and inactive versions are the human
gene sequence which lack the N-terminal death effector domain (DED) in the vector
pET15b, with the inactive mutant being the active site knock out C285A.
After co-transformation, 50-mL LB cultures were inoculated from a dense
overnight culture with the appropriate double antibiotic selection. Cells were grown,
induced, and lysed as described above in the lysate fluorescence assays section.
Fluorescence measurements of the supernatant samples were taken in a co-star 96-well
black plate on a Molecular Devices Spectramax M5 spectrophotometer (Ex. 475/ Em.
512). Fluorescence values were normalized based on the relative OD of each culture.

4.4.5. Western Blotting
Samples of supernatant were taken from E. coli cell lysate prepared as described
above for the lysate fluorescence assays. Identical SDS-PAGE gels were run of each
sample to be blotted with the required primary antibody. One of the identical SDS-
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PAGE gels was transferred to nitrocellulose and blotted with an anti-GFP (Millipore)
monoclonal mouse primary antibody. The western blots were then treated with antimouse IgG alkaline phosphatase produced in goat (Sigma) and visualized using 1-Step™
NBT/BCIP (Thermo Scientific). The identical gel was stained with Coomassie.

4.4.6 in vitro analysis of DVPA-GFP
DVPA-GFP, DVPA-GFP_v1 and DVPA-GFP_v2 were each incubated with
DVP2 at a 1:1 molar ratio in 100mM Tris pH 8.0, 50 mM NaCl at room temperature
overnight. Fluorescence was measured using a Molecular Devices Spectramax M5
spectrophotometer monitoring fluorescence (Ex. 475/ Em. 512) over 18-24 hours.

4.4.7. Two Dimensional Gel Analysis
DVPA-GFP_v1 and DVPA-GFP_v2 were incubated 18 hrs at room temperature
in 100 mM Tris pH 8.0, 50 mM NaCl with the active DVP2 at a concentration of 5
mg/mL for each protein. After 18 hrs the samples were diluted 10-fold in a rehydration
buffer of 8M Urea, 2% CHAPS, and 50 mM DTT. IPG strips (7 cm, Biorad) with a pH
range of 4-7 were incubated at room temperature in a volume of ~130 µL per sample.
After 1 hr the strips were covered with mineral oil (~1mL) and incubated at room
temperature for ~12 hours. After rehydration was complete the mineral oil was removed.
Isoelectric focusing was run on a Biorad Protean IEF Cell instrument on the ‘rapid’
ramping mode. Once the method was complete the samples were stored at -80°C
overnight. The samples were thoroughly thawed and incubated in Equilibration buffer 1
(6M urea, 2% SDS, 0.05M Tris HCl pH 8.8, 20% glycerol, 2% DTT), in a volume of 2.5
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mL. After a 10 min incubation the buffer was decanted and replaced with 2.5 mL of
equilibration buffer 2 (6M urea, 2% SDS, 0.05M Tris HCl pH 8.8, 20% glycerol, 2.5%
Iodoacetamide), and incubated for another 10 min. The IPG strips were then loaded onto
a 16% acrylamide SDS-PAGE gel and overlaid in a solution of 0.5% agarose in 1X SDSPAGE running buffer with 0.003% bromophenol blue as an indicator for the gel front.
After the solidification of the agarose the SDS-PAGE gel was run to completion and
stained with coomassie.
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CHAPTER 5
CA-GFP DEVELOPMENT AND APPLICATIONS

5.1. CA-GFP: A model reporter of apoptosis
Apoptosis is arguably one of the most widely studied cellular processes. A
PubMed search of the keyword ‘apoptosis’ yields over 92,000 references just in the last
five years. It is critical that we understand each step of the cascade not only in disease
models but also in normal cellular development and homeostasis. As we develop drug
targets throughout the apoptotic pathway it is essential we understand the ramifications of
treatment on healthy cells as well as those specifically targeted. In order to fully
understand these intricacies the ability to study apoptosis longitudinally in whole animal
models is essential.
In chapter I we set forth our criteria for an ideal apoptotic reporter. They were
that it should be genetically encoded for non-invasive monitoring. It should respond
independently of any cellular co-factors in a dark to bright mechanism for ease in
detection. Lastly it should be amenable for in vitro, E.coli, FACS, and mammalian cell
applications. Throughout this thesis we have underscored how CA-GFP fits each of these
criteria. We have sought to characterize not only the function but the mechanism by
which this reporter operates in an effort to emphasize the potential of our system. While
CA-GFP has proven effective in it’s own right, as outlined in chapters II-IV there are
challenges in engineering CA-GFP to respond to other proteases, however they are not
insurmountable. The first challenge in making CA-GFP a more ideal reporter system is
improving the kinetics of the fluorescent response to cleavage. By engineering a version
in which the fluorescent response was near instantaneous it would allow for kinetic
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analysis of protease activity in vivo, similarly to the method in which small fluorogenic
substrates are currently used in vitro. The other major challenge in the development of
CA-GFP remains the ability to thoroughly control the effects of the peptide. With a
detailed understanding of the peptide interactions the quenching mechanism has the
potential to allow for the activation of GFP fluorescence in response to other enzymatic
reactions such as phosphorylation or protein conformational changes in signaling
pathways. Lastly there is more work to be done in obtaining an optimal caspase
activatable- fluorescent protein (CA-FP) for use in whole organism models as this
application holds the greatest potential impact for CA-FP use.

5.2. Analysis of background fluorescence
The most unique and advantageous feature of CA-GFP and its derivatives is the
presence of the dark state. As discussed in chapter III our model for the existence of the
dark state is that the presence of the peptide stalls CA-GFP in it’s sample of native
folding conformations leaving CA-GFP in a ‘pro-folding’ intermediate state. There is a
noticeable difference in background between species, different colors, and different linker
sequences though all background levels are significantly less than the fluorescence of the
cleaved form. The assumption is that some level of background is from autofluorescent
proteins in the bacterial cells or lysate as it is commonly accepted that there is significant
background in this range of the spectrum. Some portion of the background is also
presumably from some fraction of the CA-FP molecules which have achieved the mature
conformation despite the presence of the peptide. The obvious explanation for the
variation from one reporter to another is that a different portion of these molecules have
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achieved this mature conformation. From our model in chapter III it would imply that the
folding rates of each reporter is slightly different. It has been observed that different
versions of the fluorescent protein family have widely different folding and maturation
rates, even when differing only by a few point mutations. When comparing the dark state
of the reporters with the range of linker sequences we have constructed (Fig. 1) we see
that the constructs which have bulky hydrophobic residues in the linker have a lower
background level than those with charged residues in the linker. As we observed
previously these reporters have a lower fluorescence recovery when cleaved and so it
correlates that the background of these versions is also lower. Lengthening the linker
does not appear to have a significant effect on the background in the case of HIVA-GFP
(linker sequence: VSFNFPQITL, Fig. 1), however this linker sequence also contains
several hydrophobic residues which lead to a decrease in fluorescence in the original
linker. It would be interesting to see if a longer, more charged linker shifted the
background properties significantly. It would also be useful to test the effect of longer
more standard fusion linkers such as a Gly-Ser linker (1) and determine if this made any
difference when still fused to the peptide.
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Figure 5.1. Comparison of the relative background fluorescence of reporters
cotransformed with an empty pET vector and are therefore uncleaved. The different
reporters are identified by their linker sequence. Reporters with more hydrophobic resides
in their linker tend towards lower background fluorescence.
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Figure 5.2.!Comparison of the relative background fluorescence in caspase activatable
reporters of varying versions of GFP when co-transformed with inactive capsase-7
(C186A).!

The background also varies greatly based on any point mutations within the fluorescent
protein portion of the reporter as well. In Figure 2 we see that the introduction of the
""#!

F64L mutation to the S65T background used in CA-GFP, which comprises the widely
used EGFP version (2), drastically changes the background of fluorescence. F64L is
known to have a much higher quantum yield that S65T, which is why it is widely used,
and so it is possible that a similar portion of the uncleaved reporter is maturely folded
however the fold increase of CA-EGFP after cleavage is only 4-fold, indicating that
either there is a higher percentage already maturely folded or it is more difficult for this
version to attain the mature conformation once it is cleaved, essentially a greater fraction
of the cleaved CA-EGFP are trapped in the ‘pro-folding’ state rather than continuing on
in the folding pathway. As the F64L mutation is only one residue from the chromophore
it is possible that this mutation directly effects the chromophore’s folding geometry. In
the case of CA-CerFP and CA-CitFP there are several point mutations near the
chromophore which shift the fluorescent properties, these mutations could also affect the
folding of the chromophore region. However some of these mutations are on the protein
surface which could effect the overall folding pathway which these reporters sample,
again shifting the small percentage of molecules which can attain the mature geometry
accounting for this dark state. Though it does not account completely for the discrepancy
Cerulean and Citrine fluorescent proteins also have very different quantum yields
(chapter IV) from GFP S65T which again would play a role in the background level. The
potential for the spectral shifting point mutations to change the folding efficiency and
pathway may also explain the discrepancy we see in the quantum yield of the fluorescent
protein vs. the brightness of the reporter. For example CA-CitFP is 12-fold brighter than
CA-GFP however the quantum yield of Citrine is only a 10 percent increase from GFP.
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These point mutations may also be having an effect on the percent conversion to the
mature folded form.!!
In the case of superfolder GFP, which was specifically engineered to have a much
faster folding and maturation rate, we do not observe a dark state. It is difficult to
directly compare CA-sfGFP and CA-GFP as both the linker, which is shortened to DELD
(chapter III) and the fluorescent protein have been changed simultaneously but it is
obvious that this dual effect leads to the lack of the dark state. This supports the
argument that the length and chemical character of the linker along with the folding
efficiency of the fluorescent protein are two of the biggest contributing factors to the dark
state.

5.3. Peptide quenching
Though it is clear that the linker plays a role in the folding and therefore
fluorescence of GFP after cleavage one aspect of the quenching mechanism which needs
to be fully understood is the specific interactions of the peptide. Our model of how the
peptide quenches fluorescence (chapter II) is that it inhibits proper folding of the GFP
barrel until it is removed by a protease. This does not address the specific interactions
that the peptide has with the residues of GFP which leads to the lack of proper folding.
One way to investigate these interactions more specifically, in the absence of structural
coordinates which we have been unable to obtain, is to perform a series of truncations of
the M2 peptide to determine a minimal length and sequence necessary for quenching.
This may also help to address the low level of toxicity of the current CA-GFP construct
in mammalian cells which has not allowed the development of a stable cell line
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containing any of the CA-FP constructs. While it is know that fluorescent proteins have
some level of toxicity due to the generation of reactive oxygen species in the
chromophore maturation reaction it does not prevent culturing of stable cell lines of the
independent fluorescent proteins. Therefore it appears as though the peptide sequence
may be contributing to this effect and a shorter length may decrease the detrimental
effects.
Another possibility is to fuse other helical bundle domains through a similar
linker to determine if it is the hydrophobic nature or the specific sequence that is playing
a larger role. One such peptide is the KCNQ (Kv7) potassium channel A-domain. The
Kv7 tail is a tetrameric coiled-coil in solution however unlike M2 it is not the
transmembrane but the cytoplasmic portion of the protein (3). As this peptide has been
shown to be tetrameric in solution even when fused to a larger protein, the probability is
that it would also tetramerize when fused to GFP.

5.4. Expression and codon usage
Another case where we have observed differences in the dark state is based on the
vector and expression conditions used for co-expression of the reporter. One of the major
challenges in being able to fully achieve the potential impact of PrA-FP reporters will be
to fully understand implications of vector and strain in terms of expression. Throughout
our studies one of the recurring challenges we have faced was optimization of coexpression conditions of our reporter with the protease. We discovered that not only does
co-expression require a double antibiotic selection but also incorporation of the two
respective genes on plasmids containing different origins of replication. After trials of
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several different plasmids, including a pET Duet vector specifically designed for coexpression applications, we found many instances where either the reporter or protease
was not well expressed. More confounding was instances where caspase-7 would be coexpressed but not processed. This was remedied by using a constitutively two-chain
version (or CT version) of the caspase in which the large and small subunits are
expressed, negating the necessity for processing for activity. The ultimate co-expression
combination we determined was optimal was a combination of the pBB75 vector and
pET21b (or any pET vector). Using these vectors we were able to co-express the
protease and reporters from either vector interchangeably, although there is some
variability in the background from each of these as well. This may be due to some subtle
expression differences such as the copy number of each plasmid. The mRNA sequences
(from the T7 to T7terminal sites in the plasmid) when compared does not have significant
differences indicating that subtle sequence differences are less likely than the inherent
differences of the plasmids.
Another consideration is the codon sequence for the reporters. The codon
sequence for CA-GFP used in all cases throughout this thesis was not optimized for E.
coli codon usage (4), but a synthetic version with S65T mutation originally designed for
plant gateway vector use (5). However, there is a only low percentage (4%) of rare
codons for E. coli and so expression is not drastically inhibited. This may mean that the
overall kinetics of translation are slowed, which could change the landscape of the folded
states sampled therefore effecting the dark state of the reporter. CA-mNeptune is also not
codon optimized for E.coli and has 8% rare codons though we still see considerable
expression levels in our experiments. In engineering of a reporter that has faster
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maturation kinetics one of the challenges mentioned above was that these versions are
also optimized for faster folding (6,7), which could effect the background level. One
possibility is that the introduction of codons less frequently used in E. coli may
sufficiently slow the translation, allowing for the sampling of folding intermediates
necessary for achieving the ‘pro-folding’ state (8). Previous studies have shown that
codon usage has a significant effect on GFP. In a study by Kudla et al. it was determined
that fluorescence levels varied 250-fold across 154 genes that all encoded the same GFP
protein sequence(9). This could potentially allow for the advantageous dark state of the
Pr-FP while allowing for much faster observation of cleavage by having a more quickly
maturing version of the fluorescent protein.
Ultimately there are other sources for background as well. Though we see what
appears to be similar expression levels of the overall amount of reporter in cotransformation of C7A- and C6A-GFPe reporters with different caspases an analysis of
the background in each case shows significant variations between the fluorescence of the
‘dark’ state. In the case of the caspase-6 full length- uncleavable construct, the active site
cysteine is still present therefore though it is reported to have very low activity it is
possible that this construct could self-activate (10) which could explain the higher
background in this case (Fig. 5.3). However for caspases -3, -7, and -8 the inactive
mutant is an active site mutation to alanine, preventing the possibility of catalytic activity
and therefore cleavage.
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Figure 5.3. Relative background fluorescence of C6A-GFPe and C7A-GFPe when cotransformed with the inactive versions of caspases -3, -6, -7, and -8.

5.5. Kinetic Control
Ultimately the kinetics of maturation is one of the aspects of CA-GFP most in
need of improvement. While the fluorescence in mammalian cells appears within 20 min,
in vitro the maximal fluorescence isn’t achieved for four hours (chapter II). In a model
where one can imagine watching the apoptotic cascade through a panel of reporters at
different wavelengths for each caspase it is critical that the response to cleavage be
essentially immediate, as is the case with small molecule fluorescent substrate probes.
The ability to control this aspect of the reporter lines primarily in attaining a full
understanding of the specific detailed interactions the linker and peptide have in the
structural context of CA-GFP. While we understand the big picture of the dark state
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mechanism, in that the presence of the peptide appears to sufficiently stall GFP folding in
a ‘pro-folding’ state prior to chromophore maturation, we must understand these specific
details in order to best engineer them. One example as given above is to control the
folding of a faster maturing version of GFP, such as the superfolder GFP which matures
within five minutes (7). Another example would be if we could mimic this ‘pro-folding’
conformation in a version of GFP in which the chromophore is allowed to mature but not
fluoresce. To my knowledge the only examples of this in the literature to date are
versions which can only be used in vitro due to the necessity of denaturing the protein to
destabilize it once the chromophore is formed. However, one can imagine that if the
interaction is specific that perhaps through fusion of the peptide to another strand or
through circular permutations of the reporter this could be achieved.

5.6. CA-FP in Drug Design: Back to Biology
In an interview after receiving his Nobel prize for his work in the development of
GFP and it’s ‘toolbox’ after being asked what he hoped to ultimately achieve from his
research Roger Tsein’s response was he wanted to develop something ‘clinically
beneficial’(11). Ultimately the same sentiment is echoed throughout this thesis. Before
we can begin to understand how to fix biological processes (ie. Develop treatments) we
first need to fully understand how they work. Then we need to understand the full effect,
in whole organisms not only of the disease state but what happens when we perturb the
healthy or unhealthy systems with potential therapies. GFP has provided us a method by
which to effectively and relatively uninvasely do this since it’s development in the 1960’s,
now more than 50 years later, we are still finding new ways to use GFP and it’s now

!

"#$!

countless derivatives to uncover more information into the beautiful intricacies of cellular
biology.
The ultimate vision for CA-FP is to see it used in transgenic model organisms. A
CA-FP transgenic mouse model has the potential to be a powerful tool in the study of the
role of apoptosis in development as well as a screening tool for drug development. With
this tool researchers would have the potential to map out the developmental apoptosis
map in mice as they have in more microscopy amenable organisms such as zebrafish (12)
and C. elegans (13). This mapping of apoptosis would allow for interrogation of genetic
factors in development, differentiating them from environmental factors. The role of
metals and other co-factors in apoptosis could be observed in all organismal systems.
Such a model organism would also be a powerful tool in drug toxicity screening.
Drug design for the past several decades has focused on the study of the effects of
molecules on a pathway or system independent from the intricacies of how each pathway
is connected in a cell or organism. Though this approach has been effective in some
cases it is clear that for success moving forward a more detailed understanding of the
underlying biology is a necessity. In the case of both mice and zebrafish a transgenic line
of organisms could be used to longitudinally observe the effects of potential therapies,
observing localized fluorescence in regions the drug was triggering apoptosis while being
able to assess the overall viability of the organism. A zebrafish line could potentially be
used in a high-throughput application for this purpose.
Each insight we gain into the intricacies of apoptosis underscores how interwoven
and compensatory systems originally believed to operate independently are. For example
apoptosis has long been a central area of study for cancer researchers working on
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methods by which to induce cell death. Recent reviews (14-16) highlight the work
showing how closely the cellular mechanisms for not only apoptosis but other methods of
cell death such as autophagy and necrosis are with the web of metabolic pathways in the
body, opening up whole new pharmacological and basic research directions. The ability
to assess the function of a single protease in this complicated web of cellular function is
critical to being able to tease out the independent role of critical proteins in these
processes. If we had the ability to simultaneously monitor the activity of initiator,
executioner, and inflammatory caspases we could better understand the delicate
regulatory balance that exists within the cell. However, caspases are near the end of this
cascade effect, in order to monitor processes more difficult to assess in vivo such as posttranslational modifications a more complete understanding of the dark state is necessary
to enable appropriate engineering of this class of reporters. With complete control of the
quenching mechanism a class of reporters could be designed to respond to any number of
cellular reactions and interactions including phosphorylation, ubiquitination, and
glycosylation. Each of these modifications is critical in the function of countless proteins
in every cellular process. A more detailed understanding of the events which elicit these
responses and their consequences in the cell is critical for understanding the ramifications
of current and potential therapies both in terms of bolstering efficacy and minimizing
adverse side effects.
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APPENDIX A
MOLECULAR DYNAMICS SIMULATIONS OF PEPTIDE STABILITY

A.1. Introduction
In a collaborative project to design helical peptides to be used as regio-regular
scaffolds for proton transfer we screened several helical peptides in silico. The focus of
this project is to understand proton transport in order to develop better materials for
proton exchange membranes in hydrogen fuel cells. Our goal was to build a helical
peptide with a photo acid generator on the N-terminus and a proton sensitive probe on the
C-terminus. By using a peptide as the scaffold the placement of the proton transferring
moieties can be easily controlled. The proton transporting moiety we chose was the
naturally occurring amino acid –histidine. Histidine is an ideal candidate as its pKa is
typically 6 and can exist as the imidazole or the imidazolium moiety, easily accepting and
donating a proton. Since we are using amino acids we can easily control the direction of
the transfer either through a linear mechanism as shown here, or by a zigzag mechanism
simply by changing the placement of the histidines in the sequence (Figure A.1). In order
to place the histidines moieties in a specific placement we first needed a sequence that
would remain helical under organic solvent conditions needed for single molecule
measurements.
Our search for alpha helical proteins and peptides in the literature yielded many
sequences, far to many to efficiently synthesize. The literature sequences also only report
the structure in an aqueous environment as it is the biologically relevant condition,

!
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though it is not an ideal media for the proton transport measurements we hoped to do
using single molecule spectroscopy. We decided to use molecular dynamics as an in
silico screen for helicity of peptide sequences in organic solvents.!

We also designed a series of synthetic
peptides using the non-natural amino acid
amino isobutaric acid. When we synthesized
these peptides with alternating alanine/AIB
residues they showed a propensity for
helicity in organic solvents as the AIB locks
Figure A.1. Design of a helical peptide
region-regular scaffold for proton
the phi/psi angles of the peptide into an alpha
transport. Our design included a Nterminal photo-acid generator and a Chelical conformation. We also screened
terminal proton sensitive probe to indicate
proton transfer across the histidine side
these sequences in silico to compare them to
chains of the helix.
the natural helical sequences.

A.2. Results
The program we chose was GROningen Machine for Chemical Simulations
(GROMACS (1)) which is an open source molecular dynamics program that is
compatible with several force fields, was applicable to our system. We have employed
molecular dynamics simulations in GROMACS to model the conformation of peptides as
a first-order screening mechanism. We selected GROMACS because it is flexible, open
source software designed specifically for molecular dynamics of biological molecules
and accommodates a variety of force fields. Most importantly it allows modeling of
explicit solvent molecules, which is critical for our analysis. Unlike many molecular
"#$!

dynamics packages that cater to protein and peptide simulations, GROMACS can be
parameterized for many different solvents.
As a control we chose GCN4 (PDBID: 2ZTA (2)), a leucine zipper transcription
factor known to be helical in water and ran a control simulation in water for 5 ns. At the
completion of this simulation the peptide had remained helical. We then moved to one of
the peptide sequences we had selected, which had existing NMR coordinates in the
protein data bank PDBID: 2MAG (3), an abbreviation for Magainin2 a peptide used as an
antibiotic, and ran a simulation again using explicit water as a solvent (Table A.1). After
confirming that 2MAG stayed helical in water as expected efforts were directed to being
able to simulate the effects of DMSO, which was originally suggested as a potential
solvent suitable for single molecule
spectroscopy. After optimizing the
parameters a 10 ns simulation of
2MAG in DMSO was run and, as
seen in Figure A.2, it unfolds almost
Figure A.2. Comparison of peptide 2MAG (initial
coordinates shown in green) after a 1 ns simulation
immediately and never regains any
in H2O on left (cyan) vs. after 10 ns simulation in
DMSO (blue).
of its’ helicity. We used the ending
coordinates of the now unfolded 2MAG and ran a 30 ns simulation (total, 10 ns and then
20ns from these coordinates, Table 2) in water as the solvent to determine if 2MAG could
refold into a helix under these conditions. Though it attempts to refold into a helix
2MAG never regains it’s initial conformation.
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GIGKFLHSAKKFGKAF
VGEIMNS-NH2 (3)

QEQLEDARRLKA
IYE (12)

9

10

8

7

6

5

3
4

2

AcWNA3LAAVAAA10LAA
VAAA17LAAV(4)
GIGAVLKVLTTGLPAL
ISWIKRKRQQ(5)
SLLSLIRKLIT(6)
DTASDAAAAAALTAA
NAKAAAELTAANAAA
AAAATAR(7)
AcEAEKEAKEAAKKKAA
A-NH2(8)
AcNELKKKLELCKAKWL
EAKKKLEALK-NH2 (9)
GAGKAAKGAGKAAK
GAGK (10)
WEAALAEALAEALAE
HLAEALAEALEALAA(
11)

1

Peptide Sequence

25%TFE/H2O
; DPC
micelles;
SDS micelles
Aq

Aq

Aq

Aq

aq

TFE, SDS
H 2O

Phosphate
buffer/
methanol
Aq

Buffer

Monomer

Monomer

Monomer

Monomer

Monomer

Monomer

Monomer or
dimer

Monomer,
tetramer

Monomer;
aggregates

Oligomeric
State
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CD, NMR

NMR

CD

CD, NMR

CD & analytical
ultracentrifugation

CD

Fluorescence,
C13NMR, CD
CD
x-ray
crystallography

Method of
structural
determination
CD

Table A.1. Potential helical peptide sequences for region-rigid scaffold

2ma
g

1wfa

PDB
ID

15

23

30

18

25

16

11
37

26

21

Length

GALA synthetic peptide;
pH 7 = random coil; pH5 =
alpha helix; mimetic of
natural membrane proteins,
W & H are spectroscopic
probes
Magainin2, antibiotic
peptide; helical in all three
solvent systems;
membrane protein
40% helical, folds into
helix as peptide, paper also

65% helical; amphipathic

89% alpha-helix at 0 °C ;
membrane binding

74% Helical

decoralin
Antifreeze protein

Synthetic melittin

Membrane helix

Notes
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11

1: BocVVALV(Lac)L(Aib)VAL
-OMe
2: BocVAL(Aib)VAL(Aib)VAL
-OMe
3:BocVAL(Aib)VALV(Lac)L(
Aib)VAL-OMe (13)

1:acetonitrile
& H 2O
2&3:
isopropanol
and H2O

Helices
aggregate
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x-ray

11,11 &
14

includes mutants with 2
mutations
They substitute lactic acid
for alanine into their
helices to see if it will still
accommodate this residue
in the helical conformation

Table A.2. Log of simulations run using GROMACS. Files are stored on ‘Solitude’ as
well as on the Hardy lab server. The File path of each simulation is indicated in the table
as it appears on the ‘Solitude’ hard drive.
Peptide
Name

2mag

PDB
ID

2MAG

Date
Simulation
Completed

Time
scale

7/14/08

1000 ps

2mag_final

2MAG

7/30/08

1000 ps

GCN4

2ZTA

7/31/08

1000 ps

2mag

2MAG

8/7/08

GCN4

2ZTA

8/14/08

2magfinal
2magunfold
ed

RMS

6.61

10 ns

9.6

5ns
(5324ps)

0.793

2MAG

8/21/08

10 ns

0.704 w/ first
8 aa; 7.36
Exec. RMS

2MAG

09/01/08

20 ns

5.491

File path
~/gromacs
/071408/D
MSO
~/gromacs
/072908/2
magunfol
d
~/gromacs
/072908/g
cn4water
gromacs/0
80508_2m
ag_dmso
~/gromacs
/080708_g
cn4_water
~/gromacs
/082108_2
magfinal_
water/ions
_water

Comments
Completely
Unfolded
did not
completely
refold

retained helicity
RMS from final
frame, sampled
extending and
retracting
retained helicity
well

In water; starts
to reform helix
Kinked helix

As mentioned previously peptides were also designed to maintain a helical
conformation in organic solvent by the incorporation of the non-natural amino acid AIB.
Though we were able to generate starting coordinates in a PDB file format using
ChemDraw software there was difficulty interfacing with the GROMACS library for the
AIB residues. The project was taken over by collaborators from UMass Amherst (Dr.
Scott Auerbach and University of Puerto Rico at Mayaguez, Mayaguez, Puerto Rico (Dr.
Gustavo Lopez)(14).
GROMACS proved to be a fairly reliable tool in terms of our controls monitoring
helical structure in water. Though we never experimentally tested peptide structure in
!
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DMSO of the peptides we ran in simulation the prediction that most native peptide
sequences will unfold in organic solvent is as we would expect. If in silico screening had
shown a peptide which stayed in a helical conformation in DMSO or another solvent I
believe it would have been a valid potential structure as it would have been an anomaly.
In terms of the effectiveness of GROMACS as an effective screen I would agree that with
a basic understanding of Unix and Linux commands GROMCAS is a relatively
straightforward program, making it accessible to a broader audience of users than many
computational programs. For effective screening of large libraries of peptides use on a
computational cluster is recommended as longer simulations take on the order of days to
complete using a single node.

A. 3. Protocol for running a GROMACS simulation (adapted from: online MD
GROMACS tutorial (15))
Molecular Dynamic (MD) Simulations with GROMACS
Performing MD Simulations:

Make a new directory for the particular run
Copy the MD-Data file folder into the new directory and make a new file using the
command ‘mkdir’
Open the new directory using the command ‘CD’

Then, copy interesting files (including the PDB coordinate file your generated with
pymol) into the current directory as following:

!
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cp -r ../MD-Data/dyna .
cp ../MD-Data/methanol216.gro .
cp ../MD-Data/dmso.itp .

You can always get more information on a Gromacs statement by typing it followed by
the '-h' flag. For simplicity, the name of the peptide is denoted ‘X’. Take care of
extensions.

1. First of all, you need to create some starting files that are required by Gromacs,
especially the topology file which gives the topology of your protein, i.e. the way atoms
are linked, angles between atoms... For this, type:
pdb2gmx -f X.pdb -o X.gro -p X.top -i X.itp -ter -ignh
* -f input file
* -o output file that will be used in further statements
* -p topology file that will be created and used later
* -i restraint file that is used when you want to freeze a given moiety in the protein
* -ter to select the type of N and C termini
* -ignh to ignore hydrogens
Gromacs will ask you to choose the force field. Select the "Improved alkane force
field".
Moreover, you will have to choose for (non-)charged termini. People who selected a
charged peptide have to choose NH3+ and COO-. Others have to choose NH2 and
COOH.

!
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It is noticeable that the number of charges of your peptide is null.

2. Then, you need to specify what kind of water box you want to solvate your peptide in.
Type (Note that you have to replace DIST by 0.7 if you started from an extended
structure and 1.4 otherwise):
editconf -f X.gro -o X_box.gro -bt cubic -d DIST -c
* -f input file
* -o output file that will be used in further statements
* -i restraint file that is used when you want to freeze a given moiety in the protein
* -bt is the box type
* -d is the distance between the water and the box
* -c centers the peptide in the box

For performing simulations in vacuum, just make a copy of the original Gromacs file
by typing:
cp X_box.gro X_solv.gro

Finally, skip the step 3 and go straight to the step 4.

3. After this, we can create water molecules (or other) in the box with the following
statement:

!
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genbox -cp X_box.gro -cs SOLVENT -o X_solv.gro -p X.top -seed 1515 >&
genbox.out
* -cp input file
* -cs structure file of the solvent model. Instead of SOLVENT, type:
o spc216.gro for water (It contains coordinates of water molecules that have
been equilibrated at 300K.
o dmso.gro for DMSO
o methanol216.gro for methanol
* -o output file that will be used in further statements
* -p topology file
* -seed table of random number

For people who are performing simulations in methanol or DMSO, you have to
modify manually the X.top file. For this, edit the file with an editor (you can use e.g. vi if
you like challenges... or more simply kedit):
kedit X.top

Change the following line:
#include "spc.itp" should become (regarding the solvent you are using):
#include "methanol.itp" or
#include "dmso.itp"

!
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Also add at the very end of the file a new line containing the number of solvent
molecules. You can find it in the output of the genbox statement (it should be written in
the genbox.out file. Edit it!) or look at the X_solv.gro file (Take the total amount of
residue and remove 4). Hence, the following lines:
[ molecules ]
; Compound

#mols

Protein

1 should become (according to the solvent you are using):

[ molecules ]
; Compound

#mols

Protein

1

DMSO

497 or

[ molecules ]
; Compound

#mols

Protein

1

Methanol

497

Again, do not put 497 (This value has been put randomly as example). Put the
number that is specified in the genbox.out file!

4. It is time now to create what we call an index file, which allows the user to group
different sets of atoms and to call them by a single name. That is very useful when you
need to work on a part of your system, like only the backbone of the protein for instance.
You will understand this concept a little bit later. To do this, type:

!
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make_ndx -f X_solv.gro -o X.ndx
* -f input topology file (Note we are using a Gromacs coordinates file in this case)
* -o Output file
Gromacs shows you all groups defined automatically. Just type q (and 'enter') to
accept. You are invited to have a look into the created index file.

5. Before launching a simulation, it is necessary to create a file that will contain all
information about the simulation. We are talking in this case of preprocession. This file
can be created by typing:
grompp -f dyna/em0.mdp -po X_em0.mdp -c X_solv.gro -r X_solv.gro -n X.ndx p X.top -o X_em0.tpr
* -f input file that contains information about the simulation
* -po ouput file that contains information about the simulation
* -c conformation file generally used for constraining a protein
* -r conformation file generally used when restraining a protein
* -n index file
* -p topology file
* -o output file that Gromacs will use

6. Now, we can perform the first simulation with:
mdrun -v -deffnm X_em0

!
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Generally, a huge amount of flags could be used with the mdrun statement. Instead
of typing all these flags, it is more convenient to use the -deffnm flag to give a general
name. Hence, all output file will contain the name given followed by standard extensions.
The -v flag will give you the step of the run and the estimated remaining time.

7. Actually, the previous simulation was a simple minimization (using a steepest descent
algorithm) to "fit the water molecules around the peptide". You have to perform three
other minimizations. During them, the protein is frozen and only water molecules are
allowed to move. For this, you are going to repeat steps 5 and 6 with different names as
following:
grompp -f dyna/em1.mdp -po X_em1.mdp -c X_em0.gro -r X_em0.gro -t
X_em0.trr -n X.ndx -p X.top -o X_em1.tpr
Maybe you noticed the new -t flag this time. This permits to read some information
from the trajectory of the previous minimization (Of course, we could not do it in the first
minimization knowing that no trajectory existed...)
mdrun -v -deffnm X_em1
Waiting for the first minimization to finish...
grompp -f dyna/em2.mdp -po X_em2.mdp -c X_em1.gro -r X_em1.gro -t
X_em1.trr -n X.ndx -p X.top -o X_em2.tpr

mdrun -v -deffnm X_em2

!
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Waiting for the second minimization to finish...

grompp -f dyna/em3.mdp -po X_em3.mdp -c X_em2.gro -r X_em2.gro -t
X_em2.trr -n X.ndx -p X.top -o X_em3.tpr

mdrun -v -deffnm X_em3

Waiting for the third minimization to finish...

8. Once all those minimizations have been done, we should not have any "wrong"
interactions between water molecules and the peptide (such as bumps) Now, we are going
to prepare the system using 5 MD simulations before launching the final one (this last
one is the one we are interesting in).

In the same way than before, you are going to type:
grompp -f dyna/pr1_SOLV.mdp -po X_pr1.mdp -c X_em3.gro -r X_em3.gro -t
X_em3.trr -n X.ndx -p X.top -o X_pr1.tpr
In the previous statements (and in all next grompp statement, think about replacing
SOLV by:
1. vacuum if you are performing simulations in vacuum
2. water if you are performing simulations in water
3. MeOH if you are performing simulations in methanol

!
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4. DMSO if you are performing simulations in DMSO
mdrun -v -deffnm X_pr1
Waiting for the first MD simulation to finish...
grompp -f dyna/pr2_SOLV.mdp -po X_pr2.mdp -c X_pr1.gro -r X_pr1.gro -t
X_pr1.trr -n X.ndx -p X.top -o X_pr2.tpr

mdrun -v -deffnm X_pr2

Waiting for the second MD simulation to finish...
grompp -f dyna/pr3_SOLV.mdp -po X_pr3.mdp -c X_pr2.gro -r X_pr2.gro -t
X_pr2.trr -n X.ndx -p X.top -o X_pr3.tpr

mdrun -v -deffnm X_pr3
Waiting for the third MD simulation to finish...
grompp -f dyna/pr4_SOLV.mdp -po X_pr4.mdp -c X_pr3.gro -r X_pr3.gro -t
X_pr3.trr -n X.ndx -p X.top -o X_pr4.tpr

mdrun -v -deffnm X_pr4

Waiting for the fourth MD simulation to finish...
grompp -f dyna/pr5_SOLV.mdp -po X_pr5.mdp -c X_pr4.gro -r X_pr4.gro -t
X_pr4.trr -n X.ndx -p X.top -o X_pr5.tpr

!
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mdrun -v -deffnm X_pr5
Waiting for the fifth MD simulation to finish...

9. Finally, you can perform the final MD simulation. To start, we are going to perform a
1ns simulation. You will be able to extend it later, if necessary or some computer time
left. Type:
grompp -f dyna/md_final_SOLV.mdp -po X_md00.mdp -c X_pr5.gro -r
X_pr5.gro -t X_pr5.trr -n X.ndx -p X.top -o X_md00.tpr

mdrun -v -deffnm X_md00
Waiting for the final MD simulation to finish...

To run the simulation in the background (so you can quit the terminal on your computer)
change the command to
Mdrun –deffnm X_md00 &

10. As we said before, the longest the simulation is, the most accurate the estimation of
the free energy will be. You can extend the previous MD simulation by typing:
tpbconv -f X_md00.trr -s X_md00.tpr -n X.ndx -o X_md01.tpr -extend 1000
* -f input file that is the trajectory of the previous MD simulation
* -s topology read from the previous preprocessed MD simulation file

!
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* -n index file
* -o output file that Gromacs will use
* -extend time in ps of the extension (1ns in in this case)
Select the entire system if your are asked for a group.
And you launch the new simulation with:
mdrun -v -deffnm X_md01
Waiting for the MD simulation to finish...

11. Sometimes, your computer can crash while performing a MD simulation. In this case,
it is not necessary to start again from the beginning, you can use the already performed
simulation restarting it just after the crashing. In the case you are in situation like that,
you can just type:
tpbconv -f X_md01.trr -s X_md01.tpr -n X.ndx -o X_md02.tpr
And you will relaunch again the simulation with:
mdrun -v -deffnm X_md01
Waiting for the MD simulation to finish...
Note that in this way you are not starting again the MD simulation rather than
continuing it just after the crashing. This is possible because you write velocities in the
trajectory files.

Once you decided all simulations are long enough, you will have to analyze results.

!
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APPENDIX B
Protocols

B1. Expression and Purification of CA-GFP and all GFP based constructs (all CAFP’s, GFP, sfGFP, Cerulean, Citrine, and mNeptune)
Expression
Day 1:
In the latter part of the day set up a 50 mL overnight culture of CA-GFP in BL21(DE3) to
obtain a dense culture
-

Add 50 µl of 100 mg/mL ampicillin (or appropriate antibiotic) to 50 mL of LB
(note* A 5 mL culture can also be used for this step if inoculating less than 5
flasks)

-

Inoculate culture media with a single colony of CA-GFP in BL21(DE3)

-

Shake at ~250 rpm at 37°C

Day 2:
Growth for induction
-

Add 1mL of 100 mg/mL ampicillin to 1L of 2xYT media

-

Inoculate culture with 1 mL of dense overnight culture

-

Shake at ~250 rpm in 37°C

Induction conditions
-

!

Monitor OD600 until it reaches 0.6-0.7 (approx. 3 hrs)
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-

At OD 0.6-0.7 induce culture by adding 1mM IPTG (1 mL of 1M IPTG for
1L culture)

-

Drop shaker temperature to 25°C

-

Allow culture to shake at 25°C for 3 hours

-

After 3 hrs harvest cells by centrifugation

-

If using a fluorescent GFP construct at this point you would be able to see
GFP fluorescence in the cell pellet by eye or when looked at under UV light

Purification (Using a COBALT-NTA column)
-

Thaw and Resuspend cells in lysis buffer, ensure a homogenous mixture

-

Break open cells (via microfluidizer), be sure to add cells into microfluidizer
through a 25 or 50 mL pipet so as not to clog the instrument

-

Spin lysed cells 15,000 rpm for 45 minutes (resulting supernatant should be
very green for GFP)

-

Filter supernatant using 0.45 µM Millipore filter in filter assembly

-

Load onto Co-NTA column at 3 mL/min, run lysis buffer until baseline
collecting flow-through in a 250 ml bottle

-

Wash until baseline, collect wash fraction as one aliquot in a 50 mL tube

-

Elute until baseline, collect elution fractions in 5-7 mL aliquots in 15 mL
tubes

-

1M Imidazole Wash, collect in one 50 mL tube. This step is important for the
life of your column as some fraction of GFP and CA-GFP proteins tend to
adhere strongly to the column.

!
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-

After purification of a fluorescent GFP construct it is necessary to wash the
column with 10 mM NaOH during recharging immediately after purification
(Order of recharging: water, EDTA, water, NaOH, water, Co- solution, water).
Be sure that there is no green color left on the column after the NaOH wash, if
so it may also be necessary to wash in a separate step with GdnHCl.

Note: GFP and cleaved CA-GFP elutes in the Wash fractions

Table B1. Buffer compositions for Co-NTA purification of GFP proteins
Lysis
50 mM NaH2PO4 pH 8.0
300 mM NaCl
2 mM Imidazole

Wash
50 mM NaH2PO4 pH 8.0
300 mM NaCl
50 mM Imidazole

Elution
50 mM NaH2PO4 pH 8.0
300 mM NaCl
250 mM Imidazole

B2. Fluorescence Lysate Assay
Day 1: Co-transform reporter (ie. CA-GFP) and protease (ie. Caspase-7) in
electrocompetent Bl21(DE3) cells and plate on double antibiotic selection plate

Day 2: Inoculate 5 mL LB cultures with 5 µL 100 mg/ml Ampicillin and 40 mg/ml
Kanamycin and a single colony from co-transformants. Incubate overnight at 37°C
shaking at ~250 rpm. Prepare appropriate number of 50 ml LB media in baffled 250 ml
flasks. Each co-transformation requires two flasks for replicates. Therefore to test one
protease requires four flasks (two for the active form of the protease and two for the
inactive form or for a co-transformation with an empty vector if no inactive version of the
protease is available)
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Day 3: For each co-transformation inoculate two 50 ml LB cultures with 50 µL of 100
mg/ml Ampicillin, 50 µL of 40 mg/ml Kanamycin, and 50 µL of the dense 5 mL
overnight culture. Incubate at 37°C for approximately 3.5 hrs until cultures reach a
OD600 of approximately 0.6. Cultures can then be induced with 1ml of 1M IPTG and the
temperature dropped to 25°C. (*Note: be sure to check OD of each flask as different cotransformations tend to grow at different rates, it may be necessary to use more than one
shaker and move flasks into different shaker as they reach the appropriate OD) The
induction time is 18hrs (overnight).

Day 4: For each flask (two for each sample) collect two 2 mL aliquots for lysate and one
1 mL aliquot for whole-cell fluorescence measurements. Spindown all aliquots in a
tabletop centrifuge at max speed for two minutes and decant supernatant. Resuspend the
lysate fractions in 800 µL of lysis buffer (0.5 mg/mL lysozyme, 2 units DNAase) and
lyse using four cycles of freeze thaw alternating between a dry ice bath and the 37°
waterbath. After lysing spin samples in tabletop centrifuge for 2 min at max speed.
Resuspend 1mL aliquots in 1mL of PBS for whole cell measurements. A sample from
each flask should also be taken to measure OD of the culture for normalization. As these
samples are very dense I measure 500 µL of culture diluted with 500 µL LB compared to
a 1mL LB blank (*Note when measuring bacterial cultures on the Nanodrop always use a
cuvette, make sure that the cuvette function is checked in the software).
In a black 96-well co-star plate add 100 µL of supernatant from each lysed sample
(each sample should have a 1A, 1B, 2A, and 2B sample the number refers to the flask
while the letter refers to the duplicate aliquot taken from each flask). Add 100 µL of each
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whole cell sample as well. Make sure to have 100 µL of lysis buffer and 100 µL of PBS
as blanks. Measure the endpoint fluorescence on the Spectramax M5 plate reader at the
wavelengths indicated in the table below for each fluorescent protein. Citrine fluorescent
protein should be read on a fluorimeter due to the proximity of the excitation and
emission wavelengths in order to avoid bleed through of signal.
Table B2. Fluorescence Parameters for FPs
Fluorescent
protein
GFP
Cerulean
Citrine

Excitation
(nm)
475
433
513

Emission
(nm)
512
475
529

mNeptune

530

650

Instrument
Spectramax M5 platereader
Spectramax M5 platereader
JASCO FP-6500
spectrofluorimeter
(Thai lab fluorometer)*
Spectramax M5 platereader

Raw fluorescence is normalized based on the OD of each culture using the equation
below.
!!!
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Western Analysis of Lysate samples
From each lysate sample collect a 60 µL aliquot, add 15 µL of SDS loading dye with
DTT and boil samples for 10 minutes. For optimal blotting normalize the amount of each
sample loaded using the equation below. Run three identical SDS-PAGE gels, two using
the kaleidoscope marker and one using the NEB protein ladder. Transfer the two gels
with kaleidoscope marker onto Hybond-ECL™ nitrocellulose membrane (GE
Healthcare) in a two hour transfer at 100V. After transfer is complete follow standard
Hardy lab western protocol. Blocking step is often performed overnight. For one
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western blot with the Millipore anti-GFP primary antibody diluted 1:1000 in blocking
solution. For the other blot with the protease specific antibody, in the case of caspase-7
the primary antibody for the C7 large subunit was used.

B3. In Vitro Cleavage Assay
Buffer exchange CA-GFP into a buffer of 135 mM NaCl, 4.5 mM NaH2PO4 pH 7,
8 mM KH2PO4 pH 7, 3 mM KCl to approximately 10 µM. For caspase-6 cleavage the
most effective buffer was the caspase-6 activity assay buffer (100 mM HEPES pH 7.5,
10% sucrose, 0.1% CHAPS, 30 mM NaCl, and 5 mM DTT), optimization may be
required for other protease/reporter combinations. Make sure to prepare enough volume
to read 100 µL and for 15 µL gel sample aliquots at each of the timepoints with at least
20 µL extra to compensate for any pipetting errors and evaporation of the sample. Take
15 µL gel samples before the addition of caspase for the 0 min time point.

At initiation

of the reaction pipet 100 µL aliquots of the digest and controls into a costar 96-well black
plate, and the fluorescence was measured in a kinetic assay format every 5 min (Ex. 475
nm/Em. 512 nm) for 15 h at 37 °C. Make sure to set up the method on the software
before the addition of caspase in order to start reading as immediately after initiation as
possible. The remainder of the sample was incubated at 37 °C in 15 µL aliquots to which
SDS loading buffer was added at time points of 0, 5, 10, 15, 20, 30, 60, 90, 120 min, and
at 15 h. These samples were then run on an SDS-PAGE gel to determine the ratio of
cleaved to uncleaved CA-GFP.
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B4. Stepwise cloning method (Overlapping primers method)
This method is useful when rearranging or piecing together a gene from already
existing sequences. I will use moving the M2 peptide from the C-terminus of GFP to the
N-terminus as an example. You will need to design four primers. The first two will
amplify the GFP portion and the second two to amplify the M2 portion. P1 is designed to
anneal to the N-terminal region of GFP with the linker region encoded in the primer (Fig.
1). P2 is designed to anneal to the C-terminus of GFP and includes a stop codon and the
C-terminal restriction site for the new gene. P3 includes the N-terminal resitriciotn site
for the new gene and the N-terminal region of the M2 portion of the gene. P4 is designed
to anneal to the C-terminus of M2 and includes the same linker sequence as P1, meaning
P1 and P4 will generate an overlapping region. This overlapping region should be
approximately 24 bp and have a Tm greater than 60°C.

Figure B1. Primer design for overlapping molecular cloning method
Amplify each section in independent PCR reactions, run each reaction on an agarose gel,
and gel purify the inserts using the Promega gel purification kit. After gel purification of
the amplified fragments combine the two fragments in a single PCR reaction (see below
for cycle parameters) and allowed to anneal through the overlapping region for five PCR
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cycles before the addition of primers P2 and P3 which then amplified the full length gene.
The full length insert and vector are then digested with the appropriate restriction
enzymes, gel purified, and ligated into the desired vector (I use the Roche Rapid DNA
Dephos & Ligation Kit, you can also use the NEB T7 ligase with this protocol so the kit
is not necessary).

Table B3. PCR Reaction for Overlapping Primers amplification of full-length gene
Component
Fragment 1 (longer fragment)
Fragment 2 (shorter fragment)
Water
10x Pfu Turbo buffer
10 mM dNTP’s
Pfu Turbo
P3 (added after 5 cycles)
P2 (added after 5 cycles)

Volume (µL)
Depends on Concentration ~160 ng
Depends on Concentration ~30 ng
Up to final volume of 50 µL
5
1
1
1
1

Table B4. PCR cycle for amplification for full-length gene, the method should be paused
after 5 cycles and primers 2 and 3 added to the reaction.
Temperature
95°C
95°C
63°C
72°C
72°C
4°C

Time
1 min
30 sec
30 sec
1 min
10 min
∞

Repeats
1
40

1

B5. NMR sample preparation and Analysis
This protocol was adapted from the Gierash lab protocol (1)
Day 1: Inoculate 5 ml overnight culture. Make minimal media and autoclave media and
flasks
M9 minimal medium (for 1 L): (autoclave or filter sterilize and store at 4oC)
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-

6.5 g Na2HPO4

-

3.0 g KH2PO4

-

0.5 g NaCl

-

1g NH4Cl (for unlabeled medium, or 1.0 g 15NH4Cl for 15N-labeled medium)

-

120 mg MgSO4

-

11 mg CaCl2

(filter sterilize)
4 g regular D-glucose (or 2 g D-[13C]-glucose for U{13C} samples only)
Vitamins (biotin and thiamine at a final concentration of 10 mg/mL for both)
(I make 10 X stocks of both glucose and vitamins)

For each L of media being grown autoclave:
-

20 mL LB in 250 mL Erlenmyer

-

100 mL M9 in 250 mL Erlenmyer (first resuspension)

-

100 mL M9 in 500 mL Erlenmyer (Dilution to 200 mL)

-

800 mL M9 in 1 L Fernbach (Final dilution to 1L)

Day 2: Add 10mL 10x vitamins and 10 ml 10x Glucose to each Erlenmyer as well as 10x
Vitamins and 10X glucose and appropriate antibiotics to cooled media before inoculation.
-

Start with a 5-ml culture of LB medium from a freshly colony (o/n @ 37oC)

-

Add 50 uL of o/n culture in 20 ml LB medium; incubate the culture until the
OD600 is 0.5 @ 37oC.
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-

Spin the cells down and wash once with PBS, resuspend in 100 ml M9 15Nlabeled medium (prepared with 15NH4Cl) (Erlenmyer 1, pre-warmed to 37°C).
Starting OD should be about 0.1, incubate the culture until the OD600 is 0.50.6.

-

Dilute the culture to 200 ml M9 15N-labeled medium (Erlenmyer 2, prewarmed to 37oC) and grow until the OD600 is 0.5-0.6.

-

Dilute the culture to 1L M9 15N-labeled medium (Fernbach, pre-warmed to
37oC) and grow until the OD600 is 0.5-0.6.

-

Induce protein overexpression.

-

Continue the growth for induction time of protein.

Purify protein by normal method. The final protein concentration should be ~0.1 mM in
the desired buffer with 5% D2O (should be exactly the same as a reported spectra if
comparing the coordinates). The minimum volume for the Shigemi BMS 005-V NMR
tube recommended for the cryogenically cooled triple-resonance probe is 0.28 mL.
Previous spectra were measured on the 700-MHz Varian NMR system at 37°C. Spectra
were processed using NMRpipe (2) and analyzed using Cara (3).

B6. Proteinase K Proteolysis Assay
Buffer exchange protein into a buffer of 50 mM Tris pH 7.5, 5 mM CaCl2 or if the
protein is sufficiently concentrated dilution into the above buffer is acceptable. The final
concentration of the protein should be between 10-30 µM. Prepare tubes for five aliquots
with 1µL of X mM protease inhibitor phenylmethylsulfonyl fluoride (PMSF) in each tube.
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Take 10 µL aliquot for 0 min timepoint and add to PMSF. Add 500 nM proteinase K to
the protein and begin timing. Take 10 µL aliquots at each of the timepoints, adding the
aliquot to the PMSF. After all timepoints have been collected add 3 µL SDS loading
buffer with DTT to each sample and boil for 10 minutes. The samples may not load into
SDS-PAGE gel easily, make sure that running buffer and gels have been incubated at 4°C
prior to running the gel. Also ensure that the samples are completely cooled and spin
down in tabletop centrifuge before loading.

B7. Two Dimensional Gel Analysis
Before performing experiment check the pI of the protein of interest and order the
appropriate IPG strip with a pH range complementing the proteins you are trying to
separate. Strips are ordered from NEB. The 7 cm size should be ordered to be compatible
with the Normanlly lab apparatus. The manual that comes with the IPG strips contains
photo instructions of many of the steps described here and is very helpful.

Day 1. Prepare sample, in my case it was an O/N digest of DVP2 with the DVPA-GFP
reporters, by diluting in a rehydration buffer of 8M Urea, 2% CHAPS, and 50 mM DTT.
I performed my digests at a high concentration (5 mg/mL of each protein) and diluted my
reactions 10-fold in the rehydration buffer. Once the sample is prepared using a pipet
dispense a continuous line of your protein solution (125-130 µL) in one well of the IpG
strip tray. Carefully place the IPG strip face down in the protein solution making sure
there are no gaps or bubbles under the strip. Repeat for each sample. Incubate at room
temperature for 1 hr. After 1 hr most of the proteins solution should have be absorbed by
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the strip. Cover the strips with mineral oil (~1mL) and incubate at room temperature for
~12 hours (approx. overnight).

Day 2. Gently blot off mineral oil with damp filter paper. Place wicks (small pieces of
filter paper) over the electrodes of the isoelectric focusing apparatus and wet with ~6 µL
of H2O. Carefully load the strips into the apparatus making sure the gel side is facing
down and that it is on top of the wicks on each side. Cover the samples with ~1 mL of
mineral oil. Load the tray onto the instrument. There are several options for the voltage
ramping mode. I selected the rapid ramping mode as I was only trying to separate two
purified proteins. Be sure to start this early in the morning as the ‘rapid’ ramping mode
took nearly 10 hours to complete. Once the ramping method is complete the samples can
be placed in the IPG strip tray and be stored at -80°C until needed. While the isoelectric
focusing step is running pour appropriate percent acrylamide gels. Only the resolving
portion is necessary and should poured within ~1cm of the top of the short glass plate.
Be sure to use a tall plate with 1 mm thickness to ensure that the IPG strip will fit.

Day 3. Thoroughly thaw the samples (~1 hr at room temp). Incubate strips in
Equilibration buffer I (6M urea, 2% SDS, 0.05M Tris HCl pH 8.8, 20% glycerol, 2%
DTT), a volume of 2.5 ml is needed for a 7 cm strip. After a 10 min incubation decant
equilibration buffer 1 and replace with 2.5 ml of equilibration buffer 2 (6M urea, 2%
SDS, 0.05M Tris HCl pH 8.8, 20% glycerol, 2.5% Iodoacetamide), incubating for
another 10 min then decant. Carefully slide the IPG gel into the SDS gel with the plastic
backing touching the tall plate. Carefully use forceps to make sure there are no air
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bubbles under the IPG gel. At this point you can add a piece of filter paper on which the
protein ladder has been loaded or place a small plastic divider on one side of the strip to
make a well. Once all the strips are properly placed pour a solution of 0.5% agarose in
1X SDS-PAGE running buffer with 0.003% bromophenol blue as an indicator for the gel
front and allow to solidify (~10 min).

If you made a well for the protein ladder then add

marker sample and run SDS-PAGE as normal.
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Table C.1: Summary of constructs and fluorescent properties tested of existing protease activatable- fluorescent proteins.

APPENDIX C
PROTEASE ACTIVATABLE- FLUORESCENT PROTEINS
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Abbreviations: NT= not tested; NA= not applicable; ND= none detected
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